ketamine has been researched along with Disease Models, Animal in 663 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades." | 9.01 | Rodent ketamine depression-related research: Finding patterns in a literature of variability. ( Fitzgerald, PJ; Hale, PJ; Polis, AJ; Watson, BO, 2019) |
| "The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia." | 8.98 | Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. ( Curic, S; Haaf, M; Leicht, G; Mulert, C, 2018) |
| "Subanesthetic doses of the psychomimetic, ketamine, have been used for many years to elicit behavioral effects reminiscent of schizophrenia in both healthy humans and in animal models of the disease." | 8.89 | Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. ( Brown, RE; Hajos, M; Kocsis, B; McCarley, RW, 2013) |
| " The sucrose consumption test, forced swim test, open field test, elevated plus maze, and Morris water maze were respectively used to assess anhedonia, behavioral despair, general locomotor activity, anxiety-like behavior and spatial reference memory." | 8.31 | Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress. ( Kingir, E; Sevinc, C; Unal, G, 2023) |
| "This study aimed to determine effects of the resveratrol on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice." | 8.31 | Resveratrol plays neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. ( Farkhakfar, A; Hassanpour, S; Zendehdel, M, 2023) |
| "This study aimed to evaluate Haloperidol's (Hal) effects on the behavioral, neurotrophic factors, and epigenetic parameters in an animal model of schizophrenia (SCZ) induced by ketamine (Ket)." | 8.31 | Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine. ( da Rosa, RT; Dal-Pont, GC; Daminelli, T; Fries, GR; Mastella, GA; Quevedo, J; Valvassori, SS; Varela, RB; Zugno, AI, 2023) |
| "The use of ketamine, an anesthetic, as a treatment for asthma has been investigated in numerous studies." | 8.12 | Ketamine Attenuates Airway Inflammation via Inducing Inflammatory Cells Apoptosis and Activating Nrf2 Pathway in a Mixed-Granulocytic Murine Asthma Model. ( Wang, Q; Xiao, S; Yang, D; Zhou, Y, 2022) |
| " The present study was conducted to develop curcumin-loaded nanophytosome (CNP) and explore their therapeutic potential in a ketamine (KET)-induced schizophrenia (SCZ) model." | 8.02 | Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. ( Bavaghar, B; Maboudi, K; Moghaddam, AH; Sangdehi, SRM; Zare, M, 2021) |
| " Therefore, we propose a hypothesis that diazepam monotherapy or diazepam-ketamine dual therapy could terminate seizures and reduce mortality in the SE model at different time points during ongoing SE." | 8.02 | Diazepam Monotherapy or Diazepam-Ketamine Dual Therapy at Different Time Points Terminates Seizures and Reduces Mortality in a Status Epilepticus Animal Model. ( Cao, X; Li, Z; Wang, Y; Yu, J; Zhou, R, 2021) |
| "Here, we used the drug-discrimination paradigm to allow rats that model a risk factor for schizophrenia (maternal immune activation, MIA) to report on the subjective internal state produced by a subanesthetic dose of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine." | 8.02 | Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk. ( Bilkey, D; Elston, TW; Meighan, W; Ward, RD, 2021) |
| "Cannabidiol (CBD), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia." | 7.96 | Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats. ( Juknat, A; Kos, T; Kozela, E; Krawczyk, M; Popik, P; Vogel, Z, 2020) |
| "Here we show that mice prenatally exposed to ketamine displayed anxiety-like behaviors during adulthood, but not during puberty." | 7.96 | Prenatal Exposure to Ketamine Leads to Anxiety-Like Behaviors and Dysfunction in Bed Nucleus of Stria Terminalis. ( Chen, Y; Feng, X; Guo, H; Hu, Y; Li, Y; Lin, J; Lin, L; Liu, T; Lu, Z; Sun, J; Xu, S, 2020) |
| " Here we aimed to compare the effects of (R)-norketamine ((R)-NK), (S)-NK, (2R,6R)-HNK, and (2S,6S)-HNK in a mouse model of depression induced by chronic corticosterone (CORT) injection." | 7.96 | (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. ( Ago, Y; Chen, L; Hashimoto, H; Hashimoto, K; Higuchi, M; Kasai, A; Naito, M; Nakagawa, S; Nakazawa, T; Seiriki, K; Tanabe, W; Tsukada, S; Yamaguchi, T; Yokoyama, R, 2020) |
| "The antioxidant and cardioprotective effects of oleuropein have been reported in several studies; however, its effect on ketamine cardiotoxicity has not been known yet." | 7.96 | Protective effect of oleuropein on ketamine-induced cardiotoxicity in rats. ( Aydın, T; Borazan, Y; Çakır, A; Cellat, M; Çömez, MS; Gökçek, İ; Güvenç, M; Özkan, H; Özsoy, ŞY; Türk, E, 2020) |
| " Considering that ketamine has significant knock-on effects, this study investigated the effects of a single coadministration with subthreshold doses of ketamine plus guanosine in a corticosterone (CORT)-induced animal model of depression and the role of anti-inflammatory and antioxidant pathways." | 7.96 | Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling. ( B Zeni, AL; Camargo, A; Dalmagro, AP; M Rosa, J; P Kaster, M; S Rodrigues, AL; Tasca, CI, 2020) |
| "To evaluate the possible neuroprotective effects of ketamine and dantrolene on the hippocampal apoptosis and spatial learning in rats exposed to repeated electroconvulsive seizures (ECS) as a model of status epilepticus (SE)." | 7.96 | Investigation of the Possible Protective Effects of Ketamine and Dantrolene on the Hippocampal Apoptosis and Spatial Learning in Rats Exposed to Repeated Electroconvulsive Seizures as a Model of Status Epilepticus. ( Atilla, P; Barun, S; Canpinar, H; Erdem, SR; Ertunc, M; Gursoy, ID; Keskin, U; Kiziltas, M; Muftuoglu, S; Narin, F; Sara, Y; Yuce, D, 2020) |
| "Ketamine has been clinically proven to ameliorate depression, including treatment-resistant depression." | 7.96 | Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model. ( Kitamura, Y; Sendo, T; Takahashi, K; Ushio, S, 2020) |
| "In CFA-treated mice that exhibited pain behavior and depression-like behavior, ketamine reversed depression-like behavior." | 7.96 | Subanesthetic Dose of Ketamine Improved CFA-induced Inflammatory Pain and Depression-like Behaviors Via Caveolin-1 in Mice. ( Han, R; Han, S; Li, J; Peng, Y; Sun, W; Wang, J; Zhao, Q; Zhou, Y, 2020) |
| "Ketamine induced drastic schizophrenia-like behaviors, lower protein levels of BDNF and PSD-95, and a change in the synaptic ultrastructure in the PCC." | 7.91 | Applying vinpocetine to reverse synaptic ultrastructure by regulating BDNF-related PSD-95 in alleviating schizophrenia-like deficits in rat. ( Deng, C; Fu, B; Liu, N; Xu, Y; Zheng, Y, 2019) |
| " The aim of the study was to investigate effects of pre-treatment with Morphine or Ketamine on hemodynamic, acid-base status, early survival, and biochemical markers of brain damage in a rat model of asphyxial cardiac arrest (ACA)." | 7.91 | The influences of morphine or ketamine pre-treatment on hemodynamic, acid-base status, biochemical markers of brain damage and early survival in rats after asphyxial cardiac arrest. ( Akhatov, N; Baigenzhin, A; Barlow, N; Dahl, V; Karibekov, T; Kondratiev, T; Konkayev, A; Konkayeva, M; Kuklin, V; Tveita, T, 2019) |
| "The present study investigated the methylation of CpG sites in the cyclooxygenase (COX)‑2 promoter via nuclear factor (NF)‑κB transcriptional regulation and elucidated its effect on the COX‑2 transcriptional expression in a ketamine‑induced ulcerative cystitis (KIC) animal model." | 7.91 | Epigenetic regulation of COX‑2 expression by DNA hypomethylation via NF‑κB activation in ketamine‑induced ulcerative cystitis. ( Chuang, SM; Hsiao, HP; Juan, YS; Lee, YC; Lin, KL; Long, CY; Lu, JH; Tsai, CC; Wu, WJ; Yang, HJ, 2019) |
| "Our findings suggest that skeletal muscular glycine contributes to the antidepressant effects of ketamine in inflammation." | 7.91 | Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression. ( Hua, D; Hua, F; Huang, N; Jiang, R; Li, S; Luo, A; Wang, Y; Wu, Y; Yang, C; Yang, L; Yu, F; Zhan, G; Zhu, B, 2019) |
| " Thus, the aim of this study was (1) to evaluate the cognitive effects and biochemical markers produced by the AIN-93 diet (control), the AIN-93 diet supplemented with different doses of FA (5, 10, and 50 mg/kg), and a FA-deficient diet during pregnancy and lactation in female mother rats (dams) and (2) to evaluate the effect of maternal diets on inflammatory parameters in the adult offspring which were subjected to an animal model of schizophrenia (SZ) induced by ketamine (Ket)." | 7.88 | The Evaluation of Folic Acid-Deficient or Folic Acid-Supplemented Diet in the Gestational Phase of Female Rats and in Their Adult Offspring Subjected to an Animal Model of Schizophrenia. ( Alves, CSV; Barcellos, AS; Budni, J; Canever, L; Citadin, S; Damázio, L; De Luca, LA; Garcez, ML; Mastella, G; Polla, JV; Quevedo, J; Zugno, AI, 2018) |
| "The use of ketamine (Ket) as a pharmacological model of schizophrenia is an important tool for understanding the main mechanisms of glutamatergic regulated neural oscillations." | 7.88 | Average spectral power changes at the hippocampal electroencephalogram in schizophrenia model induced by ketamine. ( Barbosa, TM; Borges, LTN; Dantas, LP; de Andrade, FRO; do Vale, OC; Lima, RF; Macedo, D; Oliveira, TQ; Patrocinio, MCA; Sampaio, LRL; Silva, JMF; Vasconcelos, SMM, 2018) |
| "Evidence has shown that the kynurenine pathway (KP) plays a role in the onset of oxidative stress and also in the pathophysiology of schizophrenia." | 7.88 | The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. ( Barichello, T; Becker, IRT; Ceretta, LB; Dal-Pizzol, F; Kaddurah-Daouk, R; Oses, JP; Petronilho, F; Quevedo, J; Réus, GZ; Scaini, G; Zugno, AI, 2018) |
| "This study tested the effects of ketamine on vulnerability of female adolescent mice to activity-based anorexia (ABA)." | 7.88 | Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior. ( Aoki, C; Chen, YW; Sherpa, AD, 2018) |
| "Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia." | 7.85 | Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia. ( Babinska, Z; Micale, V; Ruda-Kucerova, J; Stark, T, 2017) |
| "Ketamine-induced ulcerative cystitis (KIC) initially damaged the bladder mucosa and induced contracted bladder thereafter." | 7.85 | Elucidating Mechanisms of Bladder Repair after Hyaluronan Instillation in Ketamine-Induced Ulcerative Cystitis in Animal Model. ( Chuang, SM; Ho, WT; Juan, YS; Lee, YC; Lee, YL; Lin, KL; Lu, MC; Wu, BN; Wu, WJ; Yuan, SF, 2017) |
| "Effects of a single bilateral infusion of R-enantiomer of ketamine in rat brain regions of learned helplessness model of depression were examined." | 7.85 | Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. ( Hashimoto, K; Shirayama, Y, 2017) |
| "The acute antidepressant effects of ketamine provide hope for the development of a fast acting approach to treat depression but the consequences of chronic treatment with ketamine are still unclear." | 7.85 | Lack of effect of chronic ketamine administration on depression-like behavior and frontal cortex autophagy in female and male ICR mice. ( Agam, G; Anderson, GW; Einat, H; Kara, NZ; Zitron, N, 2017) |
| "This study compared effects of the NMDA receptor antagonists ketamine and MK-801 in assays of pain-stimulated and pain-depressed behaviour in rats." | 7.83 | Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats. ( Hillhouse, TM; Negus, SS, 2016) |
| "The aim of the present study was to investigate the effects of ketamine, imipramine, and ketamine plus imipramine on chronic depression-like behaviors of Wistar Kyoto (WKY) rats and underlying mechanism." | 7.83 | [Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats]. ( Jin, XJ; Li, QQ; Peng, LC; Ye, K, 2016) |
| "The aim of the present study was to investigate the efficacy of ketamine in attenuating osteoarthritis (OA) and modulating the expression of inflammatory mediators." | 7.83 | Ketamine attenuates osteoarthritis of the knee via modulation of inflammatory responses in a rabbit model. ( Lu, W; Wang, L; Wo, C; Yao, J, 2016) |
| " It also sets out to verify any potential protective action using an animal model of schizophrenia induced by ketamine, in behavioral and biochemical parameters." | 7.83 | Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine. ( Budni, J; Calixto, OP; Canever, L; Damázio, LS; de Oliveira, MB; Heylmann, AS; Macan, TP; Mastella, GA; Pacheco, FD; Pedro, TH; Pereira, FP; Quevedo, J; Schuck, PF; Steckert, A; Wessler, PG; Zugno, AI, 2016) |
| "Abuse of the hallucinogenic drug ketamine promotes the development of lower urinary tract symptoms that resemble interstitial cystitis." | 7.83 | Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder. ( Choi, SJ; Choo, MS; Heo, J; Kim, A; Kim, SW; Kim, Y; Lee, S; Lim, J; Oh, W; Shin, DM; Shin, JH; Song, M; Yoon, SJ; Yu, HY, 2016) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression." | 7.83 | Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. ( Chen, QX; Han, M; Hashimoto, K; Ma, M; Ren, Q; Yang, B; Yang, C; Yao, W; Zhang, JC, 2016) |
| " jatamansi treatment exhibited encouraging results in the modulation of ketamine-induced schizophrenia-like behaviours, principally the positive symptoms." | 7.83 | Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced Schizophrenia-Like Symptoms in Rats. ( Janardhanan, A; Sadanand, A; Vanisree, AJ, 2016) |
| "We investigated whether the nitric oxide (NO) precursor, L-arginine, can prevent the antidepressant-like action of the fast-acting antidepressant, ketamine, in a genetic rat model of depression, and/or induce changes in the glutamate (Glu)/N-methyl-D-aspartate receptor (NMDAR)/NO/cyclic guanosine monophosphate (cGMP) signalling pathway." | 7.81 | Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression. ( Joca, S; Liebenberg, N; Wegener, G, 2015) |
| "Studies have suggested that ketamine, a nonselective NMDA receptor antagonist, could be a new drug in the treatment of major depression, but the way ketamine presents such effects remains to be elucidated." | 7.81 | Ketamine treatment partly reverses alterations in brain derived- neurotrophic factor, oxidative stress and energy metabolism parameters induced by an animal model of depression. ( Abelaira, HM; Carlessi, AS; da Luz, JR; dos Santos, MA; Jeremias, GC; Matias, BI; Morais, MO; Nacif, MP; Quevedo, J; Réus, GZ; Scaini, G; Steckert, AV; Streck, EL; Tomaz, DB, 2015) |
| "This study aimed to evaluate the effect of sepsis on behavioral changes on the ketamine-induced animal model of schizophrenia." | 7.81 | Effect of sepsis on behavioral changes on the ketamine-induced animal model of schizophrenia. ( Barichello, T; Bittencourt, MO; Cassol, OJ; Comim, CM; Dal-Pizzol, F; Mendonça, BP; Palmas, D; Patrício, JJ; Quevedo, J; Silva, NC; Zugno, AI, 2015) |
| " Considering the lack of understanding concerning the pathophysiology of schizophrenia, the present study hypothesized that omega 3 prevents the onset of symptoms similar to schizophrenia in young Wistar rats submitted to ketamine treatment." | 7.80 | Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. ( Binatti, AR; Budni, J; Chipindo, HL; da Rosa Silveira, F; de Oliveira, MB; Gama, CS; Heylmann, AS; Maravai, SG; Mastella, GA; Panizzutti, B; Quevedo, J; Schuck, PF; Steckert, AV; Volpato, AM; Wessler, PG; Zugno, AI, 2014) |
| "We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression." | 7.80 | Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. ( Belujon, P; Grace, AA, 2014) |
| "Chronic administration of ketamine in an animal model of schizophrenia generates increased AChE levels in different brain tissues of rats that lead to cognitive deficits." | 7.80 | Evaluation of acetylcholinesterase activity and behavioural alterations induced by ketamine in an animal model of schizophrenia. ( Budni, J; Canever, L; De Luca, RD; de Oliveira, MB; Deroza, PF; Fraga, DB; Ghedim, FV; Matos, MP; Pacheco, FD; Quevedo, J; Valvassori, SS; Volpato, AM; Zugno, AI, 2014) |
| "Dexmedetomidine-ketamine combination could mitigate pulmonary inflammatory response induced by VILI in endotoxemia rats." | 7.77 | Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats. ( Chen, CH; Huang, CJ; Tsai, PS; Wang, TY; Yang, CL, 2011) |
| "Our aims were to evaluate the efficacy of ozone therapy (OT) in an experimental rat model of acute necrotizing pancreatitis (ANP) and to compare its effects with hyperbaric oxygen (HBO) therapy in this entity." | 7.76 | Efficacy of hyperbaric oxygen therapy and medical ozone therapy in experimental acute necrotizing pancreatitis. ( Cayc, T; Coskun, O; Ersoz, N; Guven, A; Kilic, A; Korkmaz, A; Kurt, B; Oter, S; Uysal, B; Yasar, M, 2010) |
| "In the present study the effectiveness of different diazepam-ketamine combinations to control kainic acid-induced status epilepticus in rats was evaluated." | 7.76 | The control of kainic acid-induced status epilepticus. ( Clinckers, R; Massie, A; Michotte, Y; Smolders, I; Vermoesen, K, 2010) |
| "Rats were subjected to hemorrhagic shock with or without subsequent Gram-negative bacterial sepsis and were either treated with ketamine 5 mg/kg or were not treated." | 7.75 | Ketamine delays mortality in an experimental model of hemorrhagic shock and subsequent sepsis. ( Artru, A; Czeiger, D; Douvdevani, A; Grinberg, G; Shaked, G; Shapira, Y; Sufaro, Y, 2009) |
| "To observe the symptoms similar to schizophrenia in mice after ketamine single or continuous injection and to evaluate the feasibility of schizophrenia model injected with different dose of ketamine." | 7.75 | [Behavior study of ketamine-induced symptoms similar to schizophrenia in mice]. ( Bian, SZ; Gu, ZL; Guo, CY; Jiang, XG; Liu, WL; Zhao, YB, 2009) |
| "To explore the correlation between signs similar to schizophrenia in mice after ketamine administration and the expressions of NRG1 and ErbB4 mRNA in order to explain the possible pathogenesis of schizophrenia." | 7.75 | [The correlation between ketamine-induced schizophrenia-like signs in mice and the expressions of NRG1, ErbB4 mRNA]. ( Bian, SZ; Gu, ZL; Guo, CY; Jiang, XG; Liu, WL; Zhang, ZX, 2009) |
| "To observe the effects of ketamine on bronchial hyperresponsiveness and airway inflammation in equal asthma." | 7.74 | [Protective effects of ketamine on allergen-induced airway inflammatory injure and high airway reactivity in asthma: experiment with rats]. ( Ding, ZN; Fu, CZ; Qian, YN; Rong, HB; Xu, YM; Zhu, MM; Zhu, W, 2007) |
| "To determine if the inhibitory effects of ketamine on the extracellular signal-regulated kinase (ERK) 1/2 are involved in reduction of the hyperglycemia-exaggerated cerebral ischemic lesion, rats with normoglycemia, hyperglycemia, or hyperglycemia supplemented with ketamine were subjected to 15 min of forebrain ischemia, and then, reperfusion for 0." | 7.74 | Inhibitory effect of ketamine on phosphorylation of the extracellular signal-regulated kinase 1/2 following brain ischemia and reperfusion in rats with hyperglycemia. ( Guo, FY; Jing, L; Ma, Y; Wang, YL; Zhang, JZ, 2007) |
| "Hypernatremia increases the speed of transition from different steps of ketamine/xylazine anesthesia with significant delay in immobility period and recovery from anesthesia in rats, hence, anesthetic dose reduction in hypernatremia is necessary." | 7.74 | Determination of sensitivity of male Wistar rats to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia in comparison with control group. ( Amini, B; Heydarpour, F; Heydarpour, P; Kalantari, S; Rostami, A, 2007) |
| "Pretreatment with intravenous ketamine inhibits inflammatory pain behavior and FLI expression following a formalin injection in rats, suggesting that pretreatment of ketamine plays an important role in preemptive analgesia." | 7.73 | Preemptive effect of intravenous ketamine in the rat: concordance between pain behavior and spinal fos-like immunoreactivity. ( Lee, IH; Lee, IO, 2005) |
| " He received therapeutic coma with intravenous diazepam and sodium thiopental to maintain an electroencephalographic burst suppression pattern, which was maintained for a period of 46 h, as well as intravenous ketamine (48 mg/kg/day) as a continuous infusion and ribavirin (48 to 128 mg/kg/day) via a nasogastric tube." | 7.73 | Failure of therapeutic coma and ketamine for therapy of human rabies. ( Desudchit, T; Hemachudha, T; Jackson, AC; Khawplod, P; Sittipunt, C; Suankratay, C; Sunsaneewitayakul, B; Wacharapluesadee, S; Wilde, H, 2006) |
| "It was investigated whether subchronic application of 30 mg/kg ketamine (Ket) induces reliable changes in behaviour and parameters of dopaminergic, glutamatergic, and serotonergic neurotransmissions, which might be the basis of an animal model in schizophrenia research." | 7.72 | Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. ( Becker, A; Grecksch, G; Huether, G; Mann, T; Peters, B; Schroeder, H, 2003) |
| " Here, we examine two neuroprotective agents, the noncompetitive NMDA antagonist ketamine and the dopaminergic antagonist acepromazine, for their efficacy in attenuating cognitive impairments in the lithium-pilocarpine (LI-PILO) model of rat limbic epilepsy." | 7.72 | Normal spatial and contextual learning for ketamine-treated rats in the pilocarpine epilepsy model. ( McKay, BE; Persinger, MA, 2004) |
| "We investigated whether repeated application of subanesthetic doses of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine, which has been shown to mimic model aspects of schizophrenia in animals, affects the hippocampal neurogenesis detected by bromodeoxyuridine incorporation." | 7.72 | Increased neurogenesis in a rat ketamine model of schizophrenia. ( Becker, A; Bernstein, HG; Grecksch, G; Keilhoff, G; Wolf, G, 2004) |
| "In dogs, intraoperative cardiac tamponade caused comparable changes in RBF under the different anesthetic techniques except that autoregulation was effective in maintaining RBF within the central nervous system only under isoflurane anesthesia." | 7.72 | Isoflurane preserves central nervous system blood flow during intraoperative cardiac tamponade in dogs. ( Crystal, GJ; Metwally, AA; Salem, MR, 2004) |
| "Previously, it was shown that subchronic application of the NMDA receptor antagonist ketamine (Ket) induces schizophrenia-related alterations, e." | 7.72 | Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. ( Becker, A; Grecksch, G, 2004) |
| " Since sedation of animals is necessary to avoid artifacts, a mixture of ketamine and xylazine is frequently used for anesthesia." | 7.72 | Ketamine/xylazine anesthesia for radiologic imaging of neurologically impaired rats: dose response, respiratory depression, and management of complications. ( Dittmar, MS; Fehm, NP; Horn, M; Vatankhah, B, 2004) |
| "Ketamine and PCP are commonly used as selective NMDA receptor antagonists to model the putative hypoglutamate state of schizophrenia and to test new antipsychotics." | 7.71 | NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. ( Kapur, S; Seeman, P, 2002) |
| " Sodium fluoride-induced cerebral ischemia in mice is used as a model of circulatory ischemic lesion." | 7.70 | [The use of ketamine in an experimental model of generalized cerebral ischemia]. ( Karaivanova, M; Konstantinov, S; Konstantinova, Zh; Nachkov, Ia; Stamenova, P; Vasilev, D, 1998) |
| "The aim of the present study was to observe the effect of repeated subcutaneous (sc) injections of low doses of ketamine for the treatment of acute inflammatory pain in a complete Freund's adjuvant-induced monoarthritic pain model in rats." | 7.70 | Repeated administration of low dose ketamine for the treatment of monoarthritic pain in the rat. ( Cao, Y; Han, JS; Huang, C; Wang, Y, 2000) |
| "The effects of prophylactic and delayed treatment with indomethacin were evaluated in a porcine model of early adult respiratory distress syndrome (ARDS) induced by endotoxaemia." | 7.67 | Prophylactic and delayed treatment with indomethacin in a porcine model of early adult respiratory distress syndrome induced by endotoxaemia. ( Borg, T; Gerdin, B; Modig, J, 1986) |
| "The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas." | 6.82 | BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression. ( Carboni, E; Carta, AR, 2022) |
| "Ketamine was also efficacious in decreasing the level of inflammation with an evident reduction in microglial activation and pro-inflammatory cytokines in the studied regions, following CUMS exposure." | 5.72 | Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. ( Akinluyi, ET; Anyanwu, CC; Edem, EE; Enye, LA; Fafure, AA; Ishola, AO; Nebo, KE, 2022) |
| "Ketamine is an anesthetic drug that is widely used in human and veterinary medicine." | 5.72 | Downregulation of the NLRP3/Caspse-1 Pathway Ameliorates Ketamine-Induced Liver Injury and Inflammation in Developing Rats. ( Chen, X; Gao, L; Li, S; Ma, X; Qiu, D; Shen, M; Zhang, Z, 2022) |
| "Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors." | 5.72 | Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine. ( Fan, W; Liao, L; Liu, B; Wei, Y; Wen, D; Xiao, L; Yang, H; Ye, Y; Zou, J, 2022) |
| "Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate receptors (NMDARs)." | 5.72 | Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia. ( Cheng, A; Fan, W; Fu, Y; Liao, L; Wang, X; Wei, Y; Wen, D; Xiao, L; Yang, H; Ye, Y, 2022) |
| "Chronic neuropathic pain can modulate DNA methylation in target genes related to neuroplasticity and mood regulation, which was induced by DNA methyltransferases (DNMTs)." | 5.62 | Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine. ( He, X; Ji, MH; Liu, R; Shen, JC; Wang, RZ; Wu, XM; Yin, XY; Zhou, F, 2021) |
| "Since neural pathways can modulate acute pancreatitis severity, we asked if Ket/Xyl affect disease severity." | 5.62 | Ketamine and xylazine effects in murine model of acute pancreatitis. ( Gorelick, FS; Wang, M, 2021) |
| "Ketamine was used to establish an animal model of schizophrenia." | 5.56 | mTOR Expression in Hippocampus and Prefrontal Cortex Is Downregulated in a Rat Model of Schizophrenia Induced by Chronic Administration of Ketamine. ( Chen, F; Liao, L; Wang, X; Xie, J; Xie, R; Yan, Y; Yang, L; Ye, Y, 2020) |
| "Patients with major depressive disorder (MDD) often have structural and functional deficits in the ventromedial prefrontal cortex (vmPFC), but the underlying molecular pathways are incompletely understood." | 5.51 | VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. ( Jiang, C; Labonté, B; Lin, WJ; Nestler, EJ; Russo, SJ; Salton, SR; Tamminga, CA; Turecki, G, 2019) |
| "Ketamine acts as a rapid clinical antidepressant at 25 min after injection with effects sustained for 7 days." | 5.51 | Differences between ketamine's short-term and long-term effects on brain circuitry in depression. ( Becker, R; Cosa-Linan, A; Gass, N; Reinwald, J; Sack, M; Sartorius, A; Vollmayr, B; Weber-Fahr, W, 2019) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 5.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "Schizophrenia is a complex neuropsychiatric disorder characterized by hallucinations, delusions, anhedonia, flat affect and cognitive impairments." | 5.48 | Prenatal exposure to ketamine in rats: Implications on animal models of schizophrenia. ( Coronel-Oliveros, CM; Pacheco-Calderón, R, 2018) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population." | 5.48 | Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018) |
| "Depression is present in a large proportion of patients suffering from chronic pain, and yet the underlying mechanisms remain to be elucidated." | 5.48 | Ketamine differentially restores diverse alterations of neuroligins in brain regions in a rat model of neuropathic pain-induced depression. ( Ji, MH; Li, HH; Li, KY; Pan, W; Yang, JJ; Zhang, GF; Zhou, ZQ, 2018) |
| "On the 14th day of treatment, schizophrenia-like symptoms were evaluated by the prepulse inhibition of the startle reflex (PPI), locomotor activity evaluated by the open field test (OFT), spatial recognition memory evaluated by the Y-maze task and social interaction test (SIT)." | 5.48 | Ethanolic extract of Erythrina velutina Willd ameliorate schizophrenia-like behavior induced by ketamine in mice. ( de Sousa, FCF; Dias, KCF; Dos Santos Júnior, MA; Jucá, MM; Leal, LKAM; Silva, AH; Vasconcelos, GS; Vasconcelos, SMM; Viana, GSB; Ximenes, NC, 2018) |
| "Schizophrenia is a chronic and devastating disease with an overall lifetime risk of 1%." | 5.46 | Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. ( Hauser, MJ; Isbrandt, D; Roeper, J, 2017) |
| " The present study aimed to investigate the effects of the typical antipsychotic chlorpromazine (CP) alone or combined with the natural antioxidant alpha-lipoic acid (ALA) on changes in the hippocampal average spectral power induced by ketamine (KET)." | 5.46 | Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017) |
| "Ketamine has been extensively studied for its antidepressant potential, with promising results in both preclinical and clinical studies." | 5.46 | Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats. ( Babinska, Z; Ruda-Kucerova, J, 2017) |
| " Systemic nicotine given before the sample phase of the CMOR task reversed the ketamine-induced impairment, but this effect was blocked by co-administration of the GABAA receptor antagonist bicuculline at a dosage that itself did not cause impairment." | 5.42 | α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia. ( Cloke, JM; Winters, BD, 2015) |
| "Ketamine treatment reduced the number of cells that expressed PV in the PFC by ∼60% as previously described." | 5.42 | Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice. ( Driskill, C; Jeevakumar, V; Kroener, S; Morris, B; Paine, A; Ramos, J; Sobhanian, M; Vakil, H, 2015) |
| "5 improved most of the parameters evaluated in this study without causing motor impairment demonstrating, thus, that possibly when combined with ALA a lower dose of CLZ is required." | 5.42 | Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. ( de Lucena, DF; de Sousa, CN; Gama, CS; Lima, LL; Macêdo, D; Oliveira, Tde Q; Vasconcelos, GS; Vasconcelos, SM; Ximenes, NC, 2015) |
| "Ketamine-treated rats were found to display bladder hyperactivity." | 5.42 | Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum. ( Chuang, SM; Ho, WT; Jang, MY; Juan, YS; Lee, YL; Lin, RJ; Liu, KM; Long, CY; Lu, JH; Lu, MC; Wang, CC; Wu, WJ, 2015) |
| "Ketamine is a centrally acting agent believed to work through blockade of N-methyl-D- aspartate receptors and is being increasingly used for the treatment of refractory CRPS, although the basis for the drug's effects and efficacy at different stages of the syndrome remains unclear." | 5.42 | Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice. ( Clark, JD; Huang, TT; Kingery, WS; Leu, D; Tajerian, M; Yang, P, 2015) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 5.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| "Ketamine is an analgesic/anesthetic drug, which, in combination with other drugs, has been used as anesthetic for over 40 years." | 5.38 | Improved methods for thermal rearrangement of alicyclic α-hydroxyimines to α-aminoketones: synthesis of ketamine analogues as antisepsis candidates. ( Byk, G; Douvdevani, A; Eini, H; Elhawi, H, 2012) |
| "Schizophrenia is a complex and debilitating disorder, characterized by positive, negative, and cognitive symptoms." | 5.38 | Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia. ( Clementino, KJ; Goel, A; Hall, AW; Jacklin, DL; Talpos, JC; Winters, BD, 2012) |
| "Ketamine was able to diminish alterations induced by I/R." | 5.36 | Ketamine and the myenteric plexus in intestinal ischemia/reperfusion injury. ( Alarcón-Galván, G; Ballesteros-Elizondo, RG; Cámara-Lemarroy, CR; Cordero-Pérez, P; Fernández-Garza, NE; Guzmán-de la Garza, FJ, 2010) |
| "Ketamine pretreatment was administered by intraperitoneal injections at doses of 100, 50, 12." | 5.36 | Ketamine reduces intestinal injury and inflammatory cell infiltration after ischemia/reperfusion in rats. ( Alarcón-Galván, G; Ballesteros-Elizondo, RG; Cámara-Lemarroy, CR; Cordero-Pérez, P; Fernández-Garza, NE; Guzmán-De La Garza, FJ, 2010) |
| "Pretreatment with risperidone (0." | 5.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| " Transient MCAO was induced during either isoflurane or ketamine/xylazine (ket/xyl) anesthesia with simultaneously measurement of cerebral blood flow (CBF) in 60 male Wistar rats (380-420 g)." | 5.17 | Effect of anesthesia and cerebral blood flow on neuronal injury in a rat middle cerebral artery occlusion (MCAO) model. ( Bleilevens, C; Dang, J; Goetzenich, A; Hein, M; Kipp, M; Roehl, AB; Rossaint, R; Tolba, R; Zoremba, N, 2013) |
| "Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades." | 5.01 | Rodent ketamine depression-related research: Finding patterns in a literature of variability. ( Fitzgerald, PJ; Hale, PJ; Polis, AJ; Watson, BO, 2019) |
| "Although the robust antidepressant effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown." | 5.01 | Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. ( Hashimoto, K; Luo, A; Yang, C; Yang, J, 2019) |
| "The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia." | 4.98 | Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. ( Curic, S; Haaf, M; Leicht, G; Mulert, C, 2018) |
| " ketamine; deep brain stimulation) that are reported to be effective in treatment-resistant depression and (iv) a parallel to a known clinical risk factor." | 4.91 | Treatment-resistant depression: are animal models of depression fit for purpose? ( Belzung, C; Willner, P, 2015) |
| "Subanesthetic doses of the psychomimetic, ketamine, have been used for many years to elicit behavioral effects reminiscent of schizophrenia in both healthy humans and in animal models of the disease." | 4.89 | Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. ( Brown, RE; Hajos, M; Kocsis, B; McCarley, RW, 2013) |
| "Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors." | 4.88 | Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. ( Heresco-Levy, U; Javitt, DC; Umbricht, D; Zukin, SR, 2012) |
| "The research of the glutamatergic system in schizophrenia has advanced with the use of non-competitive antagonists of glutamate NMDA receptors (phencyclidine, ketamine, and dizocilpine), which change both human and animal behaviour and induce schizophrenia-like manifestations." | 4.84 | Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. ( Bubeníková-Valesová, V; Horácek, J; Höschl, C; Vrajová, M, 2008) |
| "The NMDA antagonist ketamine demonstrated a fast antidepressant activity in treatment-resistant depression." | 4.31 | Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons. ( Belloch, FB; Cortés-Erice, M; Díaz-Perdigon, T; Herzog, E; Puerta, E; Tordera, RM; Zhang, XM, 2023) |
| " The sucrose consumption test, forced swim test, open field test, elevated plus maze, and Morris water maze were respectively used to assess anhedonia, behavioral despair, general locomotor activity, anxiety-like behavior and spatial reference memory." | 4.31 | Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress. ( Kingir, E; Sevinc, C; Unal, G, 2023) |
| "This study aimed to determine effects of the resveratrol on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice." | 4.31 | Resveratrol plays neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. ( Farkhakfar, A; Hassanpour, S; Zendehdel, M, 2023) |
| "This study aimed to evaluate Haloperidol's (Hal) effects on the behavioral, neurotrophic factors, and epigenetic parameters in an animal model of schizophrenia (SCZ) induced by ketamine (Ket)." | 4.31 | Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine. ( da Rosa, RT; Dal-Pont, GC; Daminelli, T; Fries, GR; Mastella, GA; Quevedo, J; Valvassori, SS; Varela, RB; Zugno, AI, 2023) |
| "The use of ketamine, an anesthetic, as a treatment for asthma has been investigated in numerous studies." | 4.12 | Ketamine Attenuates Airway Inflammation via Inducing Inflammatory Cells Apoptosis and Activating Nrf2 Pathway in a Mixed-Granulocytic Murine Asthma Model. ( Wang, Q; Xiao, S; Yang, D; Zhou, Y, 2022) |
| " The present study was conducted to develop curcumin-loaded nanophytosome (CNP) and explore their therapeutic potential in a ketamine (KET)-induced schizophrenia (SCZ) model." | 4.02 | Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. ( Bavaghar, B; Maboudi, K; Moghaddam, AH; Sangdehi, SRM; Zare, M, 2021) |
| " Therefore, we propose a hypothesis that diazepam monotherapy or diazepam-ketamine dual therapy could terminate seizures and reduce mortality in the SE model at different time points during ongoing SE." | 4.02 | Diazepam Monotherapy or Diazepam-Ketamine Dual Therapy at Different Time Points Terminates Seizures and Reduces Mortality in a Status Epilepticus Animal Model. ( Cao, X; Li, Z; Wang, Y; Yu, J; Zhou, R, 2021) |
| "Delayed emergence from anesthesia was previously reported in a case study of a child with Glycine Encephalopathy." | 4.02 | Elevated preoptic brain activity in zebrafish glial glycine transporter mutants is linked to lethargy-like behaviors and delayed emergence from anesthesia. ( Bindernagel, R; Buglo, E; Dallman, JE; Engert, F; Kelz, MB; Meng, QC; Randlett, O; Sloan, SA; Stark, MJ; Sumathipala, SH; Syed, S; Venincasa, MJ; Yan, Q; Züchner, S, 2021) |
| "The development of refractory status epilepticus (SE) induced by sarin intoxication presents a therapeutic challenge." | 4.02 | Neuroprotection by delayed triple therapy following sarin nerve agent insult in the rat. ( Baranes, S; Chapman, S; David, T; Dekel Jaoui, H; Efrati, R; Egoz, I; Gez, R; Gore, A; Grauer, E; Lazar, S; Neufeld-Cohen, A; Yampolsky, M, 2021) |
| "(R,S)-ketamine causes rapid-acting and sustained antidepressant effects in treatment-resistant patients with depression although the precise molecular mechanisms underlying its antidepressant action remain unclear." | 4.02 | Intranasal administration of transforming growth factor-β1 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: A role of TrkB signaling. ( Chang, L; Hashimoto, K; Wei, Y, 2021) |
| "Here, we used the drug-discrimination paradigm to allow rats that model a risk factor for schizophrenia (maternal immune activation, MIA) to report on the subjective internal state produced by a subanesthetic dose of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine." | 4.02 | Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk. ( Bilkey, D; Elston, TW; Meighan, W; Ward, RD, 2021) |
| " In this study, we examined whether (R)-ketamine could prevent against lethal sepsis-induced systemic inflammation and inflammatory organ injury." | 4.02 | (R)-Ketamine ameliorates lethal inflammatory responses and multi-organ injury in mice induced by cecum ligation and puncture. ( Hashimoto, K; Hashimoto, Y; Ma, L; Qu, Y; Shan, J; Wan, X; Zhang, J, 2021) |
| "Background Ketamine-related cystitis (KC) has been researched in many clinical studies, but its exact mechanism is ambiguous and needs further research." | 4.02 | Ketamine enhances autophagy and endoplasmic reticulum stress in rats and SV-HUC-1 cells via activating IRE1-TRAF2-ASK1-JNK pathway. ( Li, Y; Qiao, H; Shan, Z; Wu, D; Yu, Y, 2021) |
| " Osteoarthritis was induced in male adult control Wistar rats without any interventions and in Wisket rats after juvenile social isolation and ketamine treatment." | 3.96 | Distinct changes in chronic pain sensitivity and oxytocin receptor expression in a new rat model (Wisket) of schizophrenia. ( Banki, L; Büki, A; Horvath, G; Jancsó, G; Kekesi, G; Kis, G; Somogyvári, F; Tuboly, G; Varga, E; Vécsei, L, 2020) |
| "Cannabidiol (CBD), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia." | 3.96 | Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats. ( Juknat, A; Kos, T; Kozela, E; Krawczyk, M; Popik, P; Vogel, Z, 2020) |
| "Here we show that mice prenatally exposed to ketamine displayed anxiety-like behaviors during adulthood, but not during puberty." | 3.96 | Prenatal Exposure to Ketamine Leads to Anxiety-Like Behaviors and Dysfunction in Bed Nucleus of Stria Terminalis. ( Chen, Y; Feng, X; Guo, H; Hu, Y; Li, Y; Lin, J; Lin, L; Liu, T; Lu, Z; Sun, J; Xu, S, 2020) |
| "In rodent models of depression, (R)-ketamine has greater potency and longer-lasting antidepressant effects than (S)-ketamine; however, the precise molecular mechanisms underlying the antidepressant actions of (R)-ketamine remain unknown." | 3.96 | Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. ( Chang, L; Fujita, Y; Hashimoto, K; Hatano, M; Ishima, T; Pu, Y; Qu, Y; Sakamoto, A; Shirayama, Y; Suzuki, T; Tan, Y; Tanaka, KF; Wang, S; Wang, X; Yang, C; Zhang, K, 2020) |
| " Here we aimed to compare the effects of (R)-norketamine ((R)-NK), (S)-NK, (2R,6R)-HNK, and (2S,6S)-HNK in a mouse model of depression induced by chronic corticosterone (CORT) injection." | 3.96 | (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. ( Ago, Y; Chen, L; Hashimoto, H; Hashimoto, K; Higuchi, M; Kasai, A; Naito, M; Nakagawa, S; Nakazawa, T; Seiriki, K; Tanabe, W; Tsukada, S; Yamaguchi, T; Yokoyama, R, 2020) |
| "To induce schizophrenia, ketamine was administered at a dose of 25 mg/kg i." | 3.96 | Potential therapeutic antipsychotic effects of Naringin against ketamine-induced deficits in rats: Involvement of Akt/GSK-3β and Wnt/β-catenin signaling pathways. ( El-Demerdash, E; Esmat, A; George, MY; Menze, ET; Tadros, MG, 2020) |
| "Arc-CreERT2 × CAG-Sun1/sfGFP mice showed sex differences in social and anxiety behavior and a different pattern between ketamine and (2R,6R)-HNK in the FST in male and female mice." | 3.96 | Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hydroxynorketamine Administration. ( Herzog, DP; Lutz, B; Mellema, RM; Müller, MB; Remmers, F; Treccani, G, 2020) |
| "The antioxidant and cardioprotective effects of oleuropein have been reported in several studies; however, its effect on ketamine cardiotoxicity has not been known yet." | 3.96 | Protective effect of oleuropein on ketamine-induced cardiotoxicity in rats. ( Aydın, T; Borazan, Y; Çakır, A; Cellat, M; Çömez, MS; Gökçek, İ; Güvenç, M; Özkan, H; Özsoy, ŞY; Türk, E, 2020) |
| " Ketamine produces a rapid-onset and sustained antidepressant response, but there is no evidence whether ketamine treatment is effective for GWI depression." | 3.96 | Molecular mechanisms for the antidepressant-like effects of a low-dose ketamine treatment in a DFP-based rat model for Gulf War Illness. ( Deshpande, LS; Hawkins, E; Jahr, FM; Kronfol, MM; McClay, JL; Ribeiro, ACR; Younis, RM; Zhu, J, 2020) |
| " Considering that ketamine has significant knock-on effects, this study investigated the effects of a single coadministration with subthreshold doses of ketamine plus guanosine in a corticosterone (CORT)-induced animal model of depression and the role of anti-inflammatory and antioxidant pathways." | 3.96 | Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling. ( B Zeni, AL; Camargo, A; Dalmagro, AP; M Rosa, J; P Kaster, M; S Rodrigues, AL; Tasca, CI, 2020) |
| "To evaluate the possible neuroprotective effects of ketamine and dantrolene on the hippocampal apoptosis and spatial learning in rats exposed to repeated electroconvulsive seizures (ECS) as a model of status epilepticus (SE)." | 3.96 | Investigation of the Possible Protective Effects of Ketamine and Dantrolene on the Hippocampal Apoptosis and Spatial Learning in Rats Exposed to Repeated Electroconvulsive Seizures as a Model of Status Epilepticus. ( Atilla, P; Barun, S; Canpinar, H; Erdem, SR; Ertunc, M; Gursoy, ID; Keskin, U; Kiziltas, M; Muftuoglu, S; Narin, F; Sara, Y; Yuce, D, 2020) |
| "Ketamine has been clinically proven to ameliorate depression, including treatment-resistant depression." | 3.96 | Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model. ( Kitamura, Y; Sendo, T; Takahashi, K; Ushio, S, 2020) |
| " These were then tested experimentally using the NMDA-R antagonist ketamine, a pharmacological model of schizophrenia." | 3.96 | A circuit mechanism for decision-making biases and NMDA receptor hypofunction. ( Cavanagh, SE; Hunt, LT; Kennerley, SW; Lam, NH; Murray, JD, 2020) |
| "In CFA-treated mice that exhibited pain behavior and depression-like behavior, ketamine reversed depression-like behavior." | 3.96 | Subanesthetic Dose of Ketamine Improved CFA-induced Inflammatory Pain and Depression-like Behaviors Via Caveolin-1 in Mice. ( Han, R; Han, S; Li, J; Peng, Y; Sun, W; Wang, J; Zhao, Q; Zhou, Y, 2020) |
| "Ketamine induced drastic schizophrenia-like behaviors, lower protein levels of BDNF and PSD-95, and a change in the synaptic ultrastructure in the PCC." | 3.91 | Applying vinpocetine to reverse synaptic ultrastructure by regulating BDNF-related PSD-95 in alleviating schizophrenia-like deficits in rat. ( Deng, C; Fu, B; Liu, N; Xu, Y; Zheng, Y, 2019) |
| " The aim of the study was to investigate effects of pre-treatment with Morphine or Ketamine on hemodynamic, acid-base status, early survival, and biochemical markers of brain damage in a rat model of asphyxial cardiac arrest (ACA)." | 3.91 | The influences of morphine or ketamine pre-treatment on hemodynamic, acid-base status, biochemical markers of brain damage and early survival in rats after asphyxial cardiac arrest. ( Akhatov, N; Baigenzhin, A; Barlow, N; Dahl, V; Karibekov, T; Kondratiev, T; Konkayev, A; Konkayeva, M; Kuklin, V; Tveita, T, 2019) |
| "After peri-adolescence isolation rearing (IS) and subchronic ketamine (KET) treatment, adult, selectively bred Wistar rats (named WISKET) mimic abnormal behaviors reminiscent of human schizophrenia, including reduced prepulse-inhibition of startle reflex, disturbances in cognition, locomotor activity and thermoregulation, decreased pain sensitivity and electrophysiological alterations." | 3.91 | Impaired GAD1 expression in schizophrenia-related WISKET rat model with sex-dependent aggressive behavior and motivational deficit. ( Benedek, G; Büki, A; Ducza, E; Horvath, G; Kekesi, G, 2019) |
| "A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine." | 3.91 | Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. ( Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P, 2019) |
| "To study the effects of the standardized extract from the leaves of Erythrina velutina in behavioural and oxidative parameters in the ketamine-induced schizophrenia model." | 3.91 | Standardized extract of Erythrina velutina Willd. attenuates schizophrenia-Like behaviours and oxidative parameters in experimental animal models. ( Barbosa, TM; de Almeida, JC; Dias, KCF; Honório Junior, JER; Leal, LKAM; Leitão, APA; Louchard, BO; Patrocínio, MLV; Pimenta, ATÁ; Pinto, FDCL; Vasconcelos, LC; Vasconcelos, SMM; Ximenes, NC, 2019) |
| "The purpose of this study was to explore the possible interaction between ketamine and cannabinoid system in the modulation of depression-related responses using the forced swimming test (FST), tail suspension test (TST) and open-field test (OFT) in mice." | 3.91 | Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system. ( Alijanpour, S; Ebrahimi-Ghiri, M; Khakpai, F; Zarrindast, MR, 2019) |
| "The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine produces rapid and sustained antidepressant effects in treatment-resistant patients with depression although intranasal use of (R,S)-ketamine in ketamine abusers is popular." | 3.91 | Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. ( Chang, L; Dong, C; Fujita, Y; Hashimoto, K; Pu, Y; Qu, Y; Ren, Q; Wang, SM; Xiong, Z; Zhang, K, 2019) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| "The present study investigated the methylation of CpG sites in the cyclooxygenase (COX)‑2 promoter via nuclear factor (NF)‑κB transcriptional regulation and elucidated its effect on the COX‑2 transcriptional expression in a ketamine‑induced ulcerative cystitis (KIC) animal model." | 3.91 | Epigenetic regulation of COX‑2 expression by DNA hypomethylation via NF‑κB activation in ketamine‑induced ulcerative cystitis. ( Chuang, SM; Hsiao, HP; Juan, YS; Lee, YC; Lin, KL; Long, CY; Lu, JH; Tsai, CC; Wu, WJ; Yang, HJ, 2019) |
| "Our findings suggest that skeletal muscular glycine contributes to the antidepressant effects of ketamine in inflammation." | 3.91 | Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression. ( Hua, D; Hua, F; Huang, N; Jiang, R; Li, S; Luo, A; Wang, Y; Wu, Y; Yang, C; Yang, L; Yu, F; Zhan, G; Zhu, B, 2019) |
| " Thus, the aim of this study was (1) to evaluate the cognitive effects and biochemical markers produced by the AIN-93 diet (control), the AIN-93 diet supplemented with different doses of FA (5, 10, and 50 mg/kg), and a FA-deficient diet during pregnancy and lactation in female mother rats (dams) and (2) to evaluate the effect of maternal diets on inflammatory parameters in the adult offspring which were subjected to an animal model of schizophrenia (SZ) induced by ketamine (Ket)." | 3.88 | The Evaluation of Folic Acid-Deficient or Folic Acid-Supplemented Diet in the Gestational Phase of Female Rats and in Their Adult Offspring Subjected to an Animal Model of Schizophrenia. ( Alves, CSV; Barcellos, AS; Budni, J; Canever, L; Citadin, S; Damázio, L; De Luca, LA; Garcez, ML; Mastella, G; Polla, JV; Quevedo, J; Zugno, AI, 2018) |
| "The use of ketamine (Ket) as a pharmacological model of schizophrenia is an important tool for understanding the main mechanisms of glutamatergic regulated neural oscillations." | 3.88 | Average spectral power changes at the hippocampal electroencephalogram in schizophrenia model induced by ketamine. ( Barbosa, TM; Borges, LTN; Dantas, LP; de Andrade, FRO; do Vale, OC; Lima, RF; Macedo, D; Oliveira, TQ; Patrocinio, MCA; Sampaio, LRL; Silva, JMF; Vasconcelos, SMM, 2018) |
| " Also, they displayed higher levels of blood serum corticosterone, as well as decreased body weight." | 3.88 | Vicarious Social Defeat Stress Induces Depression-Related Outcomes in Female Mice. ( Alipio, JB; Braren, SH; Castillo, SA; Flores-Ramirez, FJ; Garcia-Carachure, I; Hernandez, MA; Iñiguez, SD; Lobo, MK; Riggs, LM; Sanchez, DO; Serrano, PA, 2018) |
| "Evidence has shown that the kynurenine pathway (KP) plays a role in the onset of oxidative stress and also in the pathophysiology of schizophrenia." | 3.88 | The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. ( Barichello, T; Becker, IRT; Ceretta, LB; Dal-Pizzol, F; Kaddurah-Daouk, R; Oses, JP; Petronilho, F; Quevedo, J; Réus, GZ; Scaini, G; Zugno, AI, 2018) |
| "(R)-Ketamine exhibits rapid and sustained antidepressant effects in animal models of depression." | 3.88 | Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine. ( Hashimoto, K; Shirayama, Y, 2018) |
| "A deficiency of maternal folic acid (FA) can compromise the function and development of the brain, and may produce a susceptibility to diseases such as schizophrenia (SZ) in the later life of offspring." | 3.88 | Changes in behavioural parameters, oxidative stress and neurotrophins in the brain of adult offspring induced to an animal model of schizophrenia: The effects of FA deficient or FA supplemented diet during the neurodevelopmental phase. ( Budni, J; Canever, L; Carvalho, G; Damázio, L; Fachim, I; Freire, TG; Gava, FF; Godói, AK; Gomes, S; Mastella, GA; Michels, C; Peterle, BR; Quevedo, J; Valvassori, SS; Zugno, AI, 2018) |
| "This study tested the effects of ketamine on vulnerability of female adolescent mice to activity-based anorexia (ABA)." | 3.88 | Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior. ( Aoki, C; Chen, YW; Sherpa, AD, 2018) |
| "Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia." | 3.85 | Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia. ( Babinska, Z; Micale, V; Ruda-Kucerova, J; Stark, T, 2017) |
| "Ketamine-induced ulcerative cystitis (KIC) initially damaged the bladder mucosa and induced contracted bladder thereafter." | 3.85 | Elucidating Mechanisms of Bladder Repair after Hyaluronan Instillation in Ketamine-Induced Ulcerative Cystitis in Animal Model. ( Chuang, SM; Ho, WT; Juan, YS; Lee, YC; Lee, YL; Lin, KL; Lu, MC; Wu, BN; Wu, WJ; Yuan, SF, 2017) |
| "Effects of a single bilateral infusion of R-enantiomer of ketamine in rat brain regions of learned helplessness model of depression were examined." | 3.85 | Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. ( Hashimoto, K; Shirayama, Y, 2017) |
| "The acute antidepressant effects of ketamine provide hope for the development of a fast acting approach to treat depression but the consequences of chronic treatment with ketamine are still unclear." | 3.85 | Lack of effect of chronic ketamine administration on depression-like behavior and frontal cortex autophagy in female and male ICR mice. ( Agam, G; Anderson, GW; Einat, H; Kara, NZ; Zitron, N, 2017) |
| "Immune dysregulation observed in schizophrenia alters tryptophan metabolism." | 3.85 | Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. ( Cordeiro, RC; da Silva Araújo, T; de Freitas Lima, R; de Jesus Souza Machado, M; Freitas de Lucena, D; Isabelle de Góis Queiroz, A; Macêdo, D; Maes, M; Maia Chaves Filho, AJ; Monte, AS, 2017) |
| "Ketamine has emerged as a novel strategy to treat refractory depression, producing rapid remission, but elicits some side effects that limit its use." | 3.83 | Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. ( Colla, AR; Cunha, MP; Lieberknecht, V; Oliveira, Á; Pazini, FL; Rodrigues, AL; Rosa, JM, 2016) |
| " In addition to anxiety and depressive-like behaviors, we previously showed that juvenile SIS increases susceptibility to pentylenetetrazole (PTZ)-induced seizures in mice through enhancing the nitrergic system activity in the hippocampus." | 3.83 | NMDA receptor antagonists attenuate the proconvulsant effect of juvenile social isolation in male mice. ( Amini-khoei, H; Amiri, S; Azizi, R; Dehpour, AR; Ghazi-Khansari, M; Haj-Mirzaian, A; Mehr, SE; Momeny, M; Rahimi-Balaei, M; Shirzadian, A; Zarrinrad, G, 2016) |
| "This study compared effects of the NMDA receptor antagonists ketamine and MK-801 in assays of pain-stimulated and pain-depressed behaviour in rats." | 3.83 | Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats. ( Hillhouse, TM; Negus, SS, 2016) |
| "The aim of the present study was to investigate the effects of ketamine, imipramine, and ketamine plus imipramine on chronic depression-like behaviors of Wistar Kyoto (WKY) rats and underlying mechanism." | 3.83 | [Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats]. ( Jin, XJ; Li, QQ; Peng, LC; Ye, K, 2016) |
| "The aim of the present study was to investigate the efficacy of ketamine in attenuating osteoarthritis (OA) and modulating the expression of inflammatory mediators." | 3.83 | Ketamine attenuates osteoarthritis of the knee via modulation of inflammatory responses in a rabbit model. ( Lu, W; Wang, L; Wo, C; Yao, J, 2016) |
| " It also sets out to verify any potential protective action using an animal model of schizophrenia induced by ketamine, in behavioral and biochemical parameters." | 3.83 | Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine. ( Budni, J; Calixto, OP; Canever, L; Damázio, LS; de Oliveira, MB; Heylmann, AS; Macan, TP; Mastella, GA; Pacheco, FD; Pedro, TH; Pereira, FP; Quevedo, J; Schuck, PF; Steckert, A; Wessler, PG; Zugno, AI, 2016) |
| "Abuse of the hallucinogenic drug ketamine promotes the development of lower urinary tract symptoms that resemble interstitial cystitis." | 3.83 | Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder. ( Choi, SJ; Choo, MS; Heo, J; Kim, A; Kim, SW; Kim, Y; Lee, S; Lim, J; Oh, W; Shin, DM; Shin, JH; Song, M; Yoon, SJ; Yu, HY, 2016) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression." | 3.83 | Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. ( Chen, QX; Han, M; Hashimoto, K; Ma, M; Ren, Q; Yang, B; Yang, C; Yao, W; Zhang, JC, 2016) |
| " jatamansi treatment exhibited encouraging results in the modulation of ketamine-induced schizophrenia-like behaviours, principally the positive symptoms." | 3.83 | Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced Schizophrenia-Like Symptoms in Rats. ( Janardhanan, A; Sadanand, A; Vanisree, AJ, 2016) |
| "We investigated whether the nitric oxide (NO) precursor, L-arginine, can prevent the antidepressant-like action of the fast-acting antidepressant, ketamine, in a genetic rat model of depression, and/or induce changes in the glutamate (Glu)/N-methyl-D-aspartate receptor (NMDAR)/NO/cyclic guanosine monophosphate (cGMP) signalling pathway." | 3.81 | Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression. ( Joca, S; Liebenberg, N; Wegener, G, 2015) |
| "Studies have suggested that ketamine, a nonselective NMDA receptor antagonist, could be a new drug in the treatment of major depression, but the way ketamine presents such effects remains to be elucidated." | 3.81 | Ketamine treatment partly reverses alterations in brain derived- neurotrophic factor, oxidative stress and energy metabolism parameters induced by an animal model of depression. ( Abelaira, HM; Carlessi, AS; da Luz, JR; dos Santos, MA; Jeremias, GC; Matias, BI; Morais, MO; Nacif, MP; Quevedo, J; Réus, GZ; Scaini, G; Steckert, AV; Streck, EL; Tomaz, DB, 2015) |
| "This study aimed to evaluate the effect of sepsis on behavioral changes on the ketamine-induced animal model of schizophrenia." | 3.81 | Effect of sepsis on behavioral changes on the ketamine-induced animal model of schizophrenia. ( Barichello, T; Bittencourt, MO; Cassol, OJ; Comim, CM; Dal-Pizzol, F; Mendonça, BP; Palmas, D; Patrício, JJ; Quevedo, J; Silva, NC; Zugno, AI, 2015) |
| "Ketamine, N-methyl-d-aspartate (NMDA) receptor antagonist and anti-inflammatory agent, has rapid therapeutic effects in a subset of patients with more intractable forms of depression." | 3.81 | Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. ( Foley, BM; Frye, MA; McGillivray, JA; Sutor, SL; Tye, SJ; Walker, AJ, 2015) |
| "CUMS induced depression-like behaviours and up-regulated the hippocampal levels of IL-1β, IL-6, TNF-α, IDO, and the KYN/TRP ratio, which were attenuated by a sub-anaesthetic dose of ketamine." | 3.81 | The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus. ( Gao, ZQ; Shen, XF; Wang, N; Yang, C; Yang, JJ; Yu, HY; Zhang, GF, 2015) |
| " Considering the lack of understanding concerning the pathophysiology of schizophrenia, the present study hypothesized that omega 3 prevents the onset of symptoms similar to schizophrenia in young Wistar rats submitted to ketamine treatment." | 3.80 | Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. ( Binatti, AR; Budni, J; Chipindo, HL; da Rosa Silveira, F; de Oliveira, MB; Gama, CS; Heylmann, AS; Maravai, SG; Mastella, GA; Panizzutti, B; Quevedo, J; Schuck, PF; Steckert, AV; Volpato, AM; Wessler, PG; Zugno, AI, 2014) |
| "Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, and group II metabotropic glutamate (mGlu2/3) receptor antagonists produce antidepressant effects in animal models of depression, which last for at least 24h, through the transient increase in glutamate release, leading to activation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptor." | 3.80 | Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. ( Chaki, S; Koike, H, 2014) |
| "We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression." | 3.80 | Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. ( Belujon, P; Grace, AA, 2014) |
| "Chronic administration of ketamine in an animal model of schizophrenia generates increased AChE levels in different brain tissues of rats that lead to cognitive deficits." | 3.80 | Evaluation of acetylcholinesterase activity and behavioural alterations induced by ketamine in an animal model of schizophrenia. ( Budni, J; Canever, L; De Luca, RD; de Oliveira, MB; Deroza, PF; Fraga, DB; Ghedim, FV; Matos, MP; Pacheco, FD; Quevedo, J; Valvassori, SS; Volpato, AM; Zugno, AI, 2014) |
| "In this study, we tested whether AMPA alone has an antidepressant effect and if the combination of AMPA and ketamine provides added benefit in Wistar-Kyoto rats, a putative animal model of depression." | 3.79 | Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. ( Akinfiresoye, L; Tizabi, Y, 2013) |
| " Ketamine/xylazine mixture induces hyperglycemia, although the mechanism involved is unknown." | 3.79 | Anesthetic-induced transient hyperglycemia and insulin resistance do not depend on the sympathoadrenal axis. ( Barella, LF; Cezar De Freitas Mathias, P; Chaves Souto Branco, R; De Oliveira, JC; Grassiolli, S; Gravena, C; Ludemann Camargo, R; Torrezan, R, 2013) |
| "Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine, provides a translational model with relevance to many of the symptoms of schizophrenia." | 3.79 | Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems. ( Dawson, N; Morris, BJ; Pratt, JA, 2013) |
| " To generate and validate a new substrain of rats with signs related to schizophrenia, we used selective breeding after postweaning social isolation and chronic ketamine treatment through several generations of animals and compared the subsequent strain to naive rats that were not genetically manipulated." | 3.79 | Characterization of gene-environment interactions by behavioral profiling of selectively bred rats: the effect of NMDA receptor inhibition and social isolation. ( Adam, G; Benedek, G; Horvath, G; Kekesi, G; Keri, S; Petrovszki, Z; Tuboly, G, 2013) |
| "Clinical studies demonstrate that the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, induces rapid antidepressant effects in patients with refractive major depressive disorder and bipolar depression." | 3.79 | Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. ( Dang, YH; Gao, CG; Hashimoto, K; Jia, M; Ma, R; Ma, XC; Wang, F; Wu, J, 2013) |
| "The aim of this study is to investigate the effects of pregabalin on the behavior of rats under the influence of ketamine, an NMDA receptor antagonist that mimics the symptoms of schizophrenia." | 3.78 | Effects of pregabalin on behavioral alterations induced by ketamine in rats. ( Baker, GB; Canever, L; Crippa, JA; Dursun, SM; Hallak, JE; Luca, RD; Nunes, EA; Oliveira, Ld; Peregrino, A; Quevedo, J; Zugno, A, 2012) |
| "To model schizophrenia-like cognitive inflexibility in rats, we evaluated the effects of repeated administration of ketamine, the noncompetitive antagonist of the N-methyl-D: -aspartate receptor, after a washout period of 14 days in the attentional set-shifting task (ASST)." | 3.78 | Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. ( Nikiforuk, A; Popik, P, 2012) |
| "5h) revealed anesthesia associated IFNγ-expression and lymphocyte activation which were not observed when animals were treated with ketamine/xylazine (p<0." | 3.78 | Inflammatory immune responses in a reproducible mouse brain death model. ( Floerchinger, B; Ge, X; Jurisch, A; Lee, YL; Schmid, C; Timsit, MO; Tullius, SG; Yuan, X, 2012) |
| "The data suggest that the combination of metoclopramide and ketamine synergistically controls acute pain in mice." | 3.78 | Antinociception by metoclopramide, ketamine and their combinations in mice. ( Al-Baggou, BKh; Mohammad, FK; Naser, AS, 2012) |
| " We hypothesized that the volatile anesthetic sevoflurane (SEVO) attenuates lung inflammation through activation of lung epithelial GABA(A) receptors." | 3.78 | Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury. ( Fortis, S; Haitsma, JJ; Lu, WY; Mazer, CD; Parotto, M; Slutsky, AS; Spieth, PM; Zhang, H; Zhong, N, 2012) |
| "The number of animals with seizures was lower in the etomidate (60%), phenytoin (40%), and phenytoin/midazolam (40%) groups (P<0." | 3.78 | Effects of pretreatment with etomidate, ketamine, phenytoin, and phenytoin/midazolam on acute, lethal cocaine toxicity. ( Degirmenci, E; Erdur, B; Ergin, A; Kortunay, S; Seyit, M; Yuksel, A, 2012) |
| "Isoflurane anesthesia reduced the recovery time and incidence of hypoglycemia and increased the survival rate in the early hours, providing a therapeutic window that is suitable for experimental studies." | 3.78 | The effects of anesthetic regimen in 90% hepatectomy in rats. ( Backes, AN; Cruz, CU; Kieling, CO; Matte, Uda S; Maurer, RL; Osvaldt, AB; Silveira, TR, 2012) |
| "Dexmedetomidine-ketamine combination could mitigate pulmonary inflammatory response induced by VILI in endotoxemia rats." | 3.77 | Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats. ( Chen, CH; Huang, CJ; Tsai, PS; Wang, TY; Yang, CL, 2011) |
| "Our aims were to evaluate the efficacy of ozone therapy (OT) in an experimental rat model of acute necrotizing pancreatitis (ANP) and to compare its effects with hyperbaric oxygen (HBO) therapy in this entity." | 3.76 | Efficacy of hyperbaric oxygen therapy and medical ozone therapy in experimental acute necrotizing pancreatitis. ( Cayc, T; Coskun, O; Ersoz, N; Guven, A; Kilic, A; Korkmaz, A; Kurt, B; Oter, S; Uysal, B; Yasar, M, 2010) |
| "In the present study the effectiveness of different diazepam-ketamine combinations to control kainic acid-induced status epilepticus in rats was evaluated." | 3.76 | The control of kainic acid-induced status epilepticus. ( Clinckers, R; Massie, A; Michotte, Y; Smolders, I; Vermoesen, K, 2010) |
| "Monocrotaline (MCT) is commonly used to experimentally induce pulmonary hypertension (PH), which might lead to chronic heart failure." | 3.76 | Analysis of heart rate variability in a rat model of induced pulmonary hypertension. ( Bernardes, J; Brandão-Nogueira, A; Gonçalves, H; Henriques-Coelho, T; Leite-Moreira, A; Rocha, AP, 2010) |
| "Ketamine-induced alterations in EEG power spectra are consistent with abnormalities in the theta and gamma frequency ranges reported in patients with schizophrenia." | 3.75 | N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. ( Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI, 2009) |
| "Although ketamine is widely used as an analgesic agent and has an anti-allodynic effect on neuropathic pain, the underlying analgesic mechanisms are not fully explained by the modern 'neuronal-based' theories." | 3.75 | Inhibiting astrocytic activation: a novel analgesic mechanism of ketamine at the spinal level? ( Li, Y; Mei, X; Wang, W; Wu, S; Xu, L; Zhang, H, 2009) |
| "Rats were subjected to hemorrhagic shock with or without subsequent Gram-negative bacterial sepsis and were either treated with ketamine 5 mg/kg or were not treated." | 3.75 | Ketamine delays mortality in an experimental model of hemorrhagic shock and subsequent sepsis. ( Artru, A; Czeiger, D; Douvdevani, A; Grinberg, G; Shaked, G; Shapira, Y; Sufaro, Y, 2009) |
| "To observe the symptoms similar to schizophrenia in mice after ketamine single or continuous injection and to evaluate the feasibility of schizophrenia model injected with different dose of ketamine." | 3.75 | [Behavior study of ketamine-induced symptoms similar to schizophrenia in mice]. ( Bian, SZ; Gu, ZL; Guo, CY; Jiang, XG; Liu, WL; Zhao, YB, 2009) |
| "To explore the correlation between signs similar to schizophrenia in mice after ketamine administration and the expressions of NRG1 and ErbB4 mRNA in order to explain the possible pathogenesis of schizophrenia." | 3.75 | [The correlation between ketamine-induced schizophrenia-like signs in mice and the expressions of NRG1, ErbB4 mRNA]. ( Bian, SZ; Gu, ZL; Guo, CY; Jiang, XG; Liu, WL; Zhang, ZX, 2009) |
| "04 mg/kg, subcutaneous) significantly enhanced mechanical allodynia and thermal hyperalgesia induced by the plantar incision during the postoperative period (each lasting between 2 h and 48 h), which was attenuated by pretreatment with ketamine (10 mg/kg, subcutaneous)." | 3.75 | Tyrosine phosphorylation of the N-Methyl-D-Aspartate receptor 2B subunit in spinal cord contributes to remifentanil-induced postoperative hyperalgesia: the preventive effect of ketamine. ( Cui, S; Gu, X; Liu, Y; Ma, Z; Wu, X, 2009) |
| "To observe the effects of ketamine on bronchial hyperresponsiveness and airway inflammation in equal asthma." | 3.74 | [Protective effects of ketamine on allergen-induced airway inflammatory injure and high airway reactivity in asthma: experiment with rats]. ( Ding, ZN; Fu, CZ; Qian, YN; Rong, HB; Xu, YM; Zhu, MM; Zhu, W, 2007) |
| "To determine if the inhibitory effects of ketamine on the extracellular signal-regulated kinase (ERK) 1/2 are involved in reduction of the hyperglycemia-exaggerated cerebral ischemic lesion, rats with normoglycemia, hyperglycemia, or hyperglycemia supplemented with ketamine were subjected to 15 min of forebrain ischemia, and then, reperfusion for 0." | 3.74 | Inhibitory effect of ketamine on phosphorylation of the extracellular signal-regulated kinase 1/2 following brain ischemia and reperfusion in rats with hyperglycemia. ( Guo, FY; Jing, L; Ma, Y; Wang, YL; Zhang, JZ, 2007) |
| "Hypernatremia increases the speed of transition from different steps of ketamine/xylazine anesthesia with significant delay in immobility period and recovery from anesthesia in rats, hence, anesthetic dose reduction in hypernatremia is necessary." | 3.74 | Determination of sensitivity of male Wistar rats to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia in comparison with control group. ( Amini, B; Heydarpour, F; Heydarpour, P; Kalantari, S; Rostami, A, 2007) |
| "Noncompetitive NMDA receptor antagonists, such as ketamine, induce a transient schizophrenia-like state in healthy individuals and exacerbate psychosis in schizophrenic patients." | 3.73 | Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats. ( Garcia, R; Hunt, MJ; Kessal, K, 2005) |
| "Pretreatment with intravenous ketamine inhibits inflammatory pain behavior and FLI expression following a formalin injection in rats, suggesting that pretreatment of ketamine plays an important role in preemptive analgesia." | 3.73 | Preemptive effect of intravenous ketamine in the rat: concordance between pain behavior and spinal fos-like immunoreactivity. ( Lee, IH; Lee, IO, 2005) |
| "Intra-arterial metabolic radiotherapy (using lipiodol labelled with iodine-131 or rhenium-188) is a therapeutic approach that can be used for the treatment of hepatocellular carcinomas (HCC)." | 3.73 | Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat. ( Benoit, JP; Bourguet, P; Denizot, B; Garin, E; Herry, JY; Laurent, JF; Lejeune, JJ; Lepareur, N; Mesba, H; Moreau, M; Noiret, N; Roux, J, 2005) |
| "To study alterations in pain sensitivity, the ketamine model in schizophrenia research was employed." | 3.73 | Pain sensitivity is altered in animals after subchronic ketamine treatment. ( Becker, A; Grecksch, G; Schröder, H, 2006) |
| " He received therapeutic coma with intravenous diazepam and sodium thiopental to maintain an electroencephalographic burst suppression pattern, which was maintained for a period of 46 h, as well as intravenous ketamine (48 mg/kg/day) as a continuous infusion and ribavirin (48 to 128 mg/kg/day) via a nasogastric tube." | 3.73 | Failure of therapeutic coma and ketamine for therapy of human rabies. ( Desudchit, T; Hemachudha, T; Jackson, AC; Khawplod, P; Sittipunt, C; Suankratay, C; Sunsaneewitayakul, B; Wacharapluesadee, S; Wilde, H, 2006) |
| "It was investigated whether subchronic application of 30 mg/kg ketamine (Ket) induces reliable changes in behaviour and parameters of dopaminergic, glutamatergic, and serotonergic neurotransmissions, which might be the basis of an animal model in schizophrenia research." | 3.72 | Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. ( Becker, A; Grecksch, G; Huether, G; Mann, T; Peters, B; Schroeder, H, 2003) |
| "Topically administered capsaicin produces thermal allodynia, and this effect has been used to investigate pain transduction and its pharmacological modulation." | 3.72 | Topical capsaicin-induced allodynia in unanesthetized primates: pharmacological modulation. ( Ball, JW; Butelman, ER; Harris, TJ; Kreek, MJ, 2003) |
| " We examined the behavior of rats treated with one of two potentially neuroprotective agents, the N-methyl-D-aspartate antagonist ketamine and the atypical neuroleptic acepromazine, on seizures induced by lithium-pilocarpine." | 3.72 | The neuromatrix and the epileptic brain: behavioral and learning preservation in limbic epileptic rats treated with ketamine but not acepromazine. ( Fournier, NM; Persinger, MA, 2004) |
| " Here, we examine two neuroprotective agents, the noncompetitive NMDA antagonist ketamine and the dopaminergic antagonist acepromazine, for their efficacy in attenuating cognitive impairments in the lithium-pilocarpine (LI-PILO) model of rat limbic epilepsy." | 3.72 | Normal spatial and contextual learning for ketamine-treated rats in the pilocarpine epilepsy model. ( McKay, BE; Persinger, MA, 2004) |
| "We investigated whether repeated application of subanesthetic doses of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine, which has been shown to mimic model aspects of schizophrenia in animals, affects the hippocampal neurogenesis detected by bromodeoxyuridine incorporation." | 3.72 | Increased neurogenesis in a rat ketamine model of schizophrenia. ( Becker, A; Bernstein, HG; Grecksch, G; Keilhoff, G; Wolf, G, 2004) |
| "In dogs, intraoperative cardiac tamponade caused comparable changes in RBF under the different anesthetic techniques except that autoregulation was effective in maintaining RBF within the central nervous system only under isoflurane anesthesia." | 3.72 | Isoflurane preserves central nervous system blood flow during intraoperative cardiac tamponade in dogs. ( Crystal, GJ; Metwally, AA; Salem, MR, 2004) |
| "Previously, it was shown that subchronic application of the NMDA receptor antagonist ketamine (Ket) induces schizophrenia-related alterations, e." | 3.72 | Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. ( Becker, A; Grecksch, G, 2004) |
| " Since sedation of animals is necessary to avoid artifacts, a mixture of ketamine and xylazine is frequently used for anesthesia." | 3.72 | Ketamine/xylazine anesthesia for radiologic imaging of neurologically impaired rats: dose response, respiratory depression, and management of complications. ( Dittmar, MS; Fehm, NP; Horn, M; Vatankhah, B, 2004) |
| "Ketamine and PCP are commonly used as selective NMDA receptor antagonists to model the putative hypoglutamate state of schizophrenia and to test new antipsychotics." | 3.71 | NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. ( Kapur, S; Seeman, P, 2002) |
| " Sodium fluoride-induced cerebral ischemia in mice is used as a model of circulatory ischemic lesion." | 3.70 | [The use of ketamine in an experimental model of generalized cerebral ischemia]. ( Karaivanova, M; Konstantinov, S; Konstantinova, Zh; Nachkov, Ia; Stamenova, P; Vasilev, D, 1998) |
| " Induction doses of ketamine 1 hour after HD exposure resulted in periods of profound apnea, with continued respiratory distress for the next 2 hours." | 3.70 | Domestic swine model for the assessment of chemical warfare agent-anesthetic interactions: some effects of sulfur mustard. ( Conley, J; Hamilton, M; Hunter, K; Lundy, P; Sawyer, TW, 2000) |
| "The aim of the present study was to observe the effect of repeated subcutaneous (sc) injections of low doses of ketamine for the treatment of acute inflammatory pain in a complete Freund's adjuvant-induced monoarthritic pain model in rats." | 3.70 | Repeated administration of low dose ketamine for the treatment of monoarthritic pain in the rat. ( Cao, Y; Han, JS; Huang, C; Wang, Y, 2000) |
| "Excessive blood loss in a rat model of uncontrolled hemorrhage has been attributed to the vasodilatory effects of a droperidol-ketamine mixture used for anesthesia." | 3.69 | Effects of anesthesia on a model of uncontrolled hemorrhage in rats. ( Barber, A; Greene, SP; Illner, H; Shires, GT; Sindlinger, JF; Soucy, DM, 1995) |
| "The effects of two non-competitive NMDA antagonists--MK-801 and ketamine--were studied in a model of generalized seizures elicited by s." | 3.69 | Effects of MK-801 (dizocilpine) and ketamine on strychnine-induced convulsions in rats: comparison with benzodiazepines and standard anticonvulsants. ( Kubová, H; Mares, P, 1994) |
| "The effects of prophylactic and delayed treatment with indomethacin were evaluated in a porcine model of early adult respiratory distress syndrome (ARDS) induced by endotoxaemia." | 3.67 | Prophylactic and delayed treatment with indomethacin in a porcine model of early adult respiratory distress syndrome induced by endotoxaemia. ( Borg, T; Gerdin, B; Modig, J, 1986) |
| "The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas." | 2.82 | BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression. ( Carboni, E; Carta, AR, 2022) |
| "While research on ketamine for PTSD is still in its early stages, it brings about the promise of novel and more effective treatments for this disabling condition." | 2.66 | The emergence of ketamine as a novel treatment for posttraumatic stress disorder. ( Charney, DS; Feder, A; Rutter, SB; Schiller, D, 2020) |
| "Major depressive disorder is a severe and complex mental disorder." | 2.55 | New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. ( Huang, YJ; Lane, HY; Lin, CH, 2017) |
| "Based on data from diverse seizure models, we hypothesized that cholinergic mechanisms are involved in the mechanisms underlying ASD resistance of SE." | 2.52 | Single versus combinatorial therapies in status epilepticus: Novel data from preclinical models. ( Löscher, W, 2015) |
| "Chronic neuropathic pain is a debilitating disease caused by a lesion of the somatosensory nervous system." | 2.48 | Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain. ( Dahan, A; Niesters, M, 2012) |
| "Drug abuse is often seen as a unitary phenomenon, partly as a result of the discovery over the past three decades of shared mechanisms of action for addictive substances." | 2.48 | The role of setting for ketamine abuse: clinical and preclinical evidence. ( Badiani, A; De Luca, MT; Meringolo, M; Spagnolo, PA, 2012) |
| "Schizophrenia is one of the common mental diseases." | 2.45 | [Receptor antagonist of NMDA and animal models of schizophrenia]. ( Bian, SZ; Gu, ZL; Jiang, XG; Liu, WL; Sun, ZH; Zhang, J, 2009) |
| "Infections during pregnancy are associated with an increased risk of neuropsychiatric disorders with developmental etiologies, such as schizophrenia and autism spectrum disorders (ASD)." | 1.91 | (R)-ketamine attenuates neurodevelopmental disease-related phenotypes in a mouse model of maternal immune activation. ( da Silva Júnior, JC; de Andrade Silva, SC; de Lima, DA; de Oliveira, EG; de Santana, JH; de Souza Barbosa, MV; Dos Santos Junior, OH; Duarte, FS; Gomes, DA; Lagranha, CJ; Lira, EC, 2023) |
| "Ketamine is an anaesthetic known to have short but rapid-acting anti-depressant effects; however, the neurobehavioural effects of its prolonged use and its role on the oxytocin system in the gut-brain axis are largely undetermined." | 1.91 | Prolonged ketamine therapy differentially rescues psychobehavioural deficits via modulation of nitro-oxidative stress and oxytocin receptors in the gut-brain-axis of chronically-stressed mice. ( Akinluyi, ET; Edem, EE; Fafure, AA; Ikuelogbon, DA; Isaac, GT; Kunlere, OE; Nebo, KE; Oguntala, OA, 2023) |
| "Ketamine was also efficacious in decreasing the level of inflammation with an evident reduction in microglial activation and pro-inflammatory cytokines in the studied regions, following CUMS exposure." | 1.72 | Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. ( Akinluyi, ET; Anyanwu, CC; Edem, EE; Enye, LA; Fafure, AA; Ishola, AO; Nebo, KE, 2022) |
| "Cuprizone (CPZ) has been used to produce demyelination which resembles demyelination in MS patients." | 1.72 | (R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: A role of gut-microbiota-brain axis. ( Chang, L; Hashimoto, K; Ma, L; Qu, Y; Shan, J; Tan, Y; Wan, X; Wang, X; Yang, Y, 2022) |
| "Autism or autism spectrum disorder (ASD) is a behavioral syndrome characterized by persistent deficits in social interaction, and repetitive patterns of behavior, interests, or activities." | 1.72 | Autistic-like social deficits in hippocampal MeCP2 knockdown rat models are rescued by ketamine. ( Choi, M; Chung, H; Kim, DG; Ko, SY; Lee, H; Seo, JY; Son, H, 2022) |
| "Ketamine is an anesthetic drug that is widely used in human and veterinary medicine." | 1.72 | Downregulation of the NLRP3/Caspse-1 Pathway Ameliorates Ketamine-Induced Liver Injury and Inflammation in Developing Rats. ( Chen, X; Gao, L; Li, S; Ma, X; Qiu, D; Shen, M; Zhang, Z, 2022) |
| "Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors." | 1.72 | Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine. ( Fan, W; Liao, L; Liu, B; Wei, Y; Wen, D; Xiao, L; Yang, H; Ye, Y; Zou, J, 2022) |
| "Senile glaucoma is a common ophthalmological disease in the elderly." | 1.72 | Explore the molecular mechanism of angle-closure glaucoma in elderly patients induced telomere shortening of retinal ganglion cells through oxidative stress. ( Chen, F; Xia, X; Yan, A; Zhou, J, 2022) |
| "Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate receptors (NMDARs)." | 1.72 | Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia. ( Cheng, A; Fan, W; Fu, Y; Liao, L; Wang, X; Wei, Y; Wen, D; Xiao, L; Yang, H; Ye, Y, 2022) |
| "Chronic neuropathic pain can modulate DNA methylation in target genes related to neuroplasticity and mood regulation, which was induced by DNA methyltransferases (DNMTs)." | 1.62 | Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine. ( He, X; Ji, MH; Liu, R; Shen, JC; Wang, RZ; Wu, XM; Yin, XY; Zhou, F, 2021) |
| "The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment." | 1.62 | Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. ( Andreatini, R; Da Cunha, C; Hocayen, PAS; Kanazawa, LKS; Miyoshi, E; Takahashi, RN; Vecchia, DD; Vital, MABF; Wendler, E, 2021) |
| "(R)-ketamine is a new safer antidepressant than (R,S)-ketamine and (S)-ketamine." | 1.62 | Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: A role of TrkB signaling. ( Chang, L; Fujita, Y; Hashimoto, H; Hashimoto, K; Hashimoto, Y, 2021) |
| "Post-traumatic stress disorder (PTSD) is a debilitating mental disease with high morbidity and major social and economic relevance." | 1.62 | Effect of ketamine on mood dysfunction and spatial cognition deficits in PTSD mouse models via HCN1-BDNF signaling. ( Du, Y; Du, Z; Li, C; Li, Q; Sun, H; Sun, L; Wang, A; Wang, Y; Zhang, W; Zhang, X; Zhao, Y, 2021) |
| "Since neural pathways can modulate acute pancreatitis severity, we asked if Ket/Xyl affect disease severity." | 1.62 | Ketamine and xylazine effects in murine model of acute pancreatitis. ( Gorelick, FS; Wang, M, 2021) |
| "(R)-ketamine has greater and longer-lasting antidepressant effects than (S)-ketamine in animal models of depression." | 1.56 | MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. ( Chang, L; Fujita, A; Fujita, Y; Hashimoto, K; Pu, Y, 2020) |
| "Ketamine is a multimodal dissociative anesthetic and analgesic that is widely used after traumatic injury." | 1.56 | Association between intravenous ketamine-induced stress hormone levels and long-term fear memory renewal in Sprague-Dawley rats. ( Berman, RY; Choi, KH; Girasek, QL; Radford, KD; Spencer, HF; Zhang, M, 2020) |
| "Ketamine is a dissociative anesthetic first developed in the 1960s but is increasingly used at subanesthetic doses for both clinical and non-clinical purposes." | 1.56 | Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval. ( Heller, CY; Trujillo, KA, 2020) |
| "Post-traumatic stress disorder (PTSD) is a chronic and disabling condition arising after exposure to a severe traumatic event, which affects approximately eight percent of the population." | 1.56 | Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice. ( Chen, WY; Lu, K; Lv, BJ; Wang, Y; Wang, YH; Wei, MD, 2020) |
| "Ketamine was used to establish an animal model of schizophrenia." | 1.56 | mTOR Expression in Hippocampus and Prefrontal Cortex Is Downregulated in a Rat Model of Schizophrenia Induced by Chronic Administration of Ketamine. ( Chen, F; Liao, L; Wang, X; Xie, J; Xie, R; Yan, Y; Yang, L; Ye, Y, 2020) |
| "Slow response to the standard treatment for depression increases suffering and risk of suicide." | 1.56 | Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. ( Chandra, J; Klein, ME; Malinow, R; Sheriff, S, 2020) |
| "Ketamine has been recently identified as a potential novel antidepressant." | 1.56 | Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant. ( de Abreu, GR; Fukushima, AR; Manes, M; Moreira, N; Ricci, EL; Spinosa, HS; Waziry, PAF; Zaccarelli-Magalhães, J, 2020) |
| "Traditional monoaminergic treatments of depression frequently exhibit suboptimal tolerability and effectiveness." | 1.56 | Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction. ( Hannan, AJ; Li, S; Renoir, T; Wilson, C, 2020) |
| "The treatment of major depressive disorder (MDD) is still a challenge." | 1.56 | Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model. ( de Almeida, RF; Elisabetsky, E; Pocharski, CB; Rodrigues, ALS; Souza, DO, 2020) |
| "Ketamine (KET) is an N-methyl-D-aspartate (NMDA) antagonist with rapid and long-lasting antidepressant effects, but how the drug shows its sustained effects is still a matter of controversy." | 1.56 | Rapid and long-lasting antidepressant-like effects of ketamine and their relationship with the expression of brain enzymes, BDNF, and astrocytes. ( Andrade, SM; Aquino, PEA; Araujo, ARA; Coelho, NC; Costa, ROD; Medeiros, IS; Neves, KRT; Sousa, CNS; Vale, EMD; Vasconcelos, SMM; Viana, GSB, 2020) |
| "Major depressive disorder is a common and debilitating condition with substantial economic impact." | 1.51 | The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive-like rats. ( Andersson, M; Bergström, N; Culley, G; Ehn, J; Engström, A; Hanse, E; Karlsson, L; Kuhn, HG; Michaëlsson, H; Savvidi, P; Seth, H; Svensson, J, 2019) |
| "MRL/lpr mice, an established model of systemic lupus erythematosus, show depression-like behavior." | 1.51 | Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus. ( Adepu, B; Bristow, LJ; Das, ML; Dudhgaonkar, S; Kalidindi, N; Kuchibhotla, VK; Li, YW; Louis, JV; Nagar, J; Naidu, PS; Paschapur, M; Pieschl, RL; Prasad, DS; Ramarao, M; Sreedhara, MV; Srikumar, BN; Srivastava, R; Subramani, S; Vikramadithyan, RK, 2019) |
| "Patients with major depressive disorder (MDD) often have structural and functional deficits in the ventromedial prefrontal cortex (vmPFC), but the underlying molecular pathways are incompletely understood." | 1.51 | VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. ( Jiang, C; Labonté, B; Lin, WJ; Nestler, EJ; Russo, SJ; Salton, SR; Tamminga, CA; Turecki, G, 2019) |
| "Ketamine has been shown to reduce chronic pain; however, the adverse events associated with ketamine makes it challenging for use outside of the perioperative setting." | 1.51 | Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain. ( Buvanendran, A; Das, V; Kroin, JS; Moric, M, 2019) |
| "Ketamine is a non-competitive NMDA receptor antagonist used as a major anesthetic agent, especially in children." | 1.51 | Oral ketamine alleviates behavioral despair without cognitive impairment in Wistar rats. ( Canbeyli, R; Ecevitoglu, A; Unal, G, 2019) |
| "Ketamine acts as a rapid clinical antidepressant at 25 min after injection with effects sustained for 7 days." | 1.51 | Differences between ketamine's short-term and long-term effects on brain circuitry in depression. ( Becker, R; Cosa-Linan, A; Gass, N; Reinwald, J; Sack, M; Sartorius, A; Vollmayr, B; Weber-Fahr, W, 2019) |
| "Gallic acid has been reported to possess a number of psychopharmacological activities." | 1.48 | Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations. ( Dhingra, MS; Dhingra, S; Jindal, DK; Kumar, A; Parle, M; Yadav, M, 2018) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 1.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "(R)-Ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine." | 1.48 | Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model. ( Dong, C; Hashimoto, K; Ma, M; Qu, Y; Ren, Q; Yang, C; Zhang, JC, 2018) |
| "Morin is a naturally occurring flavonoid with strong anti-oxidant and anti-inflammatory properties." | 1.48 | Morin Pretreatment Attenuates Schizophrenia-Like Behaviors in Experimental Animal Models. ( Aderibigbe, AO; Ajayi, AM; Ben-Azu, B; Iwalewa, EO; Omogbiya, IA, 2018) |
| "Treatment with fluoxetine for 7 days, but not 24 hours, also reinstated social interaction behavior in mice that were susceptible to chronic social defeat." | 1.48 | Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine. ( Berton, O; Browne, CA; Falcon, E; Lucki, I; Robinson, SA, 2018) |
| "Schizophrenia was induced in WT (C57BL/6) mice through intraperitoneal administration of 30mg/Kg ketamine (NMDAR antagonist) for 5days (WT/SCZ)." | 1.48 | CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4. ( Lee, CC; Ogundele, OM, 2018) |
| "Schizophrenia is a complex neuropsychiatric disorder characterized by hallucinations, delusions, anhedonia, flat affect and cognitive impairments." | 1.48 | Prenatal exposure to ketamine in rats: Implications on animal models of schizophrenia. ( Coronel-Oliveros, CM; Pacheco-Calderón, R, 2018) |
| " We studied whether 6-hydroxynorketamine could affect nociception or the effects of morphine in acute or chronic administration settings." | 1.48 | Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine. ( Jokinen, V; Kalso, EA; Lilius, TO; Niemi, M; Rauhala, PV; Viisanen, H, 2018) |
| "Treatment with ketamine, minocycline and amitriptyline were able to exert antidepressant effects in the forced swimming test." | 1.48 | Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events. ( Abelaira, HM; de Moura, AB; de Souza, TG; Fileti, ME; Garbossa, L; Goldim, MP; Maciel, AL; Mathias, K; Matos, D; Petronilho, F; Quevedo, J; Réus, GZ; Rosa, T; Strassi, AP; Tuon, T, 2018) |
| "Ketamine is a non-competitive antagonist of N-methyl-D-aspartate receptors (NMDARs)." | 1.48 | Downregulation of Egr-1 Expression Level via GluN2B Underlies the Antidepressant Effects of Ketamine in a Chronic Unpredictable Stress Animal Model of Depression. ( Liu, CC; Lv, YD; Sun, WY; Tian, LJ; Wang, HH; Zhang, WJ, 2018) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population." | 1.48 | Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018) |
| "Ketamine treatment significantly reduced nicotine self-administration in a dose-dependent manner." | 1.48 | Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats. ( Getachew, B; Levin, ED; Rezvani, AH; Slade, S; Tizabi, Y, 2018) |
| "Ketamine is an N-methyl-D-aspartate receptor antagonist, which on administration produces fast-acting antidepressant responses in patients with major depressive disorder." | 1.48 | Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine. ( Adaikkan, C; Barrera, I; David, O; Rosenblum, K; Taha, E, 2018) |
| "Post-traumatic stress disorder (PTSD) is commonly associated with concurrent anxiety and depression symptoms, and reduce the expression of the Brain-Derived Neurotrophic Factor (BDNF) which promotes the proliferation and survival of neurons." | 1.48 | Applying ketamine to alleviate the PTSD-like effects by regulating the HCN1-related BDNF. ( Du, Z; Hou, L; Li, Q; Qi, Y; Sun, H; Sun, L; Wang, G; Wang, Y; Zhang, Z, 2018) |
| "Stigmasterol treated animals showed significant decrease in locomotor activity, stereotypic behaviours, immobility duration and increased step down latency." | 1.48 | Protective effects of stigmasterol against ketamine-induced psychotic symptoms: Possible behavioral, biochemical and histopathological changes in mice. ( Dhingra, S; Jindal, DK; Parle, M; Yadav, M, 2018) |
| "Depression is present in a large proportion of patients suffering from chronic pain, and yet the underlying mechanisms remain to be elucidated." | 1.48 | Ketamine differentially restores diverse alterations of neuroligins in brain regions in a rat model of neuropathic pain-induced depression. ( Ji, MH; Li, HH; Li, KY; Pan, W; Yang, JJ; Zhang, GF; Zhou, ZQ, 2018) |
| "Schizophrenia is one of the psychotic mental disorders characterized by symptoms of thought, behavior, and social problems." | 1.48 | Protective effects of Spinacia oleracea seeds extract in an experimental model of schizophrenia: Possible behavior, biochemical, neurochemical and cellular alterations. ( Bhidhasra, A; Dhingra, MS; Dhingra, S; Jindal, DK; Kumar, A; Parle, M; Sharma, N; Yadav, M, 2018) |
| "This will promote the research and treatment of pruritus and depression." | 1.48 | The behavioral study on the interactive aggravation between pruritus and depression. ( Bai, Y; Feng, YP; Li, H; Wang, XD; Yang, G, 2018) |
| "Chronic pain is known to induce an amplified aversive reaction to peripheral nociceptive inputs." | 1.48 | Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex. ( Chen, Z; Dale, J; Hu, S; Huang, D; Liu, K; Martinez, E; Wang, J; Yang, G; Zhang, E; Zhang, Q; Zhou, H, 2018) |
| "On the 14th day of treatment, schizophrenia-like symptoms were evaluated by the prepulse inhibition of the startle reflex (PPI), locomotor activity evaluated by the open field test (OFT), spatial recognition memory evaluated by the Y-maze task and social interaction test (SIT)." | 1.48 | Ethanolic extract of Erythrina velutina Willd ameliorate schizophrenia-like behavior induced by ketamine in mice. ( de Sousa, FCF; Dias, KCF; Dos Santos Júnior, MA; Jucá, MM; Leal, LKAM; Silva, AH; Vasconcelos, GS; Vasconcelos, SMM; Viana, GSB; Ximenes, NC, 2018) |
| "Ketamine and etomidate inhibit the enzyme expression and activity of the adrenal gland at the early stage." | 1.46 | Ketamine and Etomidate Down-regulate the Hypothalamic-Pituitary-Adrenal Axis in an Endotoxemic Mouse Model. ( Besnier, E; Castel, H; Clavier, T; Compere, V; Dureuil, B; Lefevre-Scelles, A; Morin, F; Selim, J; Tamion, F; Tonon, MC, 2017) |
| "It also attenuated hyper-locomotion and memory deficits induced by chronic injection of ketamine in mice." | 1.46 | Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice. ( Aluko, OM; Annafi, OS; Eduviere, AT; Omorogbe, O; Umukoro, S, 2017) |
| "Schizophrenia is a chronic and devastating disease with an overall lifetime risk of 1%." | 1.46 | Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. ( Hauser, MJ; Isbrandt, D; Roeper, J, 2017) |
| "We studied sensitivity of mechanical hyperalgesia induced by a single intrathecal (i." | 1.46 | Role of the spinal TrkB-NMDA receptor link in the BDNF-induced long-lasting mechanical hyperalgesia in the rat: A behavioural study. ( Constandil, L; Galleguillos, D; Hernández, A; Marcos, JL; Pelissier, T; Velásquez, L; Villanueva, L, 2017) |
| "Major depression is one of the most common affective disorders caused by schizophrenia." | 1.46 | Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration. ( Briones-Aranda, A; Espinosa-Raya, J; Picazo, O; Suárez-Santiago, JE, 2017) |
| "Tramadol is an analgesic agent that is mainly used to treat moderate to severe pain." | 1.46 | Involvement of NMDA receptors in the antidepressant-like effect of tramadol in the mouse forced swimming test. ( Akbarian, R; Chamanara, M; Dehpour, AR; Ghasemi, M; Imran-Khan, M; Norouzi-Javidan, A; Ostadhadi, S, 2017) |
| "We have developed an animal model of PTSD, based on conditioning of the rabbit's eyeblink response, that addresses two key features: conditioned responses (CRs) to cues associated with an aversive event and a form of conditioned hyperarousal referred to as conditioning-specific reflex modification (CRM)." | 1.46 | Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder. ( Burhans, LB; Schreurs, BG; Smith-Bell, CA, 2017) |
| "To mimic PTSD we employed the inescapable footshock protocol." | 1.46 | Ketamine promotes increased freezing behavior in rats with experimental PTSD without changing brain glucose metabolism or BDNF. ( Bertoldi, K; Costa Da Costa, J; Greggio, S; Jeckel, CMM; Mestriner, RG; Neves, LT; Saur, L; Schallenberger, B; Siqueira, IR; Venturin, GT; Xavier, LL, 2017) |
| "(R)-ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine." | 1.46 | Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. ( Dong, C; Fujita, Y; Hashimoto, K; Ma, M; Qu, Y; Ren, Q; Yang, C, 2017) |
| "Post-traumatic stress disorder (PTSD) displays high co-morbidity with major depression and treatment-resistant depression (TRD)." | 1.46 | Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies. ( Brand, SJ; Harvey, BH, 2017) |
| " The present study aimed to investigate the effects of the typical antipsychotic chlorpromazine (CP) alone or combined with the natural antioxidant alpha-lipoic acid (ALA) on changes in the hippocampal average spectral power induced by ketamine (KET)." | 1.46 | Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017) |
| "Ketamine was shown to be capable of increasing the activity of acetylcholinesterase (AChE) in the brain structures." | 1.46 | Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia. ( Canever, L; Damiani, AP; de Andrade, VM; Fachim, I; Gomes, ST; Gress, K; Heylmann, ASA; Mastella, GA; Michels, C; Quevedo, J; Steckert, AV; Stopassoli, GC; Zugno, AI, 2017) |
| "Ketamine has been extensively studied for its antidepressant potential, with promising results in both preclinical and clinical studies." | 1.46 | Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats. ( Babinska, Z; Ruda-Kucerova, J, 2017) |
| "Ketamine pretreatment reduced both of these responses." | 1.43 | Ketamine decreases inflammatory and immune pathways after transient hypoxia in late gestation fetal cerebral cortex. ( Arndt, TJ; Chang, EI; Keller-Wood, M; Rabaglino, MB; Richards, EM; Wood, CE; Zárate, MA, 2016) |
| "Ketamine was administered with an acute (1 day) and subchronic (5 day) scheme." | 1.43 | Effect of ketamine administration, alone and in combination with E-6837, on climbing behavior. ( Briones-Aranda, A; Castellanos-Pérez, M; Picazo, O; Suárez-Santiago, JE, 2016) |
| "Vortioxetine is a multimodal-acting antidepressant that is hypothesized to exert its therapeutic activity through 5-HT reuptake inhibition and modulation of several 5-HT receptors." | 1.43 | Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. ( du Jardin, KG; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G, 2016) |
| "N,N-dimethylglycine (DMG) is a derivative of the amino acid glycine and is used as a dietary supplement." | 1.43 | N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. ( Chan, MH; Chen, HH; Chen, YC; Lee, MY; Lin, JC, 2016) |
| "Edaravone (18 mg/kg) treatment did not prevent hyperlocomotion in the mania model induced with ketamine in rats, but lithium chloride (47." | 1.43 | The effects of edaravone in ketamine-induced model of mania in rats. ( Altun, İK; Alver, A; Arslan, FC; Gedikli, Ö; İnce, İ; Özkorumak, E; Tiryaki, A; Yıldırım, M, 2016) |
| "Ketamine treatment decreased the hippocampal membrane level of phosphorylated PSD-95 on Thr-19, the target of GSK3 that promotes AMPA receptor internalization." | 1.43 | Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling. ( Amadei, C; Beurel, E; Downey, K; Grieco, SF; Jope, RS, 2016) |
| "ketamine treatment induced hyperlocomotion and oxidative damage in cerebral cortex, hippocampus and striatum such as an increase in lipid peroxidation and a decrease in the antioxidant enzymes activities (superoxide dismutase, catalase e glutatione peroxidase)." | 1.43 | Preventive effects of blueberry extract on behavioral and biochemical dysfunctions in rats submitted to a model of manic behavior induced by ketamine. ( Braganhol, E; Chaves, VC; Debom, G; do Couto, CA; Gazal, M; Ghisleni, GC; Kaster, MP; Lencina, C; Mattos, B; Reginatto, FH; Soares, MS; Spanevello, RM; Stefanello, F; Tavares, R, 2016) |
| " Systemic nicotine given before the sample phase of the CMOR task reversed the ketamine-induced impairment, but this effect was blocked by co-administration of the GABAA receptor antagonist bicuculline at a dosage that itself did not cause impairment." | 1.42 | α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia. ( Cloke, JM; Winters, BD, 2015) |
| "Ketamine treatment reduced the number of cells that expressed PV in the PFC by ∼60% as previously described." | 1.42 | Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice. ( Driskill, C; Jeevakumar, V; Kroener, S; Morris, B; Paine, A; Ramos, J; Sobhanian, M; Vakil, H, 2015) |
| " Furthermore, NMDA (N-methyl-d-aspartate) receptor antagonism by ketamine had an opposing dose-dependent effect, suggesting that the differential dosage of ketamine might have divergent effects on behavioral processes." | 1.42 | Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes. ( Báldi, R; Brown, JA; Everheart, MG; Garbett, K; Gellért, L; Horváth, S; Mirnics, K; Patel, S; Ramikie, TS; Schmidt, MJ; Warren, LE, 2015) |
| " However, a long term use of ketamine tends to elicit its adverse reactions." | 1.42 | Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects. ( Guo, J; Liu, WX; Qiu, LL; Sun, HL; Wang, XM; Yang, JJ; Zhang, GF; Zhou, ZQ, 2015) |
| "In morphine-only infusion rats, hyperalgesia and opioid insensitivity were both increased." | 1.42 | Long-Term Antihyperalgesic and Opioid-Sparing Effects of 5-Day Ketamine and Morphine Infusion ("Burst Ketamine") in Diabetic Neuropathic Rats. ( Broadbear, JH; Goodchild, CS; Kolosov, A; Mak, P, 2015) |
| "Dextromethorphan (DM) is an antitussive with rapid acting antidepressant potential based on pharmacodynamic similarities to ketamine." | 1.42 | Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. ( Matsumoto, RR; Nguyen, L, 2015) |
| " These findings are consistent with the hypothesis that the inability of memantine, AZD6765 (lanicemine) and MK-0657 to reproduce the rapid and robust antidepressant effects of ketamine in the clinic result from insufficient dosing rather than a difference in mechanism of action among these NMDAR antagonists." | 1.42 | Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test. ( Czekaj, J; Kos, T; Popik, P; Skolnick, P, 2015) |
| "Current treatments for major depressive disorder (MDD) have a time lag and are ineffective for a large number of patients." | 1.42 | Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior. ( DiLeone, RJ; Duman, RS; Dwyer, JM; Lepack, AE; Maldonado-Avilés, JG, 2015) |
| "5 improved most of the parameters evaluated in this study without causing motor impairment demonstrating, thus, that possibly when combined with ALA a lower dose of CLZ is required." | 1.42 | Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. ( de Lucena, DF; de Sousa, CN; Gama, CS; Lima, LL; Macêdo, D; Oliveira, Tde Q; Vasconcelos, GS; Vasconcelos, SM; Ximenes, NC, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Ketamine-treated rats were found to display bladder hyperactivity." | 1.42 | Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum. ( Chuang, SM; Ho, WT; Jang, MY; Juan, YS; Lee, YL; Lin, RJ; Liu, KM; Long, CY; Lu, JH; Lu, MC; Wang, CC; Wu, WJ, 2015) |
| "Ketamine treated rats showed a significantly lower temperature in the ischaemic hindpaw compared to saline (P < 0." | 1.42 | Preventive Treatment with Ketamine Attenuates the Ischaemia-Reperfusion Response in a Chronic Postischaemia Pain Model. ( Cheung, CW; Choi, SW; Irwin, M; Liman, S; Ng, KF; Qiu, Q; Tai, W; Wong, KL, 2015) |
| " The dose-response relationships of all 3 compounds in the forced swim test were also investigated in mice 30 min after IP administration." | 1.42 | Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor. ( Drabik, U; Gajdosz, R; Librowski, T; Nowak, G; Popik, P; Sałat, K; Siwek, A; Starowicz, G, 2015) |
| "Ketamine (Ketalar®) is a non-competitive glutamatergic antagonist classically used to induce sedation." | 1.42 | Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine. ( Hylton, A; Pittman, J, 2015) |
| "Ketamine is a centrally acting agent believed to work through blockade of N-methyl-D- aspartate receptors and is being increasingly used for the treatment of refractory CRPS, although the basis for the drug's effects and efficacy at different stages of the syndrome remains unclear." | 1.42 | Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice. ( Clark, JD; Huang, TT; Kingery, WS; Leu, D; Tajerian, M; Yang, P, 2015) |
| "Corticosterone levels were significantly suppressed by ketamine only in the exposed animals." | 1.40 | Immediate ketamine treatment does not prevent posttraumatic stress responses in an animal model for PTSD. ( Cohen, H; Juven-Wetzler, A; Kaplan, Z; Kohen, A; Porat, O; Zohar, J, 2014) |
| "Pretreatment with ketamine (10mg/kg, IP) completely and specifically prevented this stress-induced cognitive inflexibility." | 1.40 | Ketamine prevents stress-induced cognitive inflexibility in rats. ( Nikiforuk, A; Popik, P, 2014) |
| " Nonetheless, an adequate dosage and way of administration should be considered and established for human use." | 1.40 | The effect of ketamine on optical and electrical characteristics of spreading depolarizations in gyrencephalic swine cortex. ( Orakcioglu, B; Sakowitz, OW; Sánchez-Porras, R; Santos, E; Schiebel, P; Schöll, M; Stock, C; Unterberg, AW; Zheng, Z, 2014) |
| "Rats treated with ketamine improved survival in rats and significantly reduced CLP-induced dysfunction/injury of organs." | 1.40 | Ketamine inhibits LPS-induced HGMB1 release in vitro and in vivo. ( Wu, H; Zhang, L; Zhang, Z; Zhou, C, 2014) |
| "Ketamine was then tested as a potential therapeutic drug." | 1.39 | Bilateral central pain sensitization in rats following a unilateral thalamic lesion may be treated with high doses of ketamine. ( Beaudry, F; Castel, A; Hélie, P; Vachon, P, 2013) |
| "Demyelination was assessed by luxol fast blue staining, and immunohistological staining of myelin-binding protein (MBP)." | 1.39 | Kindling-induced learning deficiency and possible cellular and molecular involved mechanisms. ( Ahmad-Molaei, L; Ghasemi, R; Hosseini, A; Motamedi, F; Naderi, N; Nejadhoseynian, M; Ronaghi, A; Sherafat, MA, 2013) |
| "co-treatment with ketamine and pregabalin at sub-effect low doses may be a useful therapeutic method for the treatment of neuropathic pain patients." | 1.39 | Intrathecal ketamine and pregabalin at sub-effective doses synergistically reduces neuropathic pain without motor dysfunction in mice. ( Choi, JG; Jeon, BH; Kim, HW; Kim, JM; Ko, YK; Lee, JH; Lim, HS; Park, JB; Shin, YS, 2013) |
| "Chronic neuropathic pain was induced by chronic constriction injury of the sciatic nerve, and subsequently a cannula was implanted in the PAG area for the purpose of electrical stimulation and intra-PAG drug administration." | 1.38 | Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: role of opioid and N-methyl-D-aspartate receptors. ( Halder, S; Khanna, N; Mehta, AK; Sharma, KK; Tandon, OP, 2012) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 1.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| "Psychosis has been associated with glucose metabolism impairment." | 1.38 | The expression of genes involved in glucose metabolism is affected by N-methyl-D-aspartate receptor antagonism: a putative link between metabolism and an animal model of psychosis. ( Aloj, L; Avvisati, L; de Bartolomeis, A; Iasevoli, F; Latte, G; Sarappa, C, 2012) |
| "Ketamine is an analgesic/anesthetic drug, which, in combination with other drugs, has been used as anesthetic for over 40 years." | 1.38 | Improved methods for thermal rearrangement of alicyclic α-hydroxyimines to α-aminoketones: synthesis of ketamine analogues as antisepsis candidates. ( Byk, G; Douvdevani, A; Eini, H; Elhawi, H, 2012) |
| "Schizophrenia is a complex and debilitating disorder, characterized by positive, negative, and cognitive symptoms." | 1.38 | Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia. ( Clementino, KJ; Goel, A; Hall, AW; Jacklin, DL; Talpos, JC; Winters, BD, 2012) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| "Schizophrenia is a severe, disabling chronic disorder affecting approximately 1% of the population." | 1.37 | Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. ( Dedeurwaerdere, S; Langlois, X; Pemberton, D; Straetemans, R; Wintmolders, C, 2011) |
| "Anesthesia sometimes suppresses ventricular tachyarrhythmias (VT) resistant to conventional pharmacological treatment." | 1.37 | Deep anesthesia suppresses ventricular tachyarrhythmias in rabbit model of the acquired long QT syndrome. ( Ajiki, K; Hayami, N; Inaba, H; Kunishima, T; Mikamo, T; Murakawa, Y; Sugiura, A; Tsutsui, K; Watanabe, H; Yamagishi, N; Yamagishi, S, 2011) |
| "Diazepam effects were blocked by flumazenil." | 1.37 | Stress-induced hyperalgesia is associated with a reduced and delayed GABA inhibitory control that enhances post-synaptic NMDA receptor activation in the spinal cord. ( Cardenas, R; Quintero, L; Suarez-Roca, H, 2011) |
| "Long-lasting hyperalgesia was induced in male Sprague Dawley rats with subcutaneous fentanyl (4 injections, 60 μg/kg per injection at 15-minute intervals) resulting in a total dose of 240 μg/kg." | 1.37 | The median effective dose of ketamine and gabapentin in opioid-induced hyperalgesia in rats: an isobolographic analysis of their interaction. ( Benhamou, D; Mazoit, JX; Sitbon, P; Van Elstraete, AC, 2011) |
| "In prestressed rats, fULD-induced hyperalgesia and the exaggerated inflammatory hyperalgesia were prevented NMDA receptor antagonists." | 1.37 | Endogenous opioids released during non-nociceptive environmental stress induce latent pain sensitization Via a NMDA-dependent process. ( Chateauraynaud, J; Gavello-Baudy, S; Laboureyras, E; Laulin, JP; Le Roy, C; Simonnet, G, 2011) |
| "Nicotine can enhance various indices of cognitive performance, including working memory span capacity measured using the odor span task (OST)." | 1.37 | Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. ( Rushforth, SL; Shoaib, M; Steckler, T, 2011) |
| "Ketamine was able to diminish alterations induced by I/R." | 1.36 | Ketamine and the myenteric plexus in intestinal ischemia/reperfusion injury. ( Alarcón-Galván, G; Ballesteros-Elizondo, RG; Cámara-Lemarroy, CR; Cordero-Pérez, P; Fernández-Garza, NE; Guzmán-de la Garza, FJ, 2010) |
| "Influenza-associated encephalopathy (IAE) is characterized by severe neurological complications during high-grade fever with high morbidity and mortality in children." | 1.36 | Rat model of influenza-associated encephalopathy (IAE): studies of electroencephalogram (EEG) in vivo. ( Cissé, Y; Inoue, I; Kido, H; Wang, S, 2010) |
| "Ketamine is a sympathetic nervous system-activating anaesthetic that preserves cardiovascular stability." | 1.36 | Effects of ketamine on hypoxic pulmonary vasoconstriction in the isolated perfused lungs of endotoxaemic mice. ( Busch, CJ; Gebhard, MM; Martin, EO; Motsch, J; Spöhr, FA; Weimann, J, 2010) |
| "Morphine was more effective in ketamine-treated (1 and 50 mg kg(-1)) mice." | 1.36 | Opioid-induced hyperalgesia in a mice model of orthopaedic pain: preventive effect of ketamine. ( Fourcade, O; Girolami, JP; Minville, V; Tack, I, 2010) |
| "Ketamine effects were quantified by the animals' performances and latencies in a prosaccade and an antisaccade task, two oculomotor paradigms that are impaired after ketamine administration." | 1.36 | Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys. ( Gaymard, B; Pouget, P; Rivaud-Péchoux, S; Wattiez, N, 2010) |
| "Ketamine pretreatment was administered by intraperitoneal injections at doses of 100, 50, 12." | 1.36 | Ketamine reduces intestinal injury and inflammatory cell infiltration after ischemia/reperfusion in rats. ( Alarcón-Galván, G; Ballesteros-Elizondo, RG; Cámara-Lemarroy, CR; Cordero-Pérez, P; Fernández-Garza, NE; Guzmán-De La Garza, FJ, 2010) |
| "Ketamine was one of the therapeutic agents used as a therapy for a human rabies survivor who did not receive rabies vaccine." | 1.35 | Human rabies therapy: lessons learned from experimental studies in mouse models. ( Jackson, AC; Owen, J; Rossiter, JP; Scott, CA; Weli, SC, 2008) |
| "Ketamine-treated seized rats were healthier than acepromazine-treated seized rats or normal rats." | 1.35 | Large differences in blood measures, tissue weights, and focal areas of damage 1 year after postseizure treatment with acepromazine or ketamine. ( Blomme, CG; Dupont, MJ; George, KR; Mazzuchin, A; Persinger, MA; Rico, T; St-Pierre, LS; Stewart, LS, 2009) |
| " The injection coordinates and the dosage of quinolinic acid were identical." | 1.35 | Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease. ( Büchele, F; Döbrössy, M; Jiang, W; Nikkhah, G; Papazoglou, A, 2009) |
| " In this context, the present study was aimed to evaluate behavioral and physiological effects of acute and chronic administration of ketamine, a NMDA receptor antagonist, in rats exposed to chronic mild stress (CMS)." | 1.35 | Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. ( Comim, CM; Garcia, LS; Gavioli, EC; Kapczinski, F; Quevedo, J; Réus, GZ; Stertz, L; Valvassori, SS, 2009) |
| "Ketamine has been used to induce a schizophrenia-like condition as an animal model in which to study this condition." | 1.35 | Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. ( Bortolin, T; Canever, L; Dal-Pizzol, F; de Oliveira, L; Mina, FG; Petronilho, F; Quevedo, J; Spiazzi, CM; Zugno, AI, 2009) |
| " In the present retrospective study we evaluated the impact of these vendor changes on ketamine dosing to establish anaesthesia, on pilocarpine-induced seizure susceptibility, and on basal extracellular hippocampal noradrenaline, dopamine, serotonin, gamma-amino butyric acid, and glutamate levels of all pilocarpine-treated rats included in our studies." | 1.35 | Intrastrain differences in seizure susceptibility, pharmacological response and basal neurochemistry of Wistar rats. ( Aourz, N; Clinckers, R; De Bundel, D; Meurs, A; Michotte, Y; Portelli, J; Smolders, I, 2009) |
| "Schizophrenia is one of the most important forms of psychiatric illness and may be chronic and highly disabling." | 1.35 | The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia. ( Alania, M; Chikovani, M; Chkhartishvili, B; Doreulee, N; Mitaishvili, E, 2009) |
| "Diazoxide (5 mg/kg) were given 48 h before 20 min ischemia in the 48-h DZ group, whereas 15-min DZ group received diazoxide (5 mg/kg) 15 min before 20-min ischemia." | 1.35 | Delayed pharmacological pre-conditioning effect of mitochondrial ATP-sensitive potassium channel opener on neurologic injury in a rabbit model of spinal cord ischemia. ( Choe, G; Chung, SH; Kim, CS; Kim, KO, 2008) |
| " To further validate this model the mRNA levels of neurotrophic factors NGF, NT-3, and BDNF and their receptors TrkA, TrkB, and TrkC, respectively, were measured in different brain areas in Ket-pretreated rats subchronically dosed with the atypical antipsychotic drug risperidone (Ris)." | 1.35 | Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment. ( Becker, A; Grecksch, G; Roskoden, T; Schwegler, H, 2008) |
| "Septic shock was replicated by intraperitoneal injection of 20 mg/kg lipopolysaccharide (LPS)." | 1.34 | [Effect of ketamine on endotoxin-induced septic shock in rats and its mechanism]. ( Liu, H; Xiao, H; Xu, HW; Zhang, L, 2007) |
| "Treatment with ketamine, a non-competitive glutamate N-methyl-d-aspartic acid (NMDA) receptor antagonist, is known to have paradoxical effects of neuroprotection and neurotoxicity." | 1.34 | The expression of Troponin T1 gene is induced by ketamine in adult mouse brain. ( Lowe, XR; Lu, X; Marchetti, F; Wyrobek, AJ, 2007) |
| "Ketamine pretreatment prevented such a fentanyl-induced enhancement of postoperative pain and improved its management by morphine." | 1.33 | Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats. ( Laulin, JP; Maurette, P; Richebé, P; Rivat, C; Simonnet, G, 2005) |
| "Ketamine-treated pilocarpine-seized rats and normal rats were exposed continuously either to a complex sequence magnetic field or to control conditions during the acquisition of a radial arm maze task for 8 consecutive days." | 1.33 | Weak, physiologically patterned magnetic fields do not affect maze performance in normal rats, but disrupt seized rats normalized with ketamine: possible support for a neuromatrix concept? ( McKay, BE; Persinger, MA, 2006) |
| "Rats treated with isoflurane had the best cognitive recovery (p < 0." | 1.33 | Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats. ( Alexander, H; Clark, RS; Dixon, CE; Jenkins, L; Kochanek, PM; Statler, KD; Vagni, V, 2006) |
| "The approach to management of the rabies normally should be palliative." | 1.32 | Management of rabies in humans. ( Bleck, TP; Dietzschold, B; Ertl, HC; Fu, ZF; Jackson, AC; Leach, RP; O'Reilly, M; Rupprecht, CE; Warrell, MJ; Wilde, H; Wunner, WH, 2003) |
| "Ketamine hyperactivity was also reduced in a similar dose range." | 1.32 | Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. ( Anderson, JJ; Baccei, CS; Bristow, LJ; Campbell, UC; Correa, LD; Lorrain, DS; Pinkerton, AB; Rodriguez, DE; Rowe, B; Schaffhauser, H; Varney, MA; Vernier, JM, 2003) |
| "Pretreatment with risperidone (0." | 1.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "Ketamine has not elicited the HSR in this model of experimental burns and, therefore, its protective effects were not shown to be mediated through this mechanism." | 1.32 | Ketamine reduces mortality of severely burnt rats, when compared to midazolam plus fentanyl. ( Lázaro Da Silva, A; Neder Meyer, T, 2004) |
| "The initial hyperalgesia induced by 0." | 1.31 | Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. ( Assié, MB; Bardin, L; Carilla-Durand, E; Colpaert, FC; Cosi, C; Koek, W; Pauwels, PJ; Tarayre, JP; Vacher, B; Wiesenfeld-Hallin, Z; Xu, XJ, 2002) |
| "Temporary spinal cord ischemia was induced by 29 min of infrarenal balloon occlusion of the aorta in 60 anesthetized New Zealand white rabbits." | 1.31 | Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. ( Bodewits, P; de Haan, P; Dzoljic, M; Jacobs, MJ; Kalkman, CJ; Lips, J; Vanicky, I, 2000) |
| "Pretreatment with phencyclidine [PCP] at a dose of 3 mg/kg shifted the DOM dose-response relationship to the left." | 1.31 | Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. ( Doat, M; Rabin, RA; Winter, JC, 2000) |
| "Asphyxial cardiopulmonary arrest was induced and, after and 8 min cardiac arrest nonintervention interval, a standardized protocol of manual CPR with mechanical ventilation was performed." | 1.30 | Anesthetic regimen effects on a pediatric porcine model of asphyxial arrest. ( Ginn, A; Jasani, MS; Nadkarni, VM; Salzman, SK; Tice, LL, 1997) |
| "In the other 15 cats, cytotoxic brain edema (CBE) was created by an acute reduction in blood osmolality." | 1.30 | The effects of intravenous anesthetics on intracranial pressure and cerebral perfusion pressure in two feline models of brain edema. ( Nimkoff, L; Quinn, C; Sagy, M; Silver, P, 1997) |
| "The CCI rats showed hyperalgesia to thermal and mechanical pressure stimuli on the injured side of their hind paws." | 1.30 | [Suppressive effects of ketamine on neuropathic pain]. ( Omote, K; Sonoda, H, 1998) |
| "coli bacteremia was studied in rats and compared to the effect of two other anesthetic procedures in previously published studies." | 1.30 | E. Coli bacteremia-induced changes in the skeletal muscle microcirculation vary with anesthetics. ( Garrison, RN; Harris, PD; Lüebbe, AS, 1998) |
| "Ketamine was equipotent for both phenomena in 25-day-old rats and, in contrast, it decreased more AD duration than WDS number in 90-day-old rats." | 1.29 | Developmental changes of ketamine action against epileptic afterdischarges induced by hippocampal stimulation in rats. ( Mares, P; Mikolásová, R; Velísek, L; Vorlícek, J, 1994) |
| "Emesis was characterized by expulsion of solid or liquid material." | 1.29 | Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents. ( Göthert, M; Herold, H; Szelenyi, I, 1994) |
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| " Generally, an orderly inverted U-shaped dose-response curve for rates of self-injection has been observed." | 1.27 | Animal models of intravenous phencyclinoid self-administration. ( Marquis, KL; Moreton, JE, 1987) |
| "The "spontaneous" myoclonus which followed vermisectomy (MV) was "massive", but involved firstly the trunk and secondarily the face and limbs; no ECoG paraoxysm accompanied this myoclonus, but we observed a parietal evoked potential of small amplitude, 10--15 msec after its onset." | 1.26 | Myoclonus developing after vermisectomy in photosensitive Papio papio. ( Brailowsky, S; Menini, C; Naquet, R, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (2.71) | 18.7374 |
| 1990's | 27 (4.07) | 18.2507 |
| 2000's | 102 (15.38) | 29.6817 |
| 2010's | 403 (60.78) | 24.3611 |
| 2020's | 113 (17.04) | 2.80 |
| Authors | Studies |
|---|---|
| Turcu, AL | 1 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Pérez, B | 1 |
| Soto, D | 1 |
| Sureda, FX | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Vázquez, S | 1 |
| Pottenger, AE | 1 |
| Bartlett, MJ | 1 |
| Sherman, SJ | 1 |
| Falk, T | 1 |
| Morrison, HW | 1 |
| Moghaddam, AH | 2 |
| Maboudi, K | 1 |
| Bavaghar, B | 1 |
| Sangdehi, SRM | 1 |
| Zare, M | 1 |
| Verney, C | 1 |
| Legouis, D | 1 |
| Placier, S | 1 |
| Migeon, T | 1 |
| Bonnin, P | 1 |
| Buob, D | 1 |
| Hadchouel, J | 1 |
| Galichon, P | 1 |
| Davis, GL | 1 |
| Minerva, AR | 1 |
| Lario, A | 1 |
| Simmler, LD | 1 |
| Rodriguez, CI | 1 |
| Gunaydin, LA | 1 |
| Chen, ST | 1 |
| Hsieh, CP | 1 |
| Lee, MY | 2 |
| Chen, LC | 1 |
| Huang, CM | 1 |
| Chen, HH | 2 |
| Chan, MH | 2 |
| Edem, EE | 2 |
| Anyanwu, CC | 1 |
| Nebo, KE | 2 |
| Akinluyi, ET | 2 |
| Fafure, AA | 2 |
| Ishola, AO | 1 |
| Enye, LA | 1 |
| Zhou, R | 1 |
| Wang, Y | 16 |
| Cao, X | 2 |
| Li, Z | 4 |
| Yu, J | 2 |
| Tan, Y | 6 |
| Fujita, Y | 12 |
| Pu, Y | 10 |
| Chang, L | 15 |
| Qu, Y | 14 |
| Wang, X | 16 |
| Hashimoto, K | 36 |
| Zhu, X | 2 |
| Zhang, F | 2 |
| You, Y | 1 |
| Wang, H | 4 |
| Yuan, S | 1 |
| Wu, B | 1 |
| Zhu, R | 1 |
| Liu, D | 4 |
| Yan, F | 1 |
| Wang, Z | 4 |
| Wan, X | 3 |
| Shan, J | 3 |
| Yang, Y | 9 |
| Ma, L | 4 |
| Radford, KD | 2 |
| Berman, RY | 2 |
| Jaiswal, S | 1 |
| Kim, SY | 1 |
| Zhang, M | 4 |
| Spencer, HF | 2 |
| Choi, KH | 2 |
| Ju, L | 1 |
| Yang, J | 6 |
| Zhu, T | 1 |
| Liu, P | 1 |
| Moraga-Amaro, R | 1 |
| Guerrin, CGJ | 1 |
| Reali Nazario, L | 1 |
| Lima Giacobbo, B | 1 |
| J O Dierckx, RA | 1 |
| Stehberg, J | 1 |
| de Vries, EFJ | 1 |
| Doorduin, J | 1 |
| Choi, M | 2 |
| Ko, SY | 1 |
| Seo, JY | 1 |
| Kim, DG | 1 |
| Lee, H | 2 |
| Chung, H | 1 |
| Son, H | 1 |
| Zoladz, PR | 1 |
| Del Valle, CR | 1 |
| Goodman, CS | 1 |
| Dodson, JL | 1 |
| Smith, IF | 1 |
| Elmouhawesse, KM | 1 |
| Sparkman, HR | 1 |
| Naylor, MM | 1 |
| Hopson, EP | 1 |
| Bove, M | 1 |
| Schiavone, S | 3 |
| Tucci, P | 3 |
| Sikora, V | 1 |
| Dimonte, S | 1 |
| Colia, AL | 1 |
| Morgese, MG | 2 |
| Trabace, L | 3 |
| Chen, X | 4 |
| Zhang, Z | 5 |
| Shen, M | 1 |
| Ma, X | 3 |
| Qiu, D | 1 |
| Li, S | 8 |
| Gao, L | 1 |
| Eguchi, A | 1 |
| Zhang, J | 8 |
| Mori, C | 1 |
| Ibrahim, WW | 1 |
| Sayed, RH | 1 |
| Kandil, EA | 1 |
| Wadie, W | 1 |
| Azevedo, MR | 1 |
| de-Lima-Oliveira, M | 1 |
| Belon, AR | 1 |
| Brasil, S | 1 |
| Teixeira, MJ | 1 |
| Paiva, WS | 1 |
| Bor-Seng-Shu, E | 1 |
| Wei, Y | 5 |
| Xiao, L | 2 |
| Fan, W | 2 |
| Zou, J | 1 |
| Yang, H | 2 |
| Liu, B | 1 |
| Ye, Y | 4 |
| Wen, D | 2 |
| Liao, L | 3 |
| Zhou, J | 2 |
| Chen, F | 3 |
| Yan, A | 1 |
| Xia, X | 1 |
| García-Baos, A | 1 |
| Gallego-Landin, I | 1 |
| Ferreres-Álvarez, I | 1 |
| Puig-Reyne, X | 1 |
| Castro-Zavala, A | 1 |
| Valverde, O | 1 |
| Martín-Sánchez, A | 1 |
| Temizer, R | 1 |
| Chen, YW | 2 |
| Aoki, C | 2 |
| Carboni, E | 1 |
| Carta, AR | 1 |
| Ferrarelli, LK | 1 |
| Colombo, G | 1 |
| Cubero, RJA | 1 |
| Kanari, L | 1 |
| Venturino, A | 1 |
| Schulz, R | 1 |
| Scolamiero, M | 1 |
| Agerberg, J | 1 |
| Mathys, H | 1 |
| Tsai, LH | 1 |
| Chachólski, W | 1 |
| Hess, K | 1 |
| Siegert, S | 1 |
| Fu, Y | 1 |
| Cheng, A | 1 |
| Belloch, FB | 1 |
| Cortés-Erice, M | 1 |
| Herzog, E | 1 |
| Zhang, XM | 1 |
| Díaz-Perdigon, T | 1 |
| Puerta, E | 1 |
| Tordera, RM | 1 |
| Zhao, XH | 3 |
| An, N | 3 |
| Xia, MH | 3 |
| Liu, WP | 3 |
| Wang, QQ | 3 |
| Bao, JZ | 3 |
| Gu, C | 4 |
| Liu, J | 8 |
| Li, Y | 15 |
| Zhang, Q | 9 |
| Lin, C | 3 |
| Huang, J | 5 |
| Duan, W | 4 |
| Deng, Y | 3 |
| Ahmed, W | 3 |
| Li, R | 3 |
| Long, J | 3 |
| Khan, AA | 3 |
| Chen, L | 6 |
| Xiao, S | 1 |
| Zhou, Y | 7 |
| Wang, Q | 5 |
| Yang, D | 3 |
| Halff, EF | 1 |
| Natesan, S | 1 |
| Bonsall, DR | 1 |
| Veronese, M | 1 |
| Garcia-Hidalgo, A | 1 |
| Kokkinou, M | 1 |
| Tang, SP | 1 |
| Riggall, LJ | 1 |
| Gunn, RN | 1 |
| Irvine, EE | 1 |
| Withers, DJ | 1 |
| Wells, LA | 1 |
| Howes, OD | 1 |
| Kingir, E | 1 |
| Sevinc, C | 1 |
| Unal, G | 3 |
| de Oliveira, EG | 1 |
| de Lima, DA | 1 |
| da Silva Júnior, JC | 1 |
| de Souza Barbosa, MV | 1 |
| de Andrade Silva, SC | 1 |
| de Santana, JH | 1 |
| Dos Santos Junior, OH | 1 |
| Lira, EC | 1 |
| Lagranha, CJ | 1 |
| Duarte, FS | 1 |
| Gomes, DA | 1 |
| Chen, T | 1 |
| Cheng, L | 1 |
| Ma, J | 1 |
| Yuan, J | 1 |
| Pi, C | 1 |
| Xiong, L | 1 |
| Chen, J | 7 |
| Liu, H | 6 |
| Tang, J | 7 |
| Zhong, Y | 1 |
| Zhang, X | 8 |
| Liu, Z | 4 |
| Zuo, Y | 1 |
| Shen, H | 2 |
| Zhao, L | 3 |
| Akan, M | 1 |
| Skorodumov, I | 1 |
| Meinhardt, MW | 1 |
| Canbeyli, R | 2 |
| Farkhakfar, A | 1 |
| Hassanpour, S | 1 |
| Zendehdel, M | 1 |
| Valvassori, SS | 5 |
| da Rosa, RT | 1 |
| Dal-Pont, GC | 1 |
| Varela, RB | 1 |
| Mastella, GA | 6 |
| Daminelli, T | 1 |
| Fries, GR | 1 |
| Quevedo, J | 25 |
| Zugno, AI | 18 |
| Partridge, KJ | 1 |
| Olson, R | 1 |
| Hillhouse, TM | 2 |
| Oguntala, OA | 1 |
| Ikuelogbon, DA | 1 |
| Isaac, GT | 1 |
| Kunlere, OE | 1 |
| Abrahams, D | 1 |
| Ibrahim-Hashim, A | 1 |
| Ackerman, RS | 1 |
| Brown, JS | 1 |
| Whelan, CJ | 1 |
| Garfinkel, MB | 1 |
| Gatenby, RA | 1 |
| Muncey, AR | 1 |
| Brandão, AAC | 1 |
| Deus, DLS | 1 |
| Duarte-Filho, LAMS | 1 |
| Menezes, PMN | 1 |
| Massaranduba, ABR | 1 |
| Silva, FS | 1 |
| Ribeiro, LAA | 1 |
| Fujita, A | 2 |
| Polis, AJ | 1 |
| Fitzgerald, PJ | 1 |
| Hale, PJ | 1 |
| Watson, BO | 1 |
| Krimmel, SR | 1 |
| Zanos, P | 2 |
| Georgiou, P | 2 |
| Colloca, L | 1 |
| Gould, TD | 2 |
| Ding, R | 1 |
| Ren, X | 1 |
| Wen, G | 1 |
| Dong, Z | 4 |
| Yao, H | 1 |
| Yu, H | 2 |
| Zhan, X | 1 |
| Yao, J | 2 |
| Lu, Y | 2 |
| Zhang, G | 2 |
| Wu, X | 4 |
| Xu, Y | 2 |
| Deng, C | 1 |
| Zheng, Y | 3 |
| Liu, N | 1 |
| Fu, B | 1 |
| Girasek, QL | 1 |
| Trujillo, KA | 1 |
| Heller, CY | 1 |
| Banki, L | 1 |
| Büki, A | 3 |
| Horvath, G | 7 |
| Kekesi, G | 6 |
| Kis, G | 1 |
| Somogyvári, F | 1 |
| Jancsó, G | 1 |
| Vécsei, L | 1 |
| Varga, E | 1 |
| Tuboly, G | 5 |
| Tannich, F | 1 |
| Tlili, A | 1 |
| Pintard, C | 1 |
| Chniguir, A | 1 |
| Eto, B | 1 |
| Dang, PM | 1 |
| Souilem, O | 1 |
| El-Benna, J | 1 |
| Damazio Pacheco, F | 1 |
| Canever, L | 12 |
| Antunes Mastella, G | 2 |
| Gomes Wessler, P | 1 |
| Kunz Godoi, A | 1 |
| Hubbe, I | 1 |
| da Costa Afonso, A | 1 |
| Celso, D | 1 |
| Ioppi Zugno, A | 1 |
| Moretti, M | 3 |
| Werle, I | 1 |
| da Rosa, PB | 1 |
| Neis, VB | 2 |
| Platt, N | 1 |
| Souza, SVS | 1 |
| Rodrigues, ALS | 3 |
| Chaves, VC | 2 |
| Soares, MSP | 1 |
| Spohr, L | 1 |
| Teixeira, F | 1 |
| Vieira, A | 2 |
| Constantino, LS | 1 |
| Pizzol, FD | 1 |
| Lencina, CL | 1 |
| Spanevello, RM | 2 |
| Freitas, MP | 1 |
| Simões, CMO | 1 |
| Reginatto, FH | 2 |
| Stefanello, FM | 1 |
| Yang, C | 16 |
| Luo, A | 3 |
| Wei, MD | 1 |
| Wang, YH | 1 |
| Lu, K | 1 |
| Lv, BJ | 1 |
| Chen, WY | 1 |
| Ghosal, S | 1 |
| Duman, CH | 1 |
| Liu, RJ | 1 |
| Wu, M | 1 |
| Terwilliger, R | 1 |
| Girgenti, MJ | 1 |
| Wohleb, E | 1 |
| Fogaca, MV | 1 |
| Teichman, EM | 1 |
| Hare, B | 1 |
| Duman, RS | 4 |
| Rincón-Cortés, M | 2 |
| Grace, AA | 4 |
| Kuklin, V | 1 |
| Akhatov, N | 1 |
| Kondratiev, T | 1 |
| Konkayev, A | 1 |
| Baigenzhin, A | 1 |
| Konkayeva, M | 1 |
| Karibekov, T | 1 |
| Barlow, N | 1 |
| Tveita, T | 1 |
| Dahl, V | 1 |
| Nowak, W | 1 |
| Grendas, LN | 1 |
| Sanmarco, LM | 1 |
| Estecho, IG | 1 |
| Arena, ÁR | 1 |
| Eberhardt, N | 1 |
| Rodante, DE | 1 |
| Aoki, MP | 1 |
| Daray, FM | 1 |
| Carrera Silva, EA | 1 |
| Errasti, AE | 1 |
| Kim, JW | 1 |
| Monteggia, LM | 3 |
| B Hughes, R | 1 |
| Whittingham-Dowd, J | 1 |
| Simmons, RE | 1 |
| Clapcote, SJ | 1 |
| Broughton, SJ | 1 |
| Dawson, N | 3 |
| Kozela, E | 1 |
| Krawczyk, M | 1 |
| Kos, T | 6 |
| Juknat, A | 1 |
| Vogel, Z | 1 |
| Popik, P | 11 |
| Zhang, K | 11 |
| Sakamoto, A | 2 |
| Wang, S | 6 |
| Ishima, T | 4 |
| Hatano, M | 2 |
| Xie, R | 1 |
| Xie, J | 1 |
| Yang, L | 4 |
| Yan, Y | 1 |
| Klein, ME | 1 |
| Chandra, J | 1 |
| Sheriff, S | 1 |
| Malinow, R | 1 |
| Ji, MH | 4 |
| Zhang, L | 6 |
| Mao, MJ | 1 |
| Zhang, H | 10 |
| Yang, JJ | 9 |
| Qiu, LL | 2 |
| Sun, J | 3 |
| Lin, J | 1 |
| Feng, X | 1 |
| Lu, Z | 1 |
| Liu, T | 3 |
| Lin, L | 5 |
| Chen, Y | 1 |
| Hu, Y | 2 |
| Xu, S | 1 |
| Guo, H | 1 |
| Maher, DP | 1 |
| Cohen, SP | 1 |
| Zaccarelli-Magalhães, J | 1 |
| Fukushima, AR | 1 |
| Moreira, N | 1 |
| Manes, M | 1 |
| de Abreu, GR | 1 |
| Ricci, EL | 1 |
| Waziry, PAF | 1 |
| Spinosa, HS | 1 |
| Wilson, C | 1 |
| Hannan, AJ | 1 |
| Renoir, T | 1 |
| Suzuki, T | 1 |
| Shirayama, Y | 5 |
| Tanaka, KF | 1 |
| Ettenberg, A | 2 |
| Ayala, K | 2 |
| Krug, JT | 2 |
| Collins, L | 2 |
| Mayes, MS | 2 |
| Fisher, MPA | 2 |
| Yokoyama, R | 2 |
| Higuchi, M | 2 |
| Tanabe, W | 2 |
| Tsukada, S | 2 |
| Naito, M | 1 |
| Yamaguchi, T | 2 |
| Kasai, A | 2 |
| Seiriki, K | 2 |
| Nakazawa, T | 2 |
| Nakagawa, S | 2 |
| Hashimoto, H | 3 |
| Ago, Y | 2 |
| George, MY | 1 |
| Menze, ET | 1 |
| Esmat, A | 1 |
| Tadros, MG | 1 |
| El-Demerdash, E | 1 |
| Xiong, Z | 5 |
| Herzog, DP | 1 |
| Mellema, RM | 1 |
| Remmers, F | 1 |
| Lutz, B | 1 |
| Müller, MB | 1 |
| Treccani, G | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 3 |
| Zhao, Y | 4 |
| Wang, J | 14 |
| Huang, L | 4 |
| Hu, K | 1 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 3 |
| Cheng, T | 1 |
| Zhou, X | 3 |
| Wang, B | 4 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 10 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 3 |
| Jiang, H | 2 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 5 |
| Sun, Q | 1 |
| Han, D | 2 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 5 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 6 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Xu, N | 3 |
| Wang, R | 1 |
| Liu, S | 2 |
| He, H | 2 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 4 |
| Han, J | 2 |
| Zhang, C | 3 |
| Yang, X | 4 |
| Li, W | 3 |
| Wang, T | 3 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 7 |
| Yao, L | 2 |
| Sun, L | 7 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 3 |
| Yoo, JS | 1 |
| Kim, Y | 2 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 5 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Yan, R | 1 |
| Zhang, Y | 8 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 10 |
| Guo, G | 1 |
| Li, L | 5 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Huang, X | 2 |
| Xu, H | 4 |
| Yang, G | 4 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 11 |
| Du, S | 1 |
| Zhou, H | 3 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 12 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 2 |
| Choi, GH | 1 |
| Choi, J | 2 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 2 |
| Yu, X | 2 |
| Wu, Y | 4 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 3 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 2 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 3 |
| Zheng, S | 2 |
| Wang, L | 5 |
| Hu, T | 1 |
| Wang, F | 4 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 2 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Du, Q | 1 |
| Hao, P | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 3 |
| Chen, Z | 3 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Guo, W | 1 |
| Liu, M | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 2 |
| Sun, W | 2 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 3 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 3 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 2 |
| Bai, J | 1 |
| Han, R | 2 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 2 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 2 |
| Yu, Q | 1 |
| Zhou, C | 5 |
| Liu, C | 5 |
| Liu, W | 3 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 3 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Cao, Q | 1 |
| Yuan, X | 2 |
| Nie, W | 1 |
| Shao, B | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 2 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 2 |
| Fan, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 3 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 5 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 4 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 2 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Tian, J | 1 |
| Zhao, M | 2 |
| Hu, J | 2 |
| Yao, C | 1 |
| Zhang, B | 2 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 2 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 3 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 3 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 2 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 2 |
| Shen, Y | 1 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Liang, H | 1 |
| Xu, X | 2 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 3 |
| Wang, P | 2 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Xue, H | 2 |
| Zhang, W | 4 |
| Ruan, Z | 1 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 3 |
| Cai, S | 1 |
| He, Y | 4 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 2 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 2 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 2 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 2 |
| Liang, J | 2 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 3 |
| Wang, D | 1 |
| Hu, M | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 2 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 2 |
| Sun, X | 2 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Wu, JL | 1 |
| Haberman, RP | 1 |
| Gallagher, M | 3 |
| Koh, MT | 4 |
| Çömez, MS | 1 |
| Cellat, M | 1 |
| Özkan, H | 1 |
| Borazan, Y | 1 |
| Aydın, T | 1 |
| Gökçek, İ | 1 |
| Türk, E | 1 |
| Güvenç, M | 1 |
| Çakır, A | 1 |
| Özsoy, ŞY | 1 |
| Martínez-Pinteño, A | 1 |
| García-Cerro, S | 1 |
| Mas, S | 1 |
| Torres, T | 1 |
| Boloc, D | 1 |
| Rodríguez, N | 1 |
| Lafuente, A | 1 |
| Gassó, P | 1 |
| Arnaiz, JA | 1 |
| Parellada, E | 1 |
| de Almeida, RF | 1 |
| Pocharski, CB | 1 |
| Elisabetsky, E | 1 |
| Souza, DO | 1 |
| Fortea, JI | 1 |
| Puerto, M | 1 |
| Fernández-Mena, C | 1 |
| Asensio, I | 1 |
| Arriba, M | 1 |
| Almagro, J | 1 |
| Bañares, J | 1 |
| Ripoll, C | 1 |
| Bañares, R | 1 |
| Vaquero, J | 1 |
| Tang, XH | 2 |
| Zhang, GF | 6 |
| Duan, GF | 1 |
| Jia, M | 2 |
| Liu, R | 3 |
| Zhou, ZQ | 5 |
| Aleksandrova, LR | 2 |
| Wang, YT | 2 |
| Phillips, AG | 3 |
| Ribeiro, ACR | 1 |
| Kronfol, MM | 1 |
| Jahr, FM | 1 |
| Younis, RM | 1 |
| Hawkins, E | 1 |
| McClay, JL | 1 |
| Deshpande, LS | 1 |
| Feder, A | 1 |
| Rutter, SB | 1 |
| Schiller, D | 1 |
| Charney, DS | 1 |
| Pochwat, B | 1 |
| Domin, H | 1 |
| Rafało-Ulińska, A | 2 |
| Szewczyk, B | 2 |
| Nowak, G | 4 |
| Emmerzaal, TL | 1 |
| Jacobs, L | 1 |
| Geenen, B | 1 |
| Verweij, V | 1 |
| Morava, E | 1 |
| Rodenburg, RJ | 1 |
| Kozicz, T | 1 |
| Camargo, A | 1 |
| Dalmagro, AP | 1 |
| M Rosa, J | 1 |
| B Zeni, AL | 1 |
| P Kaster, M | 1 |
| Tasca, CI | 1 |
| S Rodrigues, AL | 1 |
| Gursoy, ID | 1 |
| Barun, S | 1 |
| Erdem, SR | 1 |
| Keskin, U | 1 |
| Kiziltas, M | 1 |
| Atilla, P | 1 |
| Muftuoglu, S | 1 |
| Yuce, D | 1 |
| Narin, F | 1 |
| Ertunc, M | 1 |
| Sara, Y | 1 |
| Canpinar, H | 1 |
| Kartal, S | 1 |
| Kip, G | 1 |
| Küçük, A | 1 |
| Aşçı, SS | 1 |
| Erdem, Ö | 1 |
| Arslan, M | 2 |
| Kavutçu, M | 1 |
| Takahashi, K | 1 |
| Kitamura, Y | 1 |
| Ushio, S | 1 |
| Sendo, T | 1 |
| Chen, H | 2 |
| Vandorpe, DH | 1 |
| Alper, SL | 1 |
| Zeidel, ML | 1 |
| Yu, W | 1 |
| Friesner, ID | 1 |
| Martinez, E | 2 |
| Gould, JD | 1 |
| Li, A | 1 |
| Chen, ZS | 1 |
| Cavanagh, SE | 1 |
| Lam, NH | 1 |
| Murray, JD | 1 |
| Hunt, LT | 1 |
| Kennerley, SW | 1 |
| Yamamoto, M | 1 |
| Wu, XM | 1 |
| He, X | 1 |
| Wang, RZ | 1 |
| Yin, XY | 2 |
| Zhou, F | 1 |
| Shen, JC | 2 |
| Viana, GSB | 2 |
| Vale, EMD | 1 |
| Araujo, ARA | 1 |
| Coelho, NC | 1 |
| Andrade, SM | 1 |
| Costa, ROD | 1 |
| Aquino, PEA | 1 |
| Sousa, CNS | 1 |
| Medeiros, IS | 1 |
| Vasconcelos, SMM | 6 |
| Neves, KRT | 1 |
| Vecchia, DD | 3 |
| Kanazawa, LKS | 3 |
| Wendler, E | 3 |
| Hocayen, PAS | 1 |
| Vital, MABF | 2 |
| Takahashi, RN | 1 |
| Da Cunha, C | 2 |
| Miyoshi, E | 2 |
| Andreatini, R | 3 |
| Alqahtani, F | 1 |
| Assiri, MA | 1 |
| Mohany, M | 1 |
| Imran, I | 1 |
| Javaid, S | 1 |
| Rasool, MF | 1 |
| Shakeel, W | 1 |
| Sivandzade, F | 1 |
| Alanazi, AZ | 1 |
| Al-Rejaie, SS | 1 |
| Alshammari, MA | 1 |
| Alasmari, F | 1 |
| Alanazi, MM | 1 |
| Alamri, FF | 1 |
| Andrade, YCP | 1 |
| Ropke, J | 2 |
| Viana, TG | 1 |
| Fanelli, C | 1 |
| Minaldi, E | 1 |
| Batista, LA | 1 |
| Issy, AC | 1 |
| Del Bel, EA | 1 |
| Rodrigues, LCM | 1 |
| Liégeois, JF | 1 |
| Moreira, FA | 2 |
| Pałucha-Poniewiera, A | 3 |
| Podkowa, K | 1 |
| Gao, TH | 1 |
| Ni, RJ | 1 |
| Tian, Y | 1 |
| Wei, J | 1 |
| Ni, P | 1 |
| Li, T | 1 |
| Venincasa, MJ | 1 |
| Randlett, O | 1 |
| Sumathipala, SH | 1 |
| Bindernagel, R | 1 |
| Stark, MJ | 1 |
| Yan, Q | 1 |
| Sloan, SA | 1 |
| Buglo, E | 1 |
| Meng, QC | 1 |
| Engert, F | 1 |
| Züchner, S | 1 |
| Kelz, MB | 1 |
| Syed, S | 1 |
| Dallman, JE | 1 |
| Hashimoto, Y | 2 |
| Marrero-Rosado, BM | 1 |
| Stone, MF | 1 |
| de Araujo Furtado, M | 1 |
| Schultz, CR | 1 |
| Cadieux, CL | 1 |
| Lumley, LA | 1 |
| Reddy, BR | 1 |
| Babu, NS | 1 |
| Das, T | 1 |
| Bhattacharya, D | 1 |
| Murthy, CLN | 1 |
| Kumar, A | 4 |
| Idris, MM | 1 |
| Chakravarty, S | 1 |
| Du, Y | 1 |
| Sun, H | 5 |
| Wang, A | 1 |
| Li, Q | 6 |
| Du, Z | 3 |
| Gore, A | 1 |
| Neufeld-Cohen, A | 1 |
| Egoz, I | 1 |
| Baranes, S | 1 |
| Gez, R | 1 |
| Efrati, R | 1 |
| David, T | 1 |
| Dekel Jaoui, H | 1 |
| Yampolsky, M | 1 |
| Grauer, E | 1 |
| Chapman, S | 1 |
| Lazar, S | 1 |
| Wang, M | 2 |
| Gorelick, FS | 1 |
| Sartim, AG | 1 |
| Marques, J | 1 |
| Silveira, KM | 1 |
| Gobira, PH | 1 |
| Guimarães, FS | 1 |
| Wegener, G | 6 |
| Joca, SR | 1 |
| Jiang, R | 3 |
| Wu, Z | 1 |
| Huang, C | 4 |
| Zhu, B | 3 |
| Yan, E | 1 |
| Meighan, W | 1 |
| Elston, TW | 1 |
| Bilkey, D | 1 |
| Ward, RD | 1 |
| Wu, D | 1 |
| Qiao, H | 1 |
| Shan, Z | 1 |
| Matuszko, G | 1 |
| Curreli, S | 1 |
| Kaushik, R | 1 |
| Becker, A | 7 |
| Dityatev, A | 1 |
| Alves, CSV | 1 |
| Mastella, G | 2 |
| Damázio, L | 2 |
| Polla, JV | 1 |
| Citadin, S | 1 |
| De Luca, LA | 1 |
| Barcellos, AS | 1 |
| Garcez, ML | 1 |
| Budni, J | 10 |
| Hamm, JP | 1 |
| Peterka, DS | 1 |
| Gogos, JA | 1 |
| Yuste, R | 1 |
| Orozco-Solis, R | 1 |
| Montellier, E | 1 |
| Aguilar-Arnal, L | 1 |
| Sato, S | 1 |
| Vawter, MP | 1 |
| Bunney, BG | 1 |
| Bunney, WE | 1 |
| Sassone-Corsi, P | 1 |
| Ruda-Kucerova, J | 2 |
| Babinska, Z | 2 |
| Stark, T | 1 |
| Micale, V | 1 |
| Zurawek, D | 1 |
| Salerno-Kochan, A | 1 |
| Dziedzicka-Wasylewska, M | 1 |
| Nikiforuk, A | 7 |
| Réus, GZ | 7 |
| Simões, LR | 2 |
| Colpo, GD | 1 |
| Scaini, G | 3 |
| Oses, JP | 2 |
| Generoso, JS | 1 |
| Prossin, AR | 1 |
| Kaddurah-Daouk, R | 2 |
| Barichello, T | 4 |
| Morena, M | 1 |
| Berardi, A | 1 |
| Peloso, A | 1 |
| Valeri, D | 1 |
| Palmery, M | 1 |
| Trezza, V | 1 |
| Schelling, G | 1 |
| Campolongo, P | 1 |
| Huang, YJ | 1 |
| Lane, HY | 1 |
| Lin, CH | 1 |
| Besnier, E | 1 |
| Clavier, T | 1 |
| Tonon, MC | 1 |
| Selim, J | 1 |
| Lefevre-Scelles, A | 1 |
| Morin, F | 1 |
| Tamion, F | 1 |
| Dureuil, B | 1 |
| Castel, H | 1 |
| Compere, V | 1 |
| Hołuj, M | 4 |
| Librowski, T | 2 |
| Sałat, K | 2 |
| Yadav, M | 3 |
| Jindal, DK | 3 |
| Dhingra, MS | 2 |
| Parle, M | 3 |
| Dhingra, S | 3 |
| Xie, ZM | 2 |
| Wang, XM | 3 |
| Pan, W | 3 |
| Annafi, OS | 1 |
| Aluko, OM | 1 |
| Eduviere, AT | 1 |
| Omorogbe, O | 1 |
| Umukoro, S | 5 |
| Shao, Y | 3 |
| Rosenzweig-Lipson, S | 1 |
| Hauser, MJ | 2 |
| Isbrandt, D | 1 |
| Roeper, J | 1 |
| Ren, Q | 7 |
| Zhang, JC | 3 |
| Ma, M | 8 |
| Marcos, JL | 1 |
| Galleguillos, D | 1 |
| Pelissier, T | 1 |
| Hernández, A | 1 |
| Velásquez, L | 1 |
| Villanueva, L | 1 |
| Constandil, L | 1 |
| Suárez-Santiago, JE | 2 |
| Briones-Aranda, A | 2 |
| Espinosa-Raya, J | 1 |
| Picazo, O | 2 |
| Ostadhadi, S | 1 |
| Norouzi-Javidan, A | 1 |
| Chamanara, M | 1 |
| Akbarian, R | 1 |
| Imran-Khan, M | 1 |
| Ghasemi, M | 1 |
| Dehpour, AR | 2 |
| Burhans, LB | 1 |
| Smith-Bell, CA | 1 |
| Schreurs, BG | 1 |
| Saur, L | 1 |
| Neves, LT | 1 |
| Greggio, S | 1 |
| Venturin, GT | 1 |
| Jeckel, CMM | 1 |
| Costa Da Costa, J | 1 |
| Bertoldi, K | 1 |
| Schallenberger, B | 1 |
| Siqueira, IR | 2 |
| Mestriner, RG | 1 |
| Xavier, LL | 1 |
| Lee, YL | 3 |
| Lin, KL | 2 |
| Chuang, SM | 3 |
| Lee, YC | 3 |
| Lu, MC | 2 |
| Wu, BN | 1 |
| Wu, WJ | 3 |
| Yuan, SF | 1 |
| Ho, WT | 2 |
| Juan, YS | 3 |
| Jiang, Y | 1 |
| Lian, B | 2 |
| Wang, G | 3 |
| Krystal, JH | 3 |
| Abdallah, CG | 2 |
| Averill, LA | 1 |
| Kelmendi, B | 1 |
| Harpaz-Rotem, I | 1 |
| Sanacora, G | 2 |
| Southwick, SM | 1 |
| Sampaio, LRL | 3 |
| Borges, LTN | 2 |
| Silva, JMF | 1 |
| de Andrade, FRO | 1 |
| Barbosa, TM | 3 |
| Oliveira, TQ | 1 |
| Macedo, D | 7 |
| Lima, RF | 2 |
| Dantas, LP | 1 |
| Patrocinio, MCA | 3 |
| do Vale, OC | 1 |
| Iñiguez, SD | 1 |
| Flores-Ramirez, FJ | 1 |
| Riggs, LM | 1 |
| Alipio, JB | 1 |
| Garcia-Carachure, I | 1 |
| Hernandez, MA | 1 |
| Sanchez, DO | 1 |
| Lobo, MK | 1 |
| Serrano, PA | 1 |
| Braren, SH | 1 |
| Castillo, SA | 1 |
| McGirr, A | 1 |
| LeDue, J | 1 |
| Chan, AW | 1 |
| Murphy, TH | 1 |
| Huang, BS | 2 |
| Liston, C | 2 |
| Ben-Azu, B | 5 |
| Aderibigbe, AO | 5 |
| Omogbiya, IA | 3 |
| Ajayi, AM | 5 |
| Iwalewa, EO | 5 |
| Browne, CA | 1 |
| Falcon, E | 1 |
| Robinson, SA | 1 |
| Berton, O | 1 |
| Lucki, I | 1 |
| Becker, IRT | 1 |
| Petronilho, F | 4 |
| Ceretta, LB | 1 |
| Dal-Pizzol, F | 4 |
| Hales, CA | 1 |
| Houghton, CJ | 1 |
| Robinson, ESJ | 1 |
| DeWalt, GJ | 1 |
| Mahajan, B | 1 |
| Foster, AR | 1 |
| Thompson, LDE | 1 |
| Marttini, AA | 1 |
| Schmidt, EV | 1 |
| Mansuri, S | 1 |
| D'Souza, D | 1 |
| Patel, SB | 1 |
| Tenenbaum, M | 1 |
| Brandao-Viruet, KI | 1 |
| Thompson, D | 1 |
| Duong, B | 1 |
| Smith, DH | 1 |
| Blute, TA | 1 |
| Eldred, WD | 1 |
| Ogundele, OM | 1 |
| Lee, CC | 1 |
| Coronel-Oliveros, CM | 1 |
| Pacheco-Calderón, R | 1 |
| Lilius, TO | 1 |
| Viisanen, H | 1 |
| Jokinen, V | 1 |
| Niemi, M | 1 |
| Kalso, EA | 1 |
| Rauhala, PV | 1 |
| Pham, TH | 1 |
| Defaix, C | 1 |
| Deng, SX | 1 |
| Fabresse, N | 1 |
| Alvarez, JC | 1 |
| Landry, DW | 1 |
| Brachman, RA | 1 |
| Denny, CA | 1 |
| Gardier, AM | 1 |
| Liu, JF | 1 |
| Han, Y | 1 |
| Luo, YX | 1 |
| Xue, YX | 1 |
| Zhu, WL | 1 |
| Chen, WH | 1 |
| Guo, HL | 1 |
| Ma, YN | 1 |
| Yuan, K | 1 |
| Wang, JS | 1 |
| Lu, L | 2 |
| Maciel, AL | 1 |
| Abelaira, HM | 3 |
| de Moura, AB | 1 |
| de Souza, TG | 1 |
| Rosa, T | 1 |
| Matos, D | 1 |
| Tuon, T | 1 |
| Garbossa, L | 1 |
| Strassi, AP | 1 |
| Fileti, ME | 1 |
| Goldim, MP | 1 |
| Mathias, K | 1 |
| Zhang, WJ | 1 |
| Wang, HH | 2 |
| Lv, YD | 1 |
| Liu, CC | 1 |
| Sun, WY | 1 |
| Tian, LJ | 1 |
| de Almeida Soares Hocayen, P | 2 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Wöhr, M | 2 |
| Schwarting, RKW | 2 |
| Cysne Filho, FMS | 1 |
| de Almeida, JC | 2 |
| Diniz, DDS | 1 |
| Patrocínio, CFV | 1 |
| de Sousa, CNS | 1 |
| Rezvani, AH | 1 |
| Tizabi, Y | 3 |
| Slade, S | 1 |
| Getachew, B | 1 |
| Levin, ED | 1 |
| Adaikkan, C | 1 |
| Taha, E | 1 |
| Barrera, I | 1 |
| David, O | 1 |
| Rosenblum, K | 1 |
| Xiang, L | 2 |
| Klemcke, HG | 1 |
| Wienandt, NA | 1 |
| Ryan, KL | 1 |
| Hinojosa-Laborde, C | 1 |
| Sang, K | 1 |
| Dong, Y | 1 |
| Ni, Z | 1 |
| Ma, S | 1 |
| Buratovic, S | 1 |
| Stenerlöw, B | 1 |
| Sundell-Bergman, S | 1 |
| Fredriksson, A | 2 |
| Viberg, H | 1 |
| Gordh, T | 2 |
| Eriksson, P | 2 |
| Fraga, DB | 5 |
| Olescowicz, G | 1 |
| Siteneski, A | 1 |
| Tavares, MK | 1 |
| Azevedo, D | 1 |
| Colla, ARS | 1 |
| Tu, G | 1 |
| Luo, C | 1 |
| Fang, M | 1 |
| Zhu, C | 1 |
| Ou, J | 1 |
| Yung, KKL | 1 |
| Mo, Z | 1 |
| Hultman, R | 1 |
| Ulrich, K | 1 |
| Sachs, BD | 1 |
| Blount, C | 1 |
| Carlson, DE | 1 |
| Ndubuizu, N | 1 |
| Bagot, RC | 1 |
| Parise, EM | 1 |
| Vu, MT | 1 |
| Gallagher, NM | 1 |
| Silva, AJ | 1 |
| Deisseroth, K | 2 |
| Mague, SD | 1 |
| Caron, MG | 1 |
| Nestler, EJ | 2 |
| Carin, L | 1 |
| Dzirasa, K | 1 |
| Eneni, AO | 3 |
| Kim, ID | 1 |
| Kim, SW | 2 |
| Lee, HK | 1 |
| Han, PL | 1 |
| Lee, JK | 1 |
| Sanku, RKK | 1 |
| John, JS | 1 |
| Salkovitz, M | 1 |
| Ilies, MA | 1 |
| Walker, EA | 1 |
| Hou, L | 1 |
| Qi, Y | 1 |
| Ahrens, PS | 1 |
| Xie, W | 1 |
| Li, HH | 2 |
| Li, KY | 2 |
| Xia, J | 1 |
| Gong, X | 1 |
| Gui, S | 1 |
| Mao, Q | 1 |
| Li, P | 2 |
| Qi, X | 1 |
| Xie, P | 2 |
| Thalman, C | 1 |
| Horta, G | 1 |
| Endle, H | 1 |
| Tegeder, I | 1 |
| Laube, G | 1 |
| Sigurdsson, T | 1 |
| Tenzer, S | 1 |
| Distler, U | 1 |
| Aoki, J | 1 |
| Morris, AJ | 1 |
| Geisslinger, G | 1 |
| Röper, J | 1 |
| Kirischuk, S | 1 |
| Luhmann, HJ | 1 |
| Radyushkin, K | 1 |
| Nitsch, R | 1 |
| Vogt, J | 1 |
| Freire, TG | 1 |
| Gomes, S | 1 |
| Fachim, I | 2 |
| Michels, C | 2 |
| Carvalho, G | 1 |
| Godói, AK | 1 |
| Peterle, BR | 1 |
| Gava, FF | 1 |
| Kim, D | 1 |
| Cheong, E | 1 |
| Shin, HS | 1 |
| Vranjkovic, O | 1 |
| Winkler, G | 1 |
| Winder, DG | 1 |
| Haaf, M | 1 |
| Leicht, G | 1 |
| Curic, S | 1 |
| Mulert, C | 1 |
| Chou, D | 1 |
| Peng, HY | 1 |
| Lin, TB | 1 |
| Lai, CY | 1 |
| Hsieh, MC | 1 |
| Wen, YC | 1 |
| Lee, AS | 1 |
| Yang, PS | 1 |
| Chen, GD | 1 |
| Ho, YC | 1 |
| Ren, L | 3 |
| Hao, X | 1 |
| Min, S | 1 |
| Deng, J | 1 |
| Mishra, PK | 1 |
| Behar, KL | 1 |
| Patel, AB | 1 |
| Kalmár, G | 1 |
| Benedek, G | 6 |
| Nyúl, LG | 1 |
| Sharma, N | 1 |
| Bhidhasra, A | 1 |
| Ducza, E | 1 |
| Tian, Z | 1 |
| Sherpa, AD | 1 |
| Wang, XD | 1 |
| Bai, Y | 1 |
| Feng, YP | 1 |
| Schuelert, N | 1 |
| Dorner-Ciossek, C | 1 |
| Brendel, M | 1 |
| Rosenbrock, H | 1 |
| Paredes, D | 1 |
| Silva, JD | 1 |
| Morilak, DA | 1 |
| Goodwill, HL | 1 |
| Manzano-Nieves, G | 1 |
| Gallo, M | 1 |
| Lee, HI | 1 |
| Oyerinde, E | 1 |
| Serre, T | 1 |
| Bath, KG | 1 |
| Willner, P | 3 |
| Gruca, P | 2 |
| Lason, M | 1 |
| Tota-Glowczyk, K | 1 |
| Litwa, E | 1 |
| Niemczyk, M | 1 |
| Papp, M | 2 |
| Dale, J | 1 |
| Hu, S | 1 |
| Zhang, E | 1 |
| Liu, K | 1 |
| Huang, D | 1 |
| Faure, A | 1 |
| Nosjean, A | 1 |
| Pittaras, E | 1 |
| Duchêne, A | 1 |
| Andrieux, A | 1 |
| Gory-Fauré, S | 1 |
| Charvériat, M | 1 |
| Granon, S | 1 |
| Honeycutt, JA | 1 |
| Chrobak, JJ | 1 |
| Ximenes, NC | 3 |
| Dos Santos Júnior, MA | 1 |
| Vasconcelos, GS | 2 |
| Dias, KCF | 2 |
| Jucá, MM | 1 |
| Silva, AH | 2 |
| Leal, LKAM | 2 |
| de Sousa, FCF | 1 |
| Michaëlsson, H | 1 |
| Andersson, M | 1 |
| Svensson, J | 1 |
| Karlsson, L | 1 |
| Ehn, J | 1 |
| Culley, G | 1 |
| Engström, A | 1 |
| Bergström, N | 1 |
| Savvidi, P | 1 |
| Kuhn, HG | 1 |
| Hanse, E | 1 |
| Seth, H | 1 |
| Wan, YQ | 1 |
| Feng, JG | 1 |
| Li, M | 1 |
| Wang, MZ | 1 |
| Liu, L | 4 |
| Duan, XX | 1 |
| Zhang, CX | 1 |
| Wang, XB | 1 |
| Vasconcelos, LC | 1 |
| Patrocínio, MLV | 1 |
| Leitão, APA | 1 |
| Louchard, BO | 1 |
| Pimenta, ATÁ | 1 |
| Pinto, FDCL | 1 |
| Honório Junior, JER | 1 |
| Srikumar, BN | 1 |
| Naidu, PS | 1 |
| Kalidindi, N | 1 |
| Paschapur, M | 1 |
| Adepu, B | 1 |
| Subramani, S | 1 |
| Nagar, J | 1 |
| Srivastava, R | 1 |
| Sreedhara, MV | 1 |
| Prasad, DS | 1 |
| Das, ML | 1 |
| Louis, JV | 1 |
| Kuchibhotla, VK | 1 |
| Dudhgaonkar, S | 1 |
| Pieschl, RL | 1 |
| Li, YW | 1 |
| Bristow, LJ | 3 |
| Ramarao, M | 1 |
| Vikramadithyan, RK | 1 |
| Jiang, C | 1 |
| Lin, WJ | 1 |
| Labonté, B | 1 |
| Tamminga, CA | 1 |
| Turecki, G | 1 |
| Russo, SJ | 1 |
| Salton, SR | 1 |
| Chu, X | 1 |
| Alexander, L | 1 |
| Gaskin, PLR | 1 |
| Sawiak, SJ | 1 |
| Fryer, TD | 1 |
| Hong, YT | 1 |
| Cockcroft, GJ | 1 |
| Clarke, HF | 1 |
| Roberts, AC | 1 |
| Huang, N | 2 |
| Hua, D | 2 |
| Zhan, G | 2 |
| Bi, J | 1 |
| Kroin, JS | 1 |
| Das, V | 1 |
| Moric, M | 1 |
| Buvanendran, A | 1 |
| Klein, AK | 1 |
| Purvis, EM | 1 |
| Shen, CH | 2 |
| Wang, ST | 2 |
| Wang, SC | 2 |
| Lin, SM | 2 |
| Lin, LC | 1 |
| Dai, YC | 1 |
| Liu, YW | 2 |
| Zou, H | 1 |
| Wang, LX | 1 |
| Cheng, C | 1 |
| Shen, Q | 1 |
| Fang, L | 2 |
| Tang, QK | 1 |
| Yin, LY | 1 |
| Hao, JR | 1 |
| Geng, DQ | 1 |
| Shepard, R | 1 |
| Heslin, K | 1 |
| Hagerdorn, P | 1 |
| Coutellier, L | 1 |
| Owoeye, O | 1 |
| Highland, JN | 1 |
| Stewart, BW | 1 |
| Jenne, CE | 1 |
| Lovett, J | 1 |
| Morris, PJ | 1 |
| Thomas, CJ | 1 |
| Moaddel, R | 1 |
| Zarate, CA | 2 |
| Lévesque, M | 1 |
| Avoli, M | 1 |
| Wang, SM | 2 |
| Lee, CW | 1 |
| Chen, YJ | 1 |
| Wu, HF | 1 |
| Chung, YJ | 1 |
| Li, CT | 1 |
| Lin, HC | 1 |
| Ruan, J | 1 |
| Shan, X | 1 |
| Xia, B | 4 |
| Fu, Q | 1 |
| Krzystyniak, A | 1 |
| Baczynska, E | 1 |
| Magnowska, M | 1 |
| Antoniuk, S | 1 |
| Roszkowska, M | 1 |
| Zareba-Koziol, M | 1 |
| Das, N | 1 |
| Basu, S | 1 |
| Pikula, M | 1 |
| Wlodarczyk, J | 1 |
| Khakpai, F | 1 |
| Ebrahimi-Ghiri, M | 1 |
| Alijanpour, S | 1 |
| Zarrindast, MR | 2 |
| Moda-Sava, RN | 1 |
| Murdock, MH | 1 |
| Parekh, PK | 1 |
| Fetcho, RN | 1 |
| Huynh, TN | 1 |
| Witztum, J | 1 |
| Shaver, DC | 1 |
| Rosenthal, DL | 1 |
| Alway, EJ | 1 |
| Lopez, K | 1 |
| Meng, Y | 2 |
| Nellissen, L | 1 |
| Grosenick, L | 1 |
| Milner, TA | 1 |
| Bito, H | 1 |
| Kasai, H | 1 |
| Rantamäki, T | 2 |
| Yalcin, I | 1 |
| Zhao, Q | 1 |
| Peng, Y | 1 |
| Ekwutosi Patricia, C | 1 |
| Adewale Ganiyu, B | 1 |
| Benneth, BA | 1 |
| Ezekiel Olugbenga, I | 1 |
| Kozono, N | 1 |
| Honda, S | 1 |
| Tada, M | 1 |
| Kirihara, K | 1 |
| Zhao, Z | 1 |
| Jinde, S | 1 |
| Uka, T | 1 |
| Yamada, H | 1 |
| Matsumoto, M | 1 |
| Kasai, K | 1 |
| Mihara, T | 3 |
| Openshaw, RL | 1 |
| Thomson, DM | 1 |
| Thompson, R | 1 |
| Penninger, JM | 1 |
| Pratt, JA | 2 |
| Morris, BJ | 2 |
| Pereira, VS | 1 |
| Joca, SRL | 1 |
| Harvey, BH | 2 |
| Elfving, B | 2 |
| Ecevitoglu, A | 1 |
| Gass, N | 1 |
| Becker, R | 1 |
| Reinwald, J | 1 |
| Cosa-Linan, A | 1 |
| Sack, M | 1 |
| Weber-Fahr, W | 1 |
| Vollmayr, B | 1 |
| Sartorius, A | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Lu, JH | 2 |
| Long, CY | 2 |
| Hsiao, HP | 1 |
| Tsai, CC | 1 |
| Yang, HJ | 1 |
| Yu, F | 1 |
| Hua, F | 1 |
| Tanaka, T | 1 |
| Igarashi, H | 1 |
| Reardon, S | 1 |
| Nunes, EA | 1 |
| Oliveira, Ld | 1 |
| Luca, RD | 3 |
| Zugno, A | 1 |
| Peregrino, A | 1 |
| Crippa, JA | 1 |
| Dursun, SM | 3 |
| Baker, GB | 2 |
| Hallak, JE | 3 |
| Gigliucci, V | 1 |
| O'Dowd, G | 1 |
| Casey, S | 1 |
| Egan, D | 1 |
| Gibney, S | 1 |
| Harkin, A | 1 |
| Liu, F | 1 |
| Patterson, TA | 1 |
| Paule, MG | 1 |
| Slikker, W | 2 |
| De Luca, RD | 4 |
| Ghedim, FV | 5 |
| Deroza, PF | 6 |
| Cipriano, AL | 2 |
| Oliveira, MB | 4 |
| Heylmann, AS | 7 |
| Souza, RP | 2 |
| Kavalali, ET | 2 |
| Castel, A | 1 |
| Hélie, P | 1 |
| Beaudry, F | 1 |
| Vachon, P | 1 |
| Koike, H | 4 |
| Iijima, M | 3 |
| Chaki, S | 5 |
| Schobel, SA | 1 |
| Chaudhury, NH | 1 |
| Khan, UA | 1 |
| Paniagua, B | 1 |
| Styner, MA | 1 |
| Asllani, I | 1 |
| Inbar, BP | 1 |
| Corcoran, CM | 1 |
| Lieberman, JA | 1 |
| Moore, H | 1 |
| Small, SA | 1 |
| Kocsis, B | 1 |
| Brown, RE | 2 |
| McCarley, RW | 2 |
| Hajos, M | 1 |
| Ward, KC | 1 |
| Khattak, HZ | 1 |
| Richardson, L | 1 |
| Lee, JL | 1 |
| Vreugdenhil, M | 1 |
| Hoffman, KL | 1 |
| Basurto, E | 1 |
| Blackman, RK | 1 |
| Macdonald, AW | 1 |
| Chafee, MV | 1 |
| Napolitano, A | 1 |
| Shah, K | 1 |
| Schubert, MI | 1 |
| Porkess, V | 1 |
| Fone, KC | 1 |
| Auer, DP | 1 |
| O'Connor, RM | 1 |
| Grenham, S | 1 |
| Dinan, TG | 1 |
| Cryan, JF | 1 |
| Akinfiresoye, L | 2 |
| de Miranda, IM | 1 |
| Volpato, AM | 3 |
| de Oliveira, MB | 4 |
| da Rosa Silveira, F | 2 |
| Wessler, P | 1 |
| Ji, B | 1 |
| Pinto-Duarte, A | 1 |
| Kim, M | 1 |
| Caldwell, S | 1 |
| Young, JW | 1 |
| Behrens, MM | 2 |
| Sejnowski, TJ | 1 |
| Geyer, MA | 3 |
| Sabbagh, JJ | 2 |
| Murtishaw, AS | 2 |
| Bolton, MM | 2 |
| Heaney, CF | 2 |
| Langhardt, M | 1 |
| Kinney, JW | 2 |
| Ram, E | 1 |
| Raphaeli, S | 1 |
| Avital, A | 1 |
| Gil-da-Costa, R | 1 |
| Stoner, GR | 1 |
| Fung, R | 1 |
| Albright, TD | 1 |
| Bencze, M | 1 |
| Behuliak, M | 1 |
| Zicha, J | 1 |
| Sufka, KJ | 1 |
| White, SW | 1 |
| Bortolozzi, A | 1 |
| Celada, P | 1 |
| Artigas, F | 1 |
| Ohnesorge, H | 1 |
| Feng, Z | 1 |
| Zitta, K | 1 |
| Steinfath, M | 1 |
| Albrecht, M | 1 |
| Bein, B | 1 |
| Juven-Wetzler, A | 1 |
| Cohen, H | 1 |
| Kaplan, Z | 1 |
| Kohen, A | 1 |
| Porat, O | 1 |
| Zohar, J | 1 |
| Perrine, SA | 1 |
| Ghoddoussi, F | 1 |
| Michaels, MS | 1 |
| Sheikh, IS | 1 |
| McKelvey, G | 1 |
| Galloway, MP | 1 |
| De Oliveira, JC | 1 |
| Ludemann Camargo, R | 1 |
| Barella, LF | 1 |
| Chaves Souto Branco, R | 1 |
| Gravena, C | 1 |
| Grassiolli, S | 1 |
| Torrezan, R | 1 |
| Cezar De Freitas Mathias, P | 1 |
| Chipindo, HL | 1 |
| Steckert, AV | 5 |
| Maravai, SG | 1 |
| Wessler, PG | 2 |
| Binatti, AR | 1 |
| Panizzutti, B | 2 |
| Schuck, PF | 3 |
| Gama, CS | 4 |
| Sobarzo-Sánchez, E | 1 |
| Nabavi, SF | 1 |
| Daglia, M | 1 |
| Nabavi, SM | 1 |
| Ishiwari, K | 1 |
| Conway, MW | 1 |
| Francois, J | 1 |
| Huxter, J | 1 |
| Lowry, JP | 1 |
| Schwarz, AJ | 1 |
| Tricklebank, M | 1 |
| Gilmour, G | 1 |
| Pozzi, L | 1 |
| Pollak Dorocic, I | 1 |
| Dorocic, IP | 1 |
| Carlén, M | 1 |
| Meletis, K | 1 |
| Li, XJ | 1 |
| Zhang, ZX | 2 |
| Lu, KM | 1 |
| Lagorio, CH | 1 |
| Winger, G | 1 |
| Fujáková, M | 2 |
| Páleníček, T | 2 |
| Brunovský, M | 2 |
| Gorman, I | 2 |
| Tylš, F | 2 |
| Kubešová, A | 1 |
| Řípová, D | 1 |
| Krajča, V | 2 |
| Horáček, J | 3 |
| Peng, S | 1 |
| Liu, GJ | 1 |
| Zhang, XQ | 1 |
| Wang, GL | 1 |
| Sun, HY | 1 |
| Talpos, JC | 2 |
| Aerts, N | 1 |
| Fellini, L | 1 |
| Steckler, T | 2 |
| Zhao, T | 1 |
| Wei, W | 1 |
| Savage, S | 1 |
| Ma, D | 1 |
| Sánchez-Porras, R | 1 |
| Santos, E | 1 |
| Schöll, M | 1 |
| Stock, C | 1 |
| Zheng, Z | 1 |
| Schiebel, P | 1 |
| Orakcioglu, B | 1 |
| Unterberg, AW | 1 |
| Sakowitz, OW | 1 |
| Zhou, W | 1 |
| Feng, Y | 1 |
| Teng, S | 1 |
| Song, X | 1 |
| Quiroga, C | 1 |
| Chaparro, RE | 1 |
| Karlnoski, R | 1 |
| Erasso, D | 1 |
| Gordon, M | 1 |
| Morgan, D | 1 |
| Bosco, G | 1 |
| Rubini, A | 1 |
| Parmagnani, A | 1 |
| Paoli, A | 1 |
| Mangar, D | 1 |
| Camporesi, EM | 1 |
| Belujon, P | 3 |
| Duan, X | 1 |
| Wu, H | 2 |
| Matos, MP | 2 |
| Pacheco, FD | 3 |
| Nakako, T | 2 |
| Murai, T | 2 |
| Ikejiri, M | 2 |
| Hashimoto, T | 1 |
| Kotani, M | 2 |
| Matsumoto, K | 2 |
| Manabe, S | 1 |
| Ogi, Y | 2 |
| Konoike, N | 1 |
| Nakamura, K | 1 |
| Ikeda, K | 2 |
| Zhang, LM | 1 |
| Zhou, WW | 1 |
| Ji, YJ | 1 |
| Zhao, N | 1 |
| Chen, HX | 1 |
| Xue, R | 1 |
| Mei, XG | 1 |
| Zhang, YZ | 1 |
| Wang, HL | 1 |
| Li, YF | 1 |
| Jiang, K | 1 |
| Liu, A | 1 |
| Cloke, JM | 1 |
| Winters, BD | 2 |
| Jeevakumar, V | 2 |
| Kroener, S | 2 |
| Liebenberg, N | 2 |
| Joca, S | 1 |
| Siegel, SJ | 5 |
| Ahiskalioglu, A | 1 |
| Ince, I | 2 |
| Aksoy, M | 2 |
| Ahiskalioglu, EO | 1 |
| Comez, M | 1 |
| Dostbil, A | 1 |
| Celik, M | 1 |
| Alp, HH | 1 |
| Coskun, R | 1 |
| Taghizadehghalehjoughi, A | 1 |
| Suleyman, B | 1 |
| Chiu, CT | 1 |
| Scheuing, L | 1 |
| Liu, G | 1 |
| Liao, HM | 1 |
| Linares, GR | 1 |
| Lin, D | 1 |
| Chuang, DM | 1 |
| Maia-de-Oliveira, JP | 1 |
| Lobão-Soares, B | 1 |
| Ramalho, T | 1 |
| Gavioli, EC | 2 |
| Soares, VP | 1 |
| Teixeira, L | 1 |
| Driskill, C | 1 |
| Paine, A | 1 |
| Sobhanian, M | 1 |
| Vakil, H | 1 |
| Morris, B | 1 |
| Ramos, J | 1 |
| Franceschelli, A | 1 |
| Sens, J | 1 |
| Herchick, S | 1 |
| Thelen, C | 1 |
| Pitychoutis, PM | 1 |
| Nacif, MP | 1 |
| Tomaz, DB | 1 |
| dos Santos, MA | 1 |
| Carlessi, AS | 2 |
| Matias, BI | 2 |
| da Luz, JR | 2 |
| Jeremias, GC | 1 |
| Morais, MO | 1 |
| Streck, EL | 2 |
| Zhao, G | 1 |
| Zheng, X | 1 |
| Xiao, Q | 1 |
| Brown, JA | 1 |
| Ramikie, TS | 1 |
| Schmidt, MJ | 1 |
| Báldi, R | 1 |
| Garbett, K | 1 |
| Everheart, MG | 1 |
| Warren, LE | 1 |
| Gellért, L | 1 |
| Horváth, S | 1 |
| Patel, S | 1 |
| Mirnics, K | 1 |
| Titus, SE | 1 |
| Ignácio, ZM | 1 |
| Bruchchen, L | 1 |
| Florentino, D | 1 |
| Honsberger, MJ | 1 |
| Taylor, JR | 1 |
| Corlett, PR | 1 |
| Stuart, SA | 1 |
| Butler, P | 1 |
| Munafò, MR | 1 |
| Nutt, DJ | 1 |
| Robinson, ES | 1 |
| Wu, Q | 2 |
| Xie, L | 1 |
| Gong, W | 1 |
| Zheng, P | 1 |
| Ji, Y | 1 |
| Melgiri, ND | 1 |
| Shively, C | 1 |
| Liu, WX | 1 |
| Guo, J | 2 |
| Sun, HL | 2 |
| Mak, P | 1 |
| Broadbear, JH | 1 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Nguyen, L | 1 |
| Matsumoto, RR | 1 |
| Löscher, W | 1 |
| Skolnick, P | 2 |
| Czekaj, J | 1 |
| Ito, W | 1 |
| Erisir, A | 1 |
| Morozov, A | 1 |
| Comim, CM | 2 |
| Silva, NC | 1 |
| Patrício, JJ | 1 |
| Palmas, D | 1 |
| Mendonça, BP | 1 |
| Bittencourt, MO | 1 |
| Cassol, OJ | 1 |
| Cordon, I | 1 |
| Nicolás, MJ | 1 |
| Arrieta, S | 1 |
| Lopetegui, E | 1 |
| López-Azcárate, J | 1 |
| Alegre, M | 1 |
| Artieda, J | 1 |
| Valencia, M | 1 |
| Dwyer, JM | 1 |
| Maldonado-Avilés, JG | 1 |
| Lepack, AE | 1 |
| DiLeone, RJ | 1 |
| de Sousa, CN | 1 |
| Oliveira, Tde Q | 1 |
| Lima, LL | 1 |
| de Lucena, DF | 3 |
| Vasconcelos, SM | 1 |
| Fuller, JJ | 1 |
| Murray, RC | 1 |
| Horner, KA | 1 |
| Melo, A | 1 |
| Kokras, N | 1 |
| Dalla, C | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| Liu, KM | 1 |
| Wang, CC | 1 |
| Lin, RJ | 1 |
| Jang, MY | 1 |
| Jakobowski, NL | 1 |
| Dollish, HK | 1 |
| Vogt, MA | 1 |
| Vogel, AS | 1 |
| Pfeiffer, N | 1 |
| Gass, P | 1 |
| Inta, D | 1 |
| Liman, S | 1 |
| Cheung, CW | 1 |
| Wong, KL | 1 |
| Tai, W | 1 |
| Qiu, Q | 1 |
| Ng, KF | 1 |
| Choi, SW | 1 |
| Irwin, M | 1 |
| Barbier, L | 1 |
| Canini, F | 1 |
| Giroud, C | 1 |
| Beaup, C | 1 |
| Foquin, A | 1 |
| Maury, R | 1 |
| Denis, J | 1 |
| Peinnequin, A | 1 |
| Dorandeu, F | 1 |
| Walker, AJ | 1 |
| Foley, BM | 1 |
| Sutor, SL | 1 |
| McGillivray, JA | 1 |
| Frye, MA | 1 |
| Tye, SJ | 1 |
| Sobota, R | 1 |
| Forrest, A | 1 |
| Featherstone, RE | 2 |
| Célia Moreira Borella, V | 1 |
| Seeman, MV | 1 |
| Carneiro Cordeiro, R | 1 |
| Vieira dos Santos, J | 1 |
| Romário Matos de Souza, M | 1 |
| Nunes de Sousa Fernandes, E | 1 |
| Santos Monte, A | 1 |
| Maria Mendes Vasconcelos, S | 1 |
| Quinn, JP | 1 |
| Carvalho, AF | 1 |
| Wang, N | 1 |
| Yu, HY | 3 |
| Shen, XF | 1 |
| Gao, ZQ | 1 |
| Potasiewicz, A | 2 |
| Siwek, A | 1 |
| Starowicz, G | 1 |
| Drabik, U | 1 |
| Gajdosz, R | 1 |
| Khanegheini, A | 1 |
| Nasehi, M | 1 |
| Boczek, T | 2 |
| Lisek, M | 2 |
| Ferenc, B | 2 |
| Zylinska, L | 2 |
| Belzung, C | 1 |
| Pittman, J | 1 |
| Hylton, A | 1 |
| Chun, JY | 1 |
| Shin, DM | 2 |
| Song, SH | 1 |
| Choo, MS | 2 |
| Song, YS | 1 |
| Han, M | 2 |
| Nagy, LR | 1 |
| Hahn, CG | 1 |
| Castro, AA | 1 |
| dal Pizzol, F | 1 |
| Patrizi, A | 1 |
| Picard, N | 1 |
| Simon, AJ | 1 |
| Gunner, G | 1 |
| Centofante, E | 1 |
| Andrews, NA | 1 |
| Fagiolini, M | 1 |
| Tajerian, M | 1 |
| Leu, D | 1 |
| Huang, TT | 1 |
| Kingery, WS | 1 |
| Clark, JD | 1 |
| Antonio, CB | 2 |
| Betti, AH | 2 |
| Herzfeldt, V | 1 |
| Barreiro, EJ | 2 |
| Fraga, CA | 2 |
| Rates, SM | 2 |
| Ji, L | 1 |
| Stepan, J | 1 |
| Hladky, F | 1 |
| Uribe, A | 1 |
| Holsboer, F | 1 |
| Schmidt, MV | 1 |
| Eder, M | 1 |
| Rajagopal, L | 1 |
| Burgdorf, JS | 1 |
| Moskal, JR | 2 |
| Meltzer, HY | 1 |
| Pazini, FL | 1 |
| Cunha, MP | 1 |
| Rosa, JM | 1 |
| Colla, AR | 1 |
| Lieberknecht, V | 1 |
| Oliveira, Á | 1 |
| Rodrigues, AL | 2 |
| Harraz, MM | 1 |
| Tyagi, R | 1 |
| Cortés, P | 1 |
| Snyder, SH | 1 |
| Sherwood, A | 1 |
| Smith, DR | 1 |
| Zhao, CH | 1 |
| Li, GH | 1 |
| Zhao, B | 1 |
| Wang, ZB | 1 |
| Xue, W | 4 |
| Tao, W | 3 |
| Chen, C | 2 |
| Wu, R | 3 |
| Doronc, R | 1 |
| Chen, G | 5 |
| Amiri, S | 1 |
| Haj-Mirzaian, A | 1 |
| Amini-khoei, H | 1 |
| Momeny, M | 1 |
| Shirzadian, A | 1 |
| Rahimi-Balaei, M | 1 |
| Zarrinrad, G | 1 |
| Ghazi-Khansari, M | 1 |
| Azizi, R | 1 |
| Mehr, SE | 1 |
| Negus, SS | 1 |
| Ye, K | 1 |
| Li, QQ | 1 |
| Jin, XJ | 1 |
| Peng, LC | 1 |
| Zuo, D | 1 |
| Sun, F | 1 |
| Enomoto, T | 1 |
| Iwamura, Y | 1 |
| Kiyoshi, A | 1 |
| Matsumoto, A | 1 |
| Nakayama, T | 2 |
| Chang, EI | 1 |
| Zárate, MA | 1 |
| Rabaglino, MB | 1 |
| Richards, EM | 1 |
| Arndt, TJ | 1 |
| Keller-Wood, M | 1 |
| Wood, CE | 1 |
| Castellanos-Pérez, M | 1 |
| Petrovszki, Z | 3 |
| Bodosi, B | 1 |
| Horvath, J | 1 |
| Gombkötő, P | 1 |
| Nagy, A | 1 |
| Hudson, MR | 1 |
| Rind, G | 1 |
| O'Brien, TJ | 1 |
| Jones, NC | 1 |
| Wo, C | 1 |
| Gong, T | 1 |
| Xue, L | 1 |
| du Jardin, KG | 1 |
| Müller, HK | 1 |
| Sanchez, C | 1 |
| Lin, JC | 1 |
| Chen, YC | 1 |
| Cox, DA | 1 |
| Gottschalk, MG | 1 |
| Wesseling, H | 1 |
| Ernst, A | 1 |
| Cooper, JD | 1 |
| Bahn, S | 1 |
| Steckert, A | 1 |
| Damázio, LS | 2 |
| Calixto, OP | 1 |
| Pereira, FP | 1 |
| Macan, TP | 1 |
| Pedro, TH | 1 |
| do Vale, EM | 1 |
| Xavier, CC | 1 |
| Nogueira, BG | 1 |
| Campos, BC | 1 |
| de Aquino, PE | 1 |
| da Costa, RO | 1 |
| Leal, LK | 1 |
| de Vasconcelos, SM | 1 |
| Neves, KR | 1 |
| de Barros Viana, GS | 1 |
| Song, L | 2 |
| Sen, S | 1 |
| Mo, L | 1 |
| Rosa, PB | 1 |
| Ribeiro, CM | 1 |
| Wu, JD | 1 |
| Lin, CT | 1 |
| Ardalan, M | 2 |
| Polsinelli, B | 1 |
| Madsen, TM | 1 |
| Nyengaard, JR | 2 |
| Sun, XR | 1 |
| Zhang, ZZ | 1 |
| Zhao, HT | 1 |
| Kim, A | 1 |
| Heo, J | 1 |
| Shin, JH | 1 |
| Lim, J | 1 |
| Yoon, SJ | 1 |
| Lee, S | 1 |
| Oh, W | 1 |
| Choi, SJ | 1 |
| Yang, B | 1 |
| Chen, QX | 1 |
| Han, JF | 1 |
| Sun, KJ | 1 |
| Niquet, J | 1 |
| Baldwin, R | 1 |
| Norman, K | 1 |
| Suchomelova, L | 1 |
| Lumley, L | 1 |
| Wasterlain, CG | 2 |
| Lerner, RP | 1 |
| Bimpisidis, Z | 1 |
| Agorastos, S | 1 |
| Scherrer, S | 1 |
| Dewey, SL | 1 |
| Cenci, MA | 1 |
| Eidelberg, D | 1 |
| Pešić, V | 1 |
| Petrović, J | 1 |
| M Jukić, M | 1 |
| Yamaki, VN | 1 |
| Wei, Z | 1 |
| Cai, X | 1 |
| Arslan, FC | 1 |
| Tiryaki, A | 1 |
| Yıldırım, M | 1 |
| Özkorumak, E | 1 |
| Alver, A | 1 |
| Altun, İK | 1 |
| Gedikli, Ö | 1 |
| Kara, NZ | 1 |
| Agam, G | 1 |
| Anderson, GW | 1 |
| Zitron, N | 1 |
| Einat, H | 1 |
| Beurel, E | 3 |
| Grieco, SF | 2 |
| Amadei, C | 1 |
| Downey, K | 1 |
| Jope, RS | 3 |
| Brand, SJ | 1 |
| Zou, Z | 1 |
| Lu, C | 1 |
| da Silva Araújo, T | 1 |
| Maia Chaves Filho, AJ | 1 |
| Monte, AS | 1 |
| Isabelle de Góis Queiroz, A | 1 |
| Cordeiro, RC | 1 |
| de Jesus Souza Machado, M | 1 |
| de Freitas Lima, R | 1 |
| Freitas de Lucena, D | 1 |
| Maes, M | 1 |
| Arias, HR | 1 |
| Velmeshev, D | 1 |
| Magistri, M | 1 |
| Eldar-Finkelman, H | 1 |
| Faghihi, MA | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Debom, G | 1 |
| Gazal, M | 1 |
| Soares, MS | 1 |
| do Couto, CA | 1 |
| Mattos, B | 1 |
| Lencina, C | 1 |
| Kaster, MP | 1 |
| Ghisleni, GC | 1 |
| Tavares, R | 1 |
| Braganhol, E | 1 |
| Stefanello, F | 1 |
| Pitsikas, N | 1 |
| Donegan, JJ | 1 |
| Lodge, DJ | 1 |
| Rafati, AH | 1 |
| de Souza, CP | 1 |
| Zazzeron, L | 1 |
| Franco, W | 1 |
| Nakagawa, A | 1 |
| Farinelli, WA | 1 |
| Bloch, DB | 1 |
| Anderson, RR | 1 |
| Zapol, WM | 1 |
| Wang, CQ | 1 |
| Han, WC | 1 |
| Sun, JM | 1 |
| Guo, R | 1 |
| Cao, K | 1 |
| Zheng, MJ | 1 |
| Liao, LC | 1 |
| Matos, NCB | 1 |
| Oliveira, MN | 1 |
| Gularte, VN | 1 |
| Vale, OCD | 1 |
| Abe, M | 1 |
| Nozawa, D | 1 |
| da Silveira, VT | 1 |
| Medeiros, DC | 1 |
| Guidine, PA | 1 |
| Rezende, GH | 1 |
| Moraes, MF | 1 |
| Mendes, EM | 1 |
| de Oliveira, AC | 1 |
| Lee, KW | 1 |
| Kim, WB | 1 |
| Lee, SW | 1 |
| Kim, JH | 1 |
| Kim, JM | 2 |
| Kim, YH | 1 |
| Kim, ME | 1 |
| Heylmann, ASA | 2 |
| Citadin, SA | 1 |
| de Lucca, LA | 1 |
| Malgarin, F | 1 |
| Janardhanan, A | 1 |
| Sadanand, A | 1 |
| Vanisree, AJ | 1 |
| Gress, K | 1 |
| Gomes, ST | 1 |
| Stopassoli, GC | 1 |
| Damiani, AP | 1 |
| de Andrade, VM | 1 |
| Li, F | 1 |
| Fang, Q | 1 |
| Liy-Salmeron, G | 1 |
| Meneses, A | 1 |
| Jackson, AC | 4 |
| Scott, CA | 2 |
| Owen, J | 1 |
| Weli, SC | 2 |
| Rossiter, JP | 1 |
| Yu, HM | 1 |
| Zhang, GY | 2 |
| Cámara, CR | 1 |
| Guzmán, FJ | 1 |
| Barrera, EA | 1 |
| Cabello, AJ | 1 |
| Garcia, A | 1 |
| Fernández, NE | 1 |
| Caballero, E | 1 |
| Ancer, J | 1 |
| Szabó, CA | 1 |
| Narayana, S | 1 |
| Franklin, C | 1 |
| Knape, KD | 1 |
| Davis, MD | 1 |
| Fox, PT | 1 |
| Leland, MM | 1 |
| Williams, JT | 1 |
| Tukhovskaya, EA | 1 |
| Yukin, AY | 1 |
| Khokhlova, ON | 1 |
| Murashev, AN | 1 |
| Vitek, MP | 1 |
| Zhao, H | 1 |
| Mayhan, WG | 1 |
| Ehrlichman, RS | 1 |
| Gandal, MJ | 1 |
| Maxwell, CR | 1 |
| Lazarewicz, MT | 1 |
| Finkel, LH | 1 |
| Contreras, D | 1 |
| Turetsky, BI | 2 |
| Lazar, JM | 1 |
| Qureshi, G | 1 |
| Qureshi, MR | 1 |
| Smith, E | 1 |
| Scharf, B | 1 |
| Rosenblum, LA | 1 |
| Signaevsky, M | 1 |
| Kral, JG | 1 |
| Salciccioli, L | 1 |
| Ali, SS | 1 |
| Dugan, LL | 1 |
| Ruane-O'Hora, T | 1 |
| Hall, WJ | 1 |
| Markos, F | 1 |
| George, KR | 1 |
| Rico, T | 1 |
| St-Pierre, LS | 2 |
| Dupont, MJ | 2 |
| Blomme, CG | 1 |
| Mazzuchin, A | 1 |
| Stewart, LS | 1 |
| Persinger, MA | 5 |
| Engin, E | 1 |
| Treit, D | 1 |
| Dickson, CT | 1 |
| Mei, X | 1 |
| Jiang, W | 1 |
| Büchele, F | 1 |
| Papazoglou, A | 1 |
| Döbrössy, M | 1 |
| Nikkhah, G | 1 |
| Garcia, LS | 1 |
| Stertz, L | 2 |
| Kapczinski, F | 1 |
| Spiazzi, CM | 1 |
| Bortolin, T | 1 |
| Mina, FG | 1 |
| Shaked, G | 1 |
| Grinberg, G | 1 |
| Sufaro, Y | 1 |
| Douvdevani, A | 2 |
| Shapira, Y | 1 |
| Artru, A | 1 |
| Czeiger, D | 1 |
| Yu, QJ | 1 |
| Zhou, QS | 1 |
| Huang, HB | 1 |
| Wan, YL | 1 |
| Tian, SF | 1 |
| Duan, DM | 1 |
| Ding, L | 1 |
| Shi, YS | 2 |
| Zhu, YB | 1 |
| Ma, YF | 1 |
| Adams, W | 1 |
| Ayton, S | 1 |
| van den Buuse, M | 1 |
| Ergün, Y | 1 |
| Darendeli, S | 1 |
| Imrek, S | 1 |
| Kilinç, M | 1 |
| Oksüz, H | 1 |
| Liu, WL | 3 |
| Bian, SZ | 3 |
| Gu, ZL | 3 |
| Jiang, XG | 3 |
| Guo, CY | 2 |
| Zhao, YB | 1 |
| Gołembiowska, K | 1 |
| Guzmán-de la Garza, FJ | 2 |
| Cámara-Lemarroy, CR | 2 |
| Ballesteros-Elizondo, RG | 2 |
| Alarcón-Galván, G | 2 |
| Cordero-Pérez, P | 2 |
| Fernández-Garza, NE | 2 |
| Uysal, B | 1 |
| Yasar, M | 1 |
| Ersoz, N | 1 |
| Coskun, O | 1 |
| Kilic, A | 1 |
| Cayc, T | 1 |
| Kurt, B | 1 |
| Oter, S | 1 |
| Korkmaz, A | 1 |
| Guven, A | 1 |
| Portelli, J | 1 |
| Aourz, N | 1 |
| De Bundel, D | 1 |
| Meurs, A | 1 |
| Smolders, I | 2 |
| Michotte, Y | 2 |
| Clinckers, R | 2 |
| Cissé, Y | 1 |
| Inoue, I | 1 |
| Kido, H | 1 |
| Busch, CJ | 1 |
| Spöhr, FA | 1 |
| Motsch, J | 1 |
| Gebhard, MM | 1 |
| Martin, EO | 1 |
| Weimann, J | 1 |
| Yang, SY | 1 |
| Hong, CJ | 1 |
| Huang, YH | 1 |
| Tsai, SJ | 1 |
| Lacher, SE | 1 |
| Johnson, C | 1 |
| Jessop, F | 1 |
| Holian, A | 1 |
| Migliaccio, CT | 1 |
| Minville, V | 1 |
| Fourcade, O | 1 |
| Girolami, JP | 1 |
| Tack, I | 1 |
| Gu, X | 1 |
| Cui, S | 1 |
| Ma, Z | 1 |
| Doreulee, N | 1 |
| Alania, M | 1 |
| Mitaishvili, E | 1 |
| Chikovani, M | 1 |
| Chkhartishvili, B | 1 |
| Cao, J | 1 |
| Wang, ZH | 1 |
| Jia, J | 1 |
| Yun, KM | 1 |
| Wei, ZW | 1 |
| Wang, YJ | 1 |
| Sun, ZH | 1 |
| Pouget, P | 1 |
| Wattiez, N | 1 |
| Rivaud-Péchoux, S | 1 |
| Gaymard, B | 1 |
| Roberts, BM | 1 |
| Holden, DE | 1 |
| Shaffer, CL | 1 |
| Seymour, PA | 1 |
| Menniti, FS | 1 |
| Schmidt, CJ | 1 |
| Williams, GV | 1 |
| Castner, SA | 1 |
| Vermoesen, K | 1 |
| Massie, A | 1 |
| Yang, CL | 1 |
| Chen, CH | 1 |
| Tsai, PS | 1 |
| Wang, TY | 1 |
| Huang, CJ | 1 |
| Whitaker, AM | 1 |
| Sulzer, J | 1 |
| Walker, E | 1 |
| Mathis, K | 1 |
| Molina, PE | 1 |
| Gonçalves, H | 1 |
| Henriques-Coelho, T | 1 |
| Bernardes, J | 1 |
| Rocha, AP | 1 |
| Brandão-Nogueira, A | 1 |
| Leite-Moreira, A | 1 |
| Qu, Q | 1 |
| Ou, C | 1 |
| Zhou, S | 1 |
| Prado Neto, AX | 1 |
| Guimarães, SB | 1 |
| Chatterjee, M | 2 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 2 |
| Sorce, S | 1 |
| Colaianna, M | 1 |
| Jaquet, V | 1 |
| Cuomo, V | 1 |
| Dubois-Dauphin, M | 1 |
| Krause, KH | 1 |
| Iyer, S | 1 |
| Maybhate, A | 1 |
| Presacco, A | 1 |
| All, AH | 1 |
| Rozisky, JR | 1 |
| Medeiros, LF | 2 |
| Adachi, LS | 1 |
| Espinosa, J | 1 |
| de Souza, A | 2 |
| Neto, AS | 1 |
| Bonan, CD | 1 |
| Caumo, W | 2 |
| Torres, IL | 2 |
| Dedeurwaerdere, S | 1 |
| Wintmolders, C | 1 |
| Straetemans, R | 1 |
| Pemberton, D | 1 |
| Langlois, X | 1 |
| Benneyworth, MA | 1 |
| Roseman, AS | 1 |
| Basu, AC | 1 |
| Coyle, JT | 1 |
| Gordon, CS | 1 |
| Serino, AS | 1 |
| Krause, MP | 1 |
| Campbell, JE | 1 |
| Cafarelli, E | 1 |
| Adegoke, OA | 1 |
| Hawke, TJ | 1 |
| Riddell, MC | 1 |
| Inaba, H | 1 |
| Hayami, N | 1 |
| Ajiki, K | 1 |
| Kunishima, T | 1 |
| Watanabe, H | 1 |
| Tsutsui, K | 1 |
| Yamagishi, N | 1 |
| Yamagishi, S | 1 |
| Sugiura, A | 1 |
| Mikamo, T | 1 |
| Murakawa, Y | 1 |
| Aptekman, B | 1 |
| Tarashansky, M | 1 |
| Sotman, A | 1 |
| Khoury, W | 1 |
| Khuri, W | 1 |
| Ben-Abraham, R | 1 |
| Dolkart, O | 1 |
| Weinbroum, AA | 1 |
| Mei, XP | 1 |
| Xu, LX | 1 |
| Li, YQ | 1 |
| Stringari, RB | 1 |
| Ribeiro, KF | 1 |
| Ferraro, AK | 1 |
| Vitto, MF | 1 |
| Cesconetto, P | 1 |
| Souza, CT | 1 |
| Balíková, M | 1 |
| Tišlerová, B | 1 |
| Soš, P | 1 |
| Bubeníková-Valešová, V | 2 |
| Höschl, C | 2 |
| Ding, C | 1 |
| Tian, N | 1 |
| Kreis, D | 1 |
| Schulz, D | 1 |
| Stein, M | 1 |
| Preuss, M | 1 |
| Nestler, U | 1 |
| Truin, M | 1 |
| Janssen, SP | 1 |
| van Kleef, M | 1 |
| Joosten, EA | 1 |
| Xu, CL | 1 |
| Xiong, KR | 1 |
| Quintero, L | 1 |
| Cardenas, R | 1 |
| Suarez-Roca, H | 1 |
| Van Elstraete, AC | 1 |
| Sitbon, P | 1 |
| Benhamou, D | 1 |
| Mazoit, JX | 1 |
| Autry, AE | 1 |
| Adachi, M | 1 |
| Nosyreva, E | 1 |
| Na, ES | 1 |
| Los, MF | 1 |
| Cheng, PF | 1 |
| Le Roy, C | 1 |
| Laboureyras, E | 1 |
| Gavello-Baudy, S | 1 |
| Chateauraynaud, J | 1 |
| Laulin, JP | 2 |
| Simonnet, G | 2 |
| Meng, E | 1 |
| Chang, HY | 1 |
| Chang, SY | 1 |
| Sun, GH | 1 |
| Yu, DS | 1 |
| Cha, TL | 1 |
| Mehta, AK | 2 |
| Halder, S | 2 |
| Khanna, N | 2 |
| Tandon, OP | 2 |
| Sharma, KK | 2 |
| Lindholm, JS | 1 |
| Autio, H | 1 |
| Vesa, L | 1 |
| Antila, H | 1 |
| Lindemann, L | 1 |
| Hoener, MC | 1 |
| Castrén, E | 1 |
| Malkesman, O | 1 |
| Austin, DR | 1 |
| Tragon, T | 1 |
| Rompala, G | 1 |
| Hamidi, AB | 1 |
| Cui, Z | 1 |
| Young, WS | 1 |
| Nakazawa, K | 1 |
| Manji, HK | 1 |
| Rushforth, SL | 1 |
| Shoaib, M | 1 |
| Adell, A | 1 |
| Jiménez-Sánchez, L | 1 |
| López-Gil, X | 1 |
| Romón, T | 1 |
| McNally, JM | 1 |
| McKenna, JT | 1 |
| Yanagawa, Y | 1 |
| de Souza, AC | 1 |
| Cioato, SG | 1 |
| Scarabelot, VL | 1 |
| Fernandes, LC | 1 |
| Poleszak, E | 1 |
| Pilc, A | 1 |
| Joo, G | 1 |
| Farkas, I | 1 |
| Singh, S | 1 |
| Kumari, R | 1 |
| Verma, AK | 1 |
| Murrough, JW | 1 |
| Gauberti, M | 1 |
| Obiang, P | 1 |
| Guedin, P | 1 |
| Balossier, A | 1 |
| Gakuba, C | 1 |
| Diependaele, AS | 1 |
| Chazalviel, L | 1 |
| Vivien, D | 1 |
| Young, AR | 1 |
| Agin, V | 1 |
| Orset, C | 1 |
| Ribeiro, PO | 1 |
| Valentim, AM | 1 |
| Rodrigues, P | 1 |
| Olsson, IA | 1 |
| Antunes, LM | 1 |
| Turner, CP | 1 |
| Gutierrez, S | 1 |
| Miller, L | 1 |
| Chou, J | 1 |
| Finucane, B | 1 |
| Carnes, A | 1 |
| Kim, J | 1 |
| Shing, E | 1 |
| Haddad, T | 1 |
| Phillips, A | 1 |
| Kose, EA | 1 |
| Bakar, B | 1 |
| Ayva, SK | 1 |
| Kilinc, K | 1 |
| Apan, A | 1 |
| Fuchs, K | 1 |
| Kukuk, D | 1 |
| Reischl, G | 1 |
| Föller, M | 1 |
| Eichner, M | 1 |
| Reutershan, J | 1 |
| Lang, F | 1 |
| Röcken, M | 1 |
| Pichler, BJ | 1 |
| Kneilling, M | 1 |
| Vanzella, C | 1 |
| Bianchetti, P | 1 |
| Sbaraini, S | 1 |
| Vanzin, SI | 1 |
| Melecchi, MI | 1 |
| Caramão, EB | 1 |
| Bhatti, BH | 1 |
| Manaye, KF | 1 |
| Das, JR | 1 |
| Floerchinger, B | 1 |
| Jurisch, A | 1 |
| Timsit, MO | 1 |
| Schmid, C | 1 |
| Tullius, SG | 1 |
| Cone, FE | 1 |
| Steinhart, MR | 1 |
| Oglesby, EN | 1 |
| Kalesnykas, G | 1 |
| Pease, ME | 1 |
| Quigley, HA | 1 |
| Chindo, BA | 1 |
| Adzu, B | 1 |
| Yahaya, TA | 1 |
| Gamaniel, KS | 1 |
| Magcalas, CM | 1 |
| Iasevoli, F | 1 |
| Latte, G | 1 |
| Avvisati, L | 1 |
| Sarappa, C | 1 |
| Aloj, L | 1 |
| de Bartolomeis, A | 1 |
| Oxburgh, L | 1 |
| de Caestecker, MP | 1 |
| Cannon, CE | 1 |
| Puri, V | 1 |
| Vivian, JA | 1 |
| Egbertson, MS | 1 |
| Eddins, D | 1 |
| Uslaner, JM | 1 |
| Mohammad, FK | 1 |
| Al-Baggou, BKh | 1 |
| Naser, AS | 1 |
| Elhawi, H | 1 |
| Eini, H | 1 |
| Byk, G | 1 |
| Jacklin, DL | 1 |
| Goel, A | 1 |
| Clementino, KJ | 1 |
| Hall, AW | 1 |
| Fortis, S | 1 |
| Spieth, PM | 1 |
| Lu, WY | 1 |
| Parotto, M | 1 |
| Haitsma, JJ | 1 |
| Slutsky, AS | 1 |
| Zhong, N | 1 |
| Mazer, CD | 1 |
| Sherafat, MA | 1 |
| Ronaghi, A | 1 |
| Ahmad-Molaei, L | 1 |
| Nejadhoseynian, M | 1 |
| Ghasemi, R | 1 |
| Hosseini, A | 1 |
| Naderi, N | 1 |
| Motamedi, F | 1 |
| Bosker, FJ | 1 |
| Gladkevich, AV | 1 |
| Pietersen, CY | 1 |
| Kooi, KA | 1 |
| Bakker, PL | 1 |
| Gerbens, F | 1 |
| den Boer, JA | 1 |
| Korf, J | 1 |
| te Meerman, G | 1 |
| Niesters, M | 1 |
| Dahan, A | 1 |
| Moghaddam, B | 1 |
| Gubert, C | 1 |
| Massuda, R | 1 |
| Pedrini, M | 1 |
| Jin, W | 1 |
| Ji, X | 1 |
| Javitt, DC | 1 |
| Zukin, SR | 1 |
| Heresco-Levy, U | 1 |
| Umbricht, D | 1 |
| Erdur, B | 1 |
| Degirmenci, E | 1 |
| Kortunay, S | 1 |
| Yuksel, A | 1 |
| Seyit, M | 1 |
| Ergin, A | 1 |
| Fraga, Dde B | 1 |
| Neves, G | 1 |
| Pranke, MA | 1 |
| Noël, F | 1 |
| Kieling, CO | 1 |
| Backes, AN | 1 |
| Maurer, RL | 1 |
| Cruz, CU | 1 |
| Osvaldt, AB | 1 |
| Silveira, TR | 1 |
| Matte, Uda S | 1 |
| Kron, M | 1 |
| Howell, CJ | 1 |
| Adams, IT | 1 |
| Ransbottom, M | 1 |
| Christian, D | 1 |
| Ogier, M | 1 |
| Katz, DM | 1 |
| Bleilevens, C | 1 |
| Roehl, AB | 1 |
| Goetzenich, A | 1 |
| Zoremba, N | 1 |
| Kipp, M | 1 |
| Dang, J | 1 |
| Tolba, R | 1 |
| Rossaint, R | 1 |
| Hein, M | 1 |
| Singh, UR | 1 |
| Pan, F | 1 |
| Yew, DT | 1 |
| De Luca, MT | 1 |
| Meringolo, M | 1 |
| Spagnolo, PA | 1 |
| Badiani, A | 1 |
| Olszewski, M | 1 |
| Piasecka, J | 1 |
| Goda, SA | 1 |
| Kasicki, S | 1 |
| Hunt, MJ | 2 |
| Adam, G | 1 |
| Keri, S | 1 |
| Lim, HS | 1 |
| Choi, JG | 1 |
| Ko, YK | 1 |
| Shin, YS | 1 |
| Jeon, BH | 1 |
| Park, JB | 1 |
| Kim, HW | 1 |
| Burgdorf, J | 1 |
| Zhang, XL | 1 |
| Nicholson, KL | 1 |
| Balster, RL | 1 |
| Leander, JD | 1 |
| Stanton, PK | 1 |
| Gross, AL | 1 |
| Kroes, RA | 1 |
| Eöry, ML | 1 |
| Zanuzzi, CN | 1 |
| Fuentealba, NA | 1 |
| Sguazza, GH | 1 |
| Gimeno, EJ | 1 |
| Galosi, CM | 1 |
| Barbeito, CG | 1 |
| Ma, XC | 1 |
| Dang, YH | 1 |
| Ma, R | 1 |
| Gao, CG | 1 |
| Kapur, S | 1 |
| Seeman, P | 1 |
| Nishikawa, T | 1 |
| Colpaert, FC | 1 |
| Tarayre, JP | 1 |
| Koek, W | 1 |
| Pauwels, PJ | 1 |
| Bardin, L | 1 |
| Xu, XJ | 1 |
| Wiesenfeld-Hallin, Z | 1 |
| Cosi, C | 1 |
| Carilla-Durand, E | 1 |
| Assié, MB | 1 |
| Vacher, B | 1 |
| Ho, SM | 1 |
| Waite, PM | 1 |
| Warrell, MJ | 1 |
| Rupprecht, CE | 1 |
| Ertl, HC | 1 |
| Dietzschold, B | 1 |
| O'Reilly, M | 1 |
| Leach, RP | 1 |
| Fu, ZF | 1 |
| Wunner, WH | 1 |
| Bleck, TP | 1 |
| Wilde, H | 2 |
| Ferrera, R | 1 |
| Michel, P | 1 |
| Chaves, AA | 1 |
| Dech, SJ | 1 |
| Hamlin, RL | 1 |
| Bauer, JA | 1 |
| Carnes, CA | 1 |
| Abel, KM | 1 |
| Allin, MP | 1 |
| Hemsley, DR | 1 |
| Reid, KH | 1 |
| Paskitti, M | 1 |
| Guo, SZ | 1 |
| Schmelzer, T | 1 |
| Iyer, V | 1 |
| Peters, B | 1 |
| Schroeder, H | 1 |
| Mann, T | 1 |
| Huether, G | 1 |
| Grecksch, G | 6 |
| Lorrain, DS | 1 |
| Schaffhauser, H | 2 |
| Campbell, UC | 2 |
| Baccei, CS | 1 |
| Correa, LD | 1 |
| Rowe, B | 1 |
| Rodriguez, DE | 2 |
| Anderson, JJ | 1 |
| Varney, MA | 1 |
| Pinkerton, AB | 1 |
| Vernier, JM | 2 |
| Butelman, ER | 1 |
| Ball, JW | 1 |
| Harris, TJ | 1 |
| Kreek, MJ | 1 |
| Block, F | 1 |
| Habermeyer, B | 1 |
| Taniguchi, T | 1 |
| Kanakura, H | 1 |
| Takemoto, Y | 1 |
| Kidani, Y | 1 |
| Yamamoto, K | 1 |
| Rottman, JN | 1 |
| Ni, G | 1 |
| Khoo, M | 1 |
| Anderson, ME | 1 |
| Madu, EC | 1 |
| Fournier, NM | 1 |
| Nisijima, K | 1 |
| Shioda, K | 1 |
| Yoshino, T | 1 |
| Takano, K | 1 |
| Kato, S | 1 |
| Yosunkaya, A | 1 |
| Ustün, ME | 1 |
| Bariskaner, H | 1 |
| Tavlan, A | 1 |
| Gürbilek, M | 1 |
| McKay, BE | 2 |
| Connolly, PM | 1 |
| Maxwell, C | 1 |
| Liang, Y | 1 |
| Kahn, JB | 1 |
| Kanes, SJ | 1 |
| Abel, T | 1 |
| Gur, RE | 1 |
| Song, XM | 1 |
| Li, JG | 1 |
| Du, ZH | 1 |
| Jia, BH | 1 |
| Hu, ZF | 1 |
| Zhang, SL | 1 |
| Chang, QZ | 1 |
| Li, YS | 1 |
| Qian, Z | 1 |
| Lz, D | 1 |
| Guo, X | 1 |
| Neder Meyer, T | 1 |
| Lázaro Da Silva, A | 1 |
| Rodrigues-Filho, R | 1 |
| Campos, MM | 1 |
| Ferreira, J | 1 |
| Santos, AR | 1 |
| Bertelli, JA | 1 |
| Calixto, JB | 1 |
| Keilhoff, G | 1 |
| Bernstein, HG | 2 |
| Wolf, G | 1 |
| Lees, J | 1 |
| Deakin, JF | 1 |
| Li, HT | 1 |
| Han, JS | 2 |
| Wan, Y | 1 |
| Crystal, GJ | 1 |
| Metwally, AA | 1 |
| Salem, MR | 1 |
| Kessal, K | 1 |
| Garcia, R | 1 |
| Dittmar, MS | 1 |
| Fehm, NP | 1 |
| Vatankhah, B | 1 |
| Horn, M | 1 |
| Richebé, P | 1 |
| Rivat, C | 1 |
| Maurette, P | 1 |
| Lee, IH | 1 |
| Lee, IO | 1 |
| Yagmurdur, H | 1 |
| Yagmurder, H | 1 |
| Akca, G | 1 |
| Baltaci, B | 1 |
| Dikmen, B | 1 |
| Sawada, K | 1 |
| Barr, AM | 1 |
| Nakamura, M | 1 |
| Arima, K | 1 |
| Young, CE | 1 |
| Dwork, AJ | 1 |
| Falkai, P | 1 |
| Honer, WG | 1 |
| Yin, XH | 1 |
| Zhang, QG | 1 |
| Miao, B | 1 |
| Garin, E | 1 |
| Denizot, B | 1 |
| Roux, J | 1 |
| Noiret, N | 1 |
| Lepareur, N | 1 |
| Moreau, M | 1 |
| Mesba, H | 1 |
| Laurent, JF | 1 |
| Herry, JY | 1 |
| Bourguet, P | 1 |
| Benoit, JP | 1 |
| Lejeune, JJ | 1 |
| Govek, SP | 1 |
| Bonnefous, C | 1 |
| Hutchinson, JH | 1 |
| Kamenecka, T | 1 |
| McQuiston, J | 1 |
| Pracitto, R | 1 |
| Zhao, LX | 1 |
| Gardner, MF | 1 |
| James, JK | 1 |
| Daggett, LP | 1 |
| Rowe, BA | 1 |
| Budzińska, K | 1 |
| Statler, KD | 1 |
| Alexander, H | 1 |
| Vagni, V | 1 |
| Dixon, CE | 1 |
| Clark, RS | 1 |
| Jenkins, L | 1 |
| Kochanek, PM | 1 |
| Sehdev, RS | 1 |
| Symmons, DA | 1 |
| Kindl, K | 1 |
| Cunningham, MO | 1 |
| Hunt, J | 1 |
| Middleton, S | 1 |
| LeBeau, FE | 1 |
| Gillies, MJ | 1 |
| Gillies, MG | 1 |
| Davies, CH | 1 |
| Maycox, PR | 1 |
| Whittington, MA | 1 |
| Racca, C | 1 |
| Krügel, H | 1 |
| Polten, A | 1 |
| Singh, R | 1 |
| Berg, A | 1 |
| Seidenbecher, C | 1 |
| Saluz, HP | 1 |
| Ward, CA | 1 |
| Schröder, H | 1 |
| Hemachudha, T | 1 |
| Sunsaneewitayakul, B | 1 |
| Desudchit, T | 1 |
| Suankratay, C | 1 |
| Sittipunt, C | 1 |
| Wacharapluesadee, S | 1 |
| Khawplod, P | 1 |
| Luo, B | 1 |
| Jiang, DH | 1 |
| Kong, XP | 1 |
| Zhang, NP | 1 |
| Cheng, LX | 1 |
| Ferro, MM | 1 |
| Angelucci, ME | 1 |
| Anselmo-Franci, JA | 1 |
| Canteras, NS | 1 |
| Xiao, H | 1 |
| Xu, HW | 1 |
| Bhutta, AT | 1 |
| Venkatesan, AK | 1 |
| Rovnaghi, CR | 1 |
| Anand, KJ | 1 |
| Pontén, E | 1 |
| Zhu, MM | 1 |
| Qian, YN | 1 |
| Zhu, W | 1 |
| Rong, HB | 1 |
| Ding, ZN | 1 |
| Fu, CZ | 1 |
| Lowe, XR | 1 |
| Marchetti, F | 1 |
| Wyrobek, AJ | 1 |
| Zhang, JZ | 1 |
| Jing, L | 1 |
| Guo, FY | 1 |
| Heydarpour, F | 1 |
| Amini, B | 1 |
| Kalantari, S | 1 |
| Rostami, A | 1 |
| Heydarpour, P | 1 |
| Martin, BS | 1 |
| Kapur, J | 1 |
| Hota, D | 1 |
| Bansal, V | 1 |
| Pattanaik, S | 1 |
| Kim, KO | 1 |
| Choe, G | 1 |
| Chung, SH | 1 |
| Kim, CS | 1 |
| Galici, R | 1 |
| Boggs, JD | 1 |
| Miller, KL | 1 |
| Bonaventure, P | 1 |
| Atack, JR | 1 |
| Vrajová, M | 1 |
| Schwegler, H | 1 |
| Roskoden, T | 1 |
| Smalla, KH | 1 |
| Mikhaylova, M | 1 |
| Sahin, J | 1 |
| Bogerts, B | 1 |
| Schmitt, A | 1 |
| van der Schors, R | 1 |
| Smit, AB | 1 |
| Li, KW | 1 |
| Gundelfinger, ED | 1 |
| Kreutz, MR | 1 |
| Soucy, DM | 1 |
| Sindlinger, JF | 1 |
| Greene, SP | 1 |
| Barber, A | 1 |
| Illner, H | 1 |
| Shires, GT | 1 |
| Kubová, H | 1 |
| Mares, P | 3 |
| Ellison, G | 1 |
| Mikolásová, R | 1 |
| Velísek, L | 2 |
| Vorlícek, J | 1 |
| Szelenyi, I | 1 |
| Herold, H | 1 |
| Göthert, M | 1 |
| Renis, M | 1 |
| Di Giacomo, C | 1 |
| Sorrenti, V | 1 |
| Russo, A | 1 |
| La Delfa, C | 1 |
| Reale, S | 1 |
| Barcellona, ML | 1 |
| Vanella, A | 1 |
| Lee, TY | 1 |
| Fu, MJ | 1 |
| Kuo, TB | 1 |
| Lui, PW | 1 |
| Chan, SH | 1 |
| Vondricková, R | 1 |
| Beerntsen, BT | 1 |
| Lowenberger, CA | 1 |
| Klinkhammer, JA | 1 |
| Christensen, LA | 1 |
| Christensen, BM | 1 |
| Clapp, I | 1 |
| Laidlaw, S | 1 |
| Mitchell, IJ | 1 |
| Waters, CM | 1 |
| Farber, NB | 1 |
| Wozniak, DF | 1 |
| Price, MT | 1 |
| Labruyere, J | 1 |
| Huss, J | 1 |
| St Peter, H | 1 |
| Olney, JW | 2 |
| Cazals, Y | 1 |
| Huang, ZW | 1 |
| Kolesnikov, Y | 1 |
| Jain, S | 1 |
| Wilson, R | 1 |
| Pasternak, GW | 1 |
| Jasani, MS | 1 |
| Salzman, SK | 1 |
| Tice, LL | 1 |
| Ginn, A | 1 |
| Nadkarni, VM | 1 |
| Wiedemann, M | 1 |
| Hanke, W | 1 |
| Nimkoff, L | 1 |
| Quinn, C | 1 |
| Silver, P | 1 |
| Sagy, M | 1 |
| Korcarz, CE | 1 |
| Padrid, PA | 1 |
| Shroff, SG | 1 |
| Weinert, L | 1 |
| Lang, RM | 1 |
| Van Roey, G | 1 |
| Lijnen, P | 1 |
| Verbesselt, R | 1 |
| Verbruggen, A | 1 |
| Fevery, J | 1 |
| Sonoda, H | 1 |
| Omote, K | 1 |
| Lüebbe, AS | 1 |
| Harris, PD | 1 |
| Garrison, RN | 1 |
| Vasilev, D | 1 |
| Konstantinov, S | 1 |
| Konstantinova, Zh | 1 |
| Nachkov, Ia | 1 |
| Karaivanova, M | 1 |
| Stamenova, P | 1 |
| Mazarati, AM | 1 |
| Miyamoto, TA | 2 |
| Miyamoto, KJ | 2 |
| Nishizawa, N | 1 |
| Nakao, S | 1 |
| Nagata, A | 1 |
| Hirose, T | 1 |
| Masuzawa, M | 1 |
| Shingu, K | 1 |
| Conley, J | 1 |
| Hunter, K | 1 |
| Lundy, P | 1 |
| Hamilton, M | 1 |
| Sawyer, TW | 1 |
| Cao, Y | 1 |
| Lips, J | 1 |
| de Haan, P | 1 |
| Bodewits, P | 1 |
| Vanicky, I | 1 |
| Dzoljic, M | 1 |
| Jacobs, MJ | 1 |
| Kalkman, CJ | 1 |
| Lisanby, SH | 1 |
| Luber, B | 1 |
| Finck, AD | 1 |
| Schroeder, C | 1 |
| Sackeim, HA | 1 |
| Winter, JC | 1 |
| Doat, M | 1 |
| Rabin, RA | 1 |
| Longnecker, DE | 1 |
| Sturgill, BC | 1 |
| Brailowsky, S | 1 |
| Menini, C | 1 |
| Naquet, R | 1 |
| Jasinski, DR | 1 |
| Cone, EJ | 1 |
| Gorodetzky, CW | 1 |
| Risner, ME | 1 |
| Shannon, HE | 1 |
| Su, TP | 1 |
| Vaupel, DB | 1 |
| Hirshman, CA | 1 |
| Downes, H | 1 |
| Farbood, A | 1 |
| Bergman, NA | 1 |
| Laurent, JP | 1 |
| Molinari, GF | 1 |
| Moseley, JI | 1 |
| Carlsson, M | 1 |
| Svensson, A | 1 |
| Carlsson, A | 1 |
| Martinez-Arizala, A | 1 |
| Rigamonti, DD | 1 |
| Long, JB | 1 |
| Kraimer, JM | 1 |
| Holaday, JW | 1 |
| Herrera, DG | 1 |
| Robertson, HA | 1 |
| Beal, MF | 1 |
| Kowall, NW | 1 |
| Swartz, KJ | 1 |
| Ferrante, RJ | 1 |
| Martin, JB | 1 |
| Marco, LA | 2 |
| Reed, TF | 2 |
| Joshi, RS | 1 |
| Aldes, LD | 2 |
| Chronister, RB | 2 |
| Pendleton, R | 1 |
| Brigham, TE | 1 |
| Mansbach, RS | 1 |
| Marquis, KL | 1 |
| Moreton, JE | 1 |
| Estel, S | 1 |
| Thiele, C | 1 |
| Borg, T | 1 |
| Gerdin, B | 1 |
| Modig, J | 1 |
| Harrison, GG | 1 |
| Moore, MR | 1 |
| Meissner, PN | 1 |
| Carlson, RP | 1 |
| Datko, LJ | 1 |
| O'Neill-Davis, L | 1 |
| Blazek, EM | 1 |
| DeLustro, F | 1 |
| Beideman, R | 1 |
| Lewis, AJ | 1 |
| Jennings, PB | 1 |
| Alden, ER | 1 |
| Brenz, RW | 1 |
| Cheney, DH | 1 |
| Slogoff, S | 1 |
| Allen, GW | 1 |
| Albin, MS | 1 |
| Bunegin, L | 1 |
| Massopust, LC | 1 |
| Jannetta, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| (2R,6R)-Hydroxynorketamine a Novel Therapeutic Analgesic for the Treatment of Neuropathic Pain: A Randomized Double Blind Cross-Over Trial.[NCT05864053] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD[NCT06036511] | Phase 1/Phase 2 | 14 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Randomized, Parallel-group，Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Chinese Patients With Treatment-Resistant Depression.[NCT03887624] | Early Phase 1 | 16 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to Participates could not stand the side effects) | ||
| Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics[NCT04780152] | Phase 2/Phase 3 | 172 participants (Anticipated) | Interventional | 2021-10-31 | Recruiting | ||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Spreading Depolarization and Ketamine Suppression[NCT02501941] | Phase 1 | 10 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder - Fear of Harm Phenotype[NCT05209217] | 20 participants (Anticipated) | Observational | 2019-06-04 | Recruiting | |||
| Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial[NCT03788759] | Phase 2/Phase 3 | 48 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| Efficacy and Safety of Esketamine or Sevoflurane Add to Dexmedetomidine-based Sedation for Ophthalmology Procedure in Children[NCT05321160] | 116 participants (Actual) | Interventional | 2021-03-10 | Completed | |||
| The Prevention of Post Operative Cognitive Dysfunction by Ketamine: a Prospective Multicenter Randomized Blinded Placebo-controlled Trial in Elderly Patients Undergoing Elective Orthopaedic Surgery[NCT02892916] | Phase 3 | 307 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Efficacy of Combined Ketamine and Midazolam for Treatment of Generalized Convulsive Status Epilepticus in Children .[NCT05779657] | Phase 2/Phase 3 | 144 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | ||
| A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia[NCT02074319] | Phase 1 | 92 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine[NCT03096444] | Phase 2 | 13 participants (Actual) | Interventional | 2017-05-23 | Terminated (stopped due to Efficacy was not seen after interim analysis) | ||
| Fentanyl Ultra Low Doses Effects on Human Volunteer's Nociceptive Threshold. Towards a Simple Pharmacological Test Able to Predict Pain Vulnerability, Post Operative Hyperalgesia Development Risk?[NCT00454259] | Phase 4 | 48 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
"Peak itch intensity between the vehicle and 4 other active treatments (individual ketamine, amitriptyline, or lidocaine, and KeAmLi-combo). Itch intensity was measured on a 100mm scale visual analog scale for 10 minutes. 0 was weighted with no itch and 100 was weighted with most itch imaginable." (NCT03096444)
Timeframe: 10 minutes
| Intervention | Intensity score (Mean) |
|---|---|
| Topical KeAmLi Combo | 62.7 |
| Topical Ketamine | 63.1 |
| Topical Amitriptyline | 69.2 |
| Topical Lidocaine | 65.8 |
| Topical Vehicle | 61.9 |
Assess mechanical detection and pain thresholds using von Frey filaments stimulators (measured in force mN) to calculate the final threshold as the geometric mean of five series of ascending and descending stimuli. (NCT03096444)
Timeframe: 5 minutes
| Intervention | mN (Mean) | |
|---|---|---|
| Mechanical Detection Threshold | Mechanical Pain Threshold | |
| Topical Amitriptyline | 3.573423965 | 152.4768146 |
| Topical KeAmLi Combo | 3.519376956 | 152.3293608 |
| Topical Ketamine | 3.464204768 | 135.9 |
| Topical Lidocaine | 3.546037659 | 126.9 |
| Topical Vehicle | 3.525692637 | 148.7138273 |
Two standardized quantitative sensory tests are performed to measure warmth detection threshold (assesses the threshold of which warmth sensation is first detected) and heat pain threshold (assesses the threshold at which heat pain sensation is first detected). Measured in change in celsius. (NCT03096444)
Timeframe: 3 minutes
| Intervention | Degrees celsius (Mean) | |
|---|---|---|
| Warm Detection Threshold | Heat Pain Threshold | |
| Topical Amitriptyline | 33.9 | 40.0 |
| Topical KeAmLi Combo | 33.6 | 39.8 |
| Topical Ketamine | 34.0 | 40.0 |
| Topical Lidocaine | 33.7 | 39.4 |
| Topical Vehicle | 33.8 | 39.7 |
37 reviews available for ketamine and Disease Models, Animal
| Article | Year |
|---|---|
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Depressive Dis | 2022 |
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Ketamine; Mice; | 2023 |
Rodent ketamine depression-related research: Finding patterns in a literature of variability.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; Huma | 2019 |
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Anima | 2019 |
Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Dop | 2020 |
Emerging concepts on the use of ketamine for chronic pain.
Topics: Analgesics; Animals; Chronic Pain; Depression; Disease Models, Animal; Excitatory Amino Acid Antagon | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
The emergence of ketamine as a novel treatment for posttraumatic stress disorder.
Topics: Animals; Antidepressive Agents; Disease Models, Animal; Humans; Ketamine; Practice Patterns, Physici | 2020 |
New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
Topics: Animals; Antidepressive Agents; Brain; Clinical Trials as Topic; Depressive Disorder, Major; Disease | 2017 |
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Ketamine; Neurobiology; | 2017 |
The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Topics: Animals; Antidepressive Agents; Biomarkers; Depression; Disease Models, Animal; Drug Development; Gl | 2018 |
Overcoming Depression by Inhibition of Neural Burst Firing.
Topics: Anhedonia; Animals; Behavior, Animal; Calcium Channels, T-Type; Depressive Disorder; Disease Models, | 2018 |
Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.
Topics: Animals; Biomarkers; Disease Models, Animal; Electroencephalography; Excitatory Amino Acid Antagonis | 2018 |
The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug.
Topics: Animals; Antidepressive Agents; Disease Models, Animal; Excitatory Amino Acid Agents; Glutamic Acid; | 2018 |
Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Hippocampus; Ket | 2019 |
Preclinical assessment of ketamine.
Topics: Animals; Brain Diseases; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Ketamine; Neu | 2013 |
Synaptic mechanisms underlying rapid antidepressant action of ketamine.
Topics: Animals; Antidepressive Agents; Brain; Disease Models, Animal; Humans; Ketamine; Mice; Neuronal Plas | 2012 |
Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.
Topics: Analgesics; Animals; Brain; Disease Models, Animal; Electroencephalography; Evoked Potentials; Human | 2013 |
Novel therapeutic strategies in major depression: focus on RNAi and ketamine.
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Deep Brain Stimulation; Depressive Disorde | 2014 |
Single versus combinatorial therapies in status epilepticus: Novel data from preclinical models.
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug T | 2015 |
Treatment-resistant depression: are animal models of depression fit for purpose?
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Disea | 2015 |
Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.
Topics: Animals; Antidepressive Agents; Brain; Depression; Disease Models, Animal; Humans; Ketamine; Swimmin | 2016 |
The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Enzyme Inhibitors; Humans; Ketamine; NG-Nitroargi | 2016 |
[Receptor antagonist of NMDA and animal models of schizophrenia].
Topics: Animals; Behavior, Animal; Brain; Consciousness Disorders; Disease Models, Animal; Dizocilpine Malea | 2009 |
Investigational NMDA receptor modulators for depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Design; Drugs, Investigatio | 2012 |
Ketamine as a novel antidepressant: from synapse to behavior.
Topics: Animals; Antidepressive Agents; Brain; Clinical Trials as Topic; Depressive Disorder, Treatment-Resi | 2012 |
Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain.
Topics: Animals; Chronic Disease; Disease Models, Animal; Humans; Ketamine; Neuralgia; Randomized Controlled | 2012 |
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cerebral Corte | 2012 |
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Brain Mapping; Cerebral Cortex; Cognition Disorders; Contingen | 2012 |
The role of setting for ketamine abuse: clinical and preclinical evidence.
Topics: Animals; Clinical Trials as Topic; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug | 2012 |
[Genetic study on schizophrenia and its recurrence utilizing pharmacological models].
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cocaine; Disease Models, Animal; Dopamine A | 2002 |
[Glutamate antagonists for treatment of neuropathic pain].
Topics: Amantadine; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Ketamine; Me | 2003 |
Ketamine for rapid sequence induction in patients with head injury in the emergency department.
Topics: Anesthesia; Anesthetics, Dissociative; Animals; Cerebrovascular Circulation; Craniocerebral Trauma; | 2006 |
Anaesthetic neurotoxicity in rodents: is the ketamine controversy real?
Topics: Anesthetics, Dissociative; Animals; Brain Injuries; Cell Death; Disease Models, Animal; Ketamine; Ne | 2007 |
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Topics: Adaptation, Physiological; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Human | 2008 |
Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system.
Topics: Anesthetics; Animals; Animals, Newborn; Behavior, Animal; Biomedical Research; Cell Death; Disease M | 2008 |
The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias.
Topics: Animals; Behavior, Animal; Dementia; Disease Models, Animal; Dizocilpine Maleate; Humans; Ketamine; | 1995 |
4 trials available for ketamine and Disease Models, Animal
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Chronic Administration of the N-Methyl-D-Aspartate Receptor Antagonist Ketamine Improves Rett Syndrome Phenotype.
Topics: Animals; Disease Models, Animal; GABAergic Neurons; Ketamine; Methyl-CpG-Binding Protein 2; Mice; Mi | 2016 |
Effect of anesthesia and cerebral blood flow on neuronal injury in a rat middle cerebral artery occlusion (MCAO) model.
Topics: Anesthesia; Anesthetics; Animals; Blood Pressure; Brain Edema; Brain Injuries; Cerebral Infarction; | 2013 |
Low dose ketamine increases prepulse inhibition in healthy men.
Topics: Acoustic Stimulation; Cognition; Cross-Over Studies; Disease Models, Animal; Double-Blind Method; El | 2003 |
623 other studies available for ketamine and Disease Models, Animal
| Article | Year |
|---|---|
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Corpus Striatum; Disease Models, A | 2021 |
Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice.
Topics: Administration, Oral; Animals; Biological Availability; Curcumin; Disease Models, Animal; Humans; Ke | 2021 |
Anaesthesia-Induced Transcriptomic Changes in the Context of Renal Ischemia Uncovered by the Use of a Novel Clamping Device.
Topics: Anesthesia; Animals; Disease Models, Animal; Ketamine; Kidney; Kidney Diseases; Male; Mice; Reperfus | 2021 |
Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice.
Topics: Animals; Compulsive Behavior; Corpus Striatum; Disease Models, Animal; Female; Grooming; Humans; Ket | 2021 |
Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Betaine; Cognition; Disease Models, Animal; Disks L | 2021 |
Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Depressive Disorder, Major; Disease Models, A | 2022 |
Diazepam Monotherapy or Diazepam-Ketamine Dual Therapy at Different Time Points Terminates Seizures and Reduces Mortality in a Status Epilepticus Animal Model.
Topics: Analgesics; Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Drug Administration Schedule | 2021 |
Repeated intermittent administration of (R)-ketamine during juvenile and adolescent stages prevents schizophrenia-relevant phenotypes in adult offspring after maternal immune activation: a role of TrkB signaling.
Topics: Adolescent; Adult Children; Animals; Disease Models, Animal; Female; Humans; Ketamine; Membrane Glyc | 2022 |
S-Ketamine Exerts Antidepressant Effects by Regulating Rac1 GTPase Mediated Synaptic Plasticity in the Hippocampus of Stressed Rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; GTP | 2023 |
(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: A role of gut-microbiota-brain axis.
Topics: Animals; Brain; Cuprizone; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Huma | 2022 |
Enhanced Fear Memories and Altered Brain Glucose Metabolism (
Topics: Anesthetics, Dissociative; Animals; Brain; Conditioning, Psychological; Disease Models, Animal; Dose | 2022 |
BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Depression; D | 2022 |
A single dose of ketamine cannot prevent protracted stress-induced anhedonia and neuroinflammation in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Carrier Proteins; Corticosterone; Depression; Disease Mod | 2022 |
Autistic-like social deficits in hippocampal MeCP2 knockdown rat models are rescued by ketamine.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Hippocampus; Ketamine; | 2022 |
Ketamine sex- and dose-dependently mitigates behavioral sequelae induced by a predator-based psychosocial stress model of post-traumatic stress disorder.
Topics: Animals; Anxiety; Disease Models, Animal; Female; Ketamine; Male; Rats; Rats, Sprague-Dawley; Stress | 2022 |
Ketamine administration in early postnatal life as a tool for mimicking Autism Spectrum Disorders core symptoms.
Topics: Animals; Autism Spectrum Disorder; Brain-Derived Neurotrophic Factor; Disease Models, Animal; gamma- | 2022 |
Downregulation of the NLRP3/Caspse-1 Pathway Ameliorates Ketamine-Induced Liver Injury and Inflammation in Developing Rats.
Topics: Animals; Caspase 1; Chemical and Drug Induced Liver Injury, Chronic; Disease Models, Animal; Down-Re | 2022 |
Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: A role of gut microbiota.
Topics: Animals; Bone Density; Disease Models, Animal; Female; Gastrointestinal Microbiome; Humans; Ketamine | 2022 |
Niacin mitigates blood-brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: Role of GPR109A receptor.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Encephalitis; Hypolipidemic Agents; Ketamine; | 2022 |
Assessing ultrasonographic optic nerve sheath diameter in animal model with anesthesia regimens.
Topics: Anesthesia; Animals; Disease Models, Animal; Ketamine; Optic Nerve; Propofol; Swine; Thiopental; Xyl | 2022 |
Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine.
Topics: Animals; Astrocytes; Disease Models, Animal; Hippocampus; Humans; Ketamine; Mice; Microglia; Recepto | 2022 |
Explore the molecular mechanism of angle-closure glaucoma in elderly patients induced telomere shortening of retinal ganglion cells through oxidative stress.
Topics: Animals; beta-Galactosidase; Disease Models, Animal; Fluorescent Dyes; Glaucoma; Glaucoma, Angle-Clo | 2022 |
Effects of fast-acting antidepressant drugs on a postpartum depression mice model.
Topics: Anhedonia; Animals; Antidepressive Agents; Depression, Postpartum; Disease Models, Animal; Female; H | 2022 |
Individual differences in the positive outcome from adolescent ketamine treatment in a female mouse model of anorexia nervosa involve drebrin A at excitatory synapses of the medial prefrontal cortex.
Topics: Animals; Anorexia; Anorexia Nervosa; Cytoplasm; Disease Models, Animal; Female; gamma-Aminobutyric A | 2023 |
Stress with ketamine tackles depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hormones; Ketamine; Stress, Psyc | 2022 |
A tool for mapping microglial morphology, morphOMICs, reveals brain-region and sex-dependent phenotypes.
Topics: Animals; Brain; Disease Models, Animal; Female; Ketamine; Male; Mice; Microglia; Phenotype | 2022 |
Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia.
Topics: Amino Acids; Animals; Antipsychotic Agents; Biomarkers; Disease Models, Animal; gamma-Aminobutyric A | 2022 |
Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Mo | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model.
Topics: Anesthesia; Animals; Disease Models, Animal; Infarction, Middle Cerebral Artery; Isoflurane; Ketamin | 2023 |
Ketamine Attenuates Airway Inflammation via Inducing Inflammatory Cells Apoptosis and Activating Nrf2 Pathway in a Mixed-Granulocytic Murine Asthma Model.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Inflammation; Kelch-Like ECH- | 2022 |
Evaluation of Intraperitoneal [
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Humans; Ketamine; Mice; Positron-Emission Tomograp | 2022 |
Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress.
Topics: Anhedonia; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Habenula; Ketamine; M | 2023 |
(R)-ketamine attenuates neurodevelopmental disease-related phenotypes in a mouse model of maternal immune activation.
Topics: Animals; Behavior, Animal; Cytokines; Disease Models, Animal; Female; Humans; Ketamine; Male; Mice; | 2023 |
A shea butter-based ketamine ointment: The antidepressant effects of transdermal ketamine in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Ketamine; Male; Ointments; Rats; | 2023 |
Resveratrol plays neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice.
Topics: Animals; Disease Models, Animal; Ketamine; Male; Memory Disorders; Mice; Oxidative Stress; Resveratr | 2023 |
Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Epigenesis, Genetic; Glial Cell | 2023 |
Methodological approach: using a within-subjects design in the marble burying assay.
Topics: Animals; Behavior, Animal; Buspirone; Calcium Carbonate; Disease Models, Animal; Female; Fluoxetine; | 2023 |
Prolonged ketamine therapy differentially rescues psychobehavioural deficits via modulation of nitro-oxidative stress and oxytocin receptors in the gut-brain-axis of chronically-stressed mice.
Topics: Animals; Brain-Gut Axis; Depression; Disease Models, Animal; Female; Hippocampus; Ketamine; Mice; Ox | 2023 |
Immunomodulatory and pro-oncologic effects of ketamine and isoflurane anesthetics in a murine model.
Topics: Anesthetics; Anesthetics, Inhalation; Animals; Disease Models, Animal; Immunity; Isoflurane; Ketamin | 2023 |
Nebulized and intraperitoneal ketamine have equivalent antidepressant-like effect in the forced swim and tail suspension tests in mice.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Dexamethasone; Disease Model | 2023 |
MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; | 2020 |
Classical conditioning of antidepressant placebo effects in mice.
Topics: Animals; Antidepressive Agents; Conditioning, Classical; Depressive Disorder; Disease Models, Animal | 2020 |
Long-term ketamine administration causes Tau protein phosphorylation and Tau protein-dependent AMPA receptor reduction in the hippocampus of mice.
Topics: Animals; Disease Models, Animal; Hippocampus; Ketamine; Male; Mice; Mice, Inbred C57BL; Phosphorylat | 2019 |
Applying vinpocetine to reverse synaptic ultrastructure by regulating BDNF-related PSD-95 in alleviating schizophrenia-like deficits in rat.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Disks Large Homolog 4 Protein; K | 2019 |
Association between intravenous ketamine-induced stress hormone levels and long-term fear memory renewal in Sprague-Dawley rats.
Topics: Administration, Intravenous; Anesthetics, Dissociative; Animals; Behavior, Animal; Corticosterone; D | 2020 |
Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval.
Topics: Anesthetics, Dissociative; Animals; Behavior, Animal; Central Nervous System Sensitization; Disease | 2020 |
Distinct changes in chronic pain sensitivity and oxytocin receptor expression in a new rat model (Wisket) of schizophrenia.
Topics: Analgesics, Opioid; Animals; Ankle Joint; Brain; Brain Stem; Chronic Pain; Diencephalon; Disease Mod | 2020 |
Activation of the phagocyte NADPH oxidase/NOX2 and myeloperoxidase in the mouse brain during pilocarpine-induced temporal lobe epilepsy and inhibition by ketamine.
Topics: Animals; Brain; Disease Models, Animal; Epilepsy, Temporal Lobe; Excitatory Amino Acid Antagonists; | 2020 |
Effects of ketamine on prepubertal Wistar rats: Implications on behavioral parameters for Childhood-Onset Schizophrenia.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; | 2019 |
A single coadministration of subeffective doses of ascorbic acid and ketamine reverses the depressive-like behavior induced by chronic unpredictable stress in mice.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Behavior, Animal; Depression; Depressive Disorder, Ma | 2019 |
Early Celastrol Administration Prevents Ketamine-Induced Psychotic-Like Behavioral Dysfunctions, Oxidative Stress and IL-10 Reduction in The Cerebellum of Adult Mice.
Topics: Animals; Cerebellum; Disease Models, Animal; Interleukin-10; Ketamine; Male; Membrane Glycoproteins; | 2019 |
Blackberry extract improves behavioral and neurochemical dysfunctions in a ketamine-induced rat model of mania.
Topics: Animals; Anthocyanins; Antimanic Agents; Behavior, Animal; Catalase; Cerebral Cortex; Cytokines; Dis | 2020 |
Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice.
Topics: Age Factors; Animals; Antidepressive Agents; Behavior, Animal; Conditioning, Classical; Depression; | 2020 |
Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the prefrontal cortex in male rodents.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Inhibit | 2020 |
The influences of morphine or ketamine pre-treatment on hemodynamic, acid-base status, biochemical markers of brain damage and early survival in rats after asphyxial cardiac arrest.
Topics: Analgesics, Opioid; Animals; Asphyxia; Blood Gas Analysis; Brain Injuries; Cardiopulmonary Resuscita | 2019 |
Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR.
Topics: Adult; Animals; Biomarkers; Cytokines; Depressive Disorder, Major; Disease Models, Animal; Female; G | 2019 |
Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depressive Diso | 2020 |
Ketamine Restores Thalamic-Prefrontal Cortex Functional Connectivity in a Mouse Model of Neurodevelopmental Disorder-Associated 2p16.3 Deletion.
Topics: Animals; Calcium-Binding Proteins; Disease Models, Animal; Gene Deletion; Injections, Intraperitonea | 2020 |
Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats.
Topics: Animals; Antipsychotic Agents; Cannabidiol; Cognitive Dysfunction; Disease Models, Animal; Ketamine; | 2020 |
Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine.
Topics: Animals; Antidepressive Agents; Autopsy; Behavior, Animal; Depressive Disorder, Major; Disease Model | 2021 |
mTOR Expression in Hippocampus and Prefrontal Cortex Is Downregulated in a Rat Model of Schizophrenia Induced by Chronic Administration of Ketamine.
Topics: Animals; Disease Models, Animal; Down-Regulation; Hippocampus; Ketamine; Male; Prefrontal Cortex; Ra | 2020 |
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Ketamine; Male; Narcotic | 2020 |
Overinhibition mediated by parvalbumin interneurons might contribute to depression-like behavior and working memory impairment induced by lipopolysaccharide challenge.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Fl | 2020 |
Prenatal Exposure to Ketamine Leads to Anxiety-Like Behaviors and Dysfunction in Bed Nucleus of Stria Terminalis.
Topics: Age Factors; Anesthetics, Dissociative; Animals; Anxiety; Behavior, Animal; Disease Models, Animal; | 2020 |
Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Dose-Response | 2020 |
Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dizocilpine Maleate; Female; Ket | 2020 |
Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Ketamine; Mice; Mice, Inbred C57 | 2020 |
Differential effects of lithium isotopes in a ketamine-induced hyperactivity model of mania.
Topics: Animals; Antimanic Agents; Behavior, Animal; Disease Models, Animal; Isotopes; Ketamine; Lithium; Li | 2020 |
(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Mod | 2020 |
Potential therapeutic antipsychotic effects of Naringin against ketamine-induced deficits in rats: Involvement of Akt/GSK-3β and Wnt/β-catenin signaling pathways.
Topics: Animals; Antipsychotic Agents; beta Catenin; Clozapine; Disease Models, Animal; Flavanones; Glycogen | 2020 |
Neuronal brain injury after cerebral ischemic stroke is ameliorated after subsequent administration of (R)-ketamine, but not (S)-ketamine.
Topics: Animals; Behavior, Animal; Brain Injuries; Disease Models, Animal; Infarction, Middle Cerebral Arter | 2020 |
Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hydroxynorketamine Administration.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Nucleus; Disease Models, | 2020 |
Probing for Conditioned Hallucinations Through Neural Activation in a Ketamine Mouse Model of Schizophrenia.
Topics: Animals; Disease Models, Animal; Hallucinations; Ketamine; Mice; Schizophrenia | 2020 |
Protective effect of oleuropein on ketamine-induced cardiotoxicity in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cardiotoxicity; Disease Models, Animal; Heart Disea | 2020 |
The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Ketamine; Mice; Parvalbumins; Schizophrenia | 2020 |
Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Mod | 2020 |
Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with non-cirrhotic portal hypertension.
Topics: Anesthesia, Inhalation; Anesthesiology; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; | 2020 |
Extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model.
Topics: Animals; Antidepressive Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depression; Dise | 2020 |
Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression.
Topics: Animals; Depression; Disease Models, Animal; Hippocampus; Immobilization; Ketamine; Long-Term Potent | 2020 |
Molecular mechanisms for the antidepressant-like effects of a low-dose ketamine treatment in a DFP-based rat model for Gulf War Illness.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Calcium | 2020 |
Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction.
Topics: Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major | 2020 |
Chronic fluoxetine or ketamine treatment differentially affects brain energy homeostasis which is not exacerbated in mice with trait suboptimal mitochondrial function.
Topics: Animals; Brain; Disease Models, Animal; Electron Transport Complex I; Fluoxetine; Homeostasis; Ketam | 2021 |
Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Disease Models, Animal; Drug Therapy, Co | 2020 |
Investigation of the Possible Protective Effects of Ketamine and Dantrolene on the Hippocampal Apoptosis and Spatial Learning in Rats Exposed to Repeated Electroconvulsive Seizures as a Model of Status Epilepticus.
Topics: Animals; Apoptosis; Dantrolene; Disease Models, Animal; Electroshock; Hippocampus; Ketamine; Male; M | 2020 |
The Effects of Dexmedetomidine and Ketamine on Oxidative Injuries and Histological Changes Following Blunt Chest Trauma.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Ketamine; Male; Oxidative Stress; Protective Agent | 2020 |
Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Humans; Ketamine; Prefrontal Cortex; | 2020 |
Disruption of Cav1.2-mediated signaling is a pathway for ketamine-induced pathology.
Topics: Animals; Calcium; Calcium Channels, L-Type; Cell Proliferation; Cystitis; Disease Models, Animal; Hu | 2020 |
Ketamine normalizes high-gamma power in the anterior cingulate cortex in a rat chronic pain model.
Topics: Action Potentials; Animals; Chronic Pain; Disease Models, Animal; Freund's Adjuvant; Gamma Rhythm; G | 2020 |
A circuit mechanism for decision-making biases and NMDA receptor hypofunction.
Topics: Animals; Behavior, Animal; Choice Behavior; Decision Making; Disease Models, Animal; Excitatory Amin | 2020 |
Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling.
Topics: Animals; Antidepressive Agents; Azepines; Behavior, Animal; Benzamides; Depression; Disease Models, | 2021 |
Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine.
Topics: Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models | 2021 |
Rapid and long-lasting antidepressant-like effects of ketamine and their relationship with the expression of brain enzymes, BDNF, and astrocytes.
Topics: Animals; Antidepressive Agents; Astrocytes; Brain; Brain-Derived Neurotrophic Factor; Disease Models | 2020 |
Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Imipramine; Ketamine; Male; Memory, S | 2021 |
Coadministration of Ketamine and Perampanel Improves Behavioral Function and Reduces Inflammation in Acute Traumatic Brain Injury Mouse Model.
Topics: Animals; Behavior, Animal; Brain; Brain Injuries, Traumatic; Disease Models, Animal; Inflammation; K | 2020 |
Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity.
Topics: Animals; Antipsychotic Agents; Cocaine; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dose- | 2021 |
The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
Topics: Amino Acids; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Excitatory Amino Ac | 2021 |
Chronic lithium exposure attenuates ketamine-induced mania-like behavior and c-Fos expression in the forebrain of mice.
Topics: Amygdala; Animals; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Depr | 2021 |
Elevated preoptic brain activity in zebrafish glial glycine transporter mutants is linked to lethargy-like behaviors and delayed emergence from anesthesia.
Topics: Aminobenzoates; Anesthesia, General; Anesthetics; Animals; Animals, Genetically Modified; Craniotomy | 2021 |
Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: A role of TrkB signaling.
Topics: Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Anim | 2021 |
Novel Genetically Modified Mouse Model to Assess Soman-Induced Toxicity and Medical Countermeasure Efficacy: Human Acetylcholinesterase Knock-in Serum Carboxylesterase Knockout Mice.
Topics: Acetylcholinesterase; Anesthetics; Animals; Brain; Carboxylesterase; Chemical Warfare Agents; Diseas | 2021 |
Proteome profile of telencephalon associates attenuated neurogenesis with chronic stress induced mood disorder phenotypes in zebrafish model.
Topics: Affect; Animals; Antidepressive Agents; Anxiety; Cell Proliferation; Depression; Disease Models, Ani | 2021 |
Effect of ketamine on mood dysfunction and spatial cognition deficits in PTSD mouse models via HCN1-BDNF signaling.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognition; Disease Models, Animal; Hippocampus; Humans; | 2021 |
Neuroprotection by delayed triple therapy following sarin nerve agent insult in the rat.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Carrier Proteins; Dinoprostone; Disease Models, A | 2021 |
Ketamine and xylazine effects in murine model of acute pancreatitis.
Topics: Analgesics; Animals; Atropine; Autophagy; Cell Proliferation; Disease Models, Animal; Drug Therapy, | 2021 |
Intranasal administration of transforming growth factor-β1 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: A role of TrkB signaling.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depre | 2021 |
Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cannabidiol; Depression; Disease Models, Animal; H | 2021 |
Gut microbiota is involved in the antidepressant-like effect of (S)-norketamine in an inflammation model of depression.
Topics: Animals; Antidepressive Agents; Bacteria; Depression; Disease Models, Animal; Gastrointestinal Micro | 2021 |
Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk.
Topics: Animals; Discrimination, Psychological; Disease Models, Animal; Excitatory Amino Acid Antagonists; F | 2021 |
(R)-Ketamine ameliorates lethal inflammatory responses and multi-organ injury in mice induced by cecum ligation and puncture.
Topics: Animals; Biomarkers; Cecum; Cytokines; Disease Models, Animal; Inflammation; Inflammation Mediators; | 2021 |
Ketamine enhances autophagy and endoplasmic reticulum stress in rats and SV-HUC-1 cells via activating IRE1-TRAF2-ASK1-JNK pathway.
Topics: Animals; Apoptosis; Autophagy; Cell Line; Cystitis; Disease Models, Animal; Endoplasmic Reticulum St | 2021 |
Extracellular matrix alterations in the ketamine model of schizophrenia.
Topics: Amygdala; Animals; Disease Models, Animal; Extracellular Matrix; Hippocampus; Immunohistochemistry; | 2017 |
The Evaluation of Folic Acid-Deficient or Folic Acid-Supplemented Diet in the Gestational Phase of Female Rats and in Their Adult Offspring Subjected to an Animal Model of Schizophrenia.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Female; Folic Acid; Folic Acid Deficiency; Inf | 2018 |
Altered Cortical Ensembles in Mouse Models of Schizophrenia.
Topics: Action Potentials; Animals; Brain; DiGeorge Syndrome; Disease Models, Animal; Evoked Potentials, Vis | 2017 |
A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex.
Topics: Animals; Antidepressive Agents; Circadian Rhythm Signaling Peptides and Proteins; Computational Biol | 2017 |
Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.
Topics: Analysis of Variance; Animals; Central Nervous System Stimulants; Conditioning, Operant; Disease Mod | 2017 |
Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in a ketamine-based animal model of schizophrenia.
Topics: Animals; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Disease Models, Animal; Exploratory Behav | 2018 |
Ketamine potentiates oxidative stress and influences behavior and inflammation in response to lipolysaccharide (LPS) exposure in early life.
Topics: Animals; Animals, Newborn; Behavior, Animal; Brain; Corpus Striatum; Cytokines; Disease Models, Anim | 2017 |
Effects of ketamine, dexmedetomidine and propofol anesthesia on emotional memory consolidation in rats: Consequences for the development of post-traumatic stress disorder.
Topics: Animals; Avoidance Learning; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Dr | 2017 |
Ketamine and Etomidate Down-regulate the Hypothalamic-Pituitary-Adrenal Axis in an Endotoxemic Mouse Model.
Topics: Analgesics; Animals; Corticosterone; Corticotropin-Releasing Hormone; Disease Models, Animal; Down-R | 2017 |
Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Disease Models, Animal; Excit | 2017 |
Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Disease Models, Animal; Female; Gallic Acid; gamma-A | 2018 |
Sex-Dependent Effects of Stress on Immobility Behavior and VTA Dopamine Neuron Activity: Modulation by Ketamine.
Topics: Action Potentials; Acute Disease; Animals; Antidepressive Agents; Chronic Disease; Disease Models, A | 2017 |
Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine.
Topics: Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Dis | 2017 |
Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice.
Topics: Acetates; Animals; Antioxidants; Antipsychotic Agents; Brain; Bromocriptine; Cyclopentanes; Disease | 2017 |
Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Animal | 2018 |
Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia.
Topics: Animals; Brain; Chronic Disease; Disease Models, Animal; Exploratory Behavior; Ketamine; Male; Memor | 2017 |
Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.
Topics: Aminoacetonitrile; Animals; Antidepressive Agents; Brain; Chronic Disease; Depressive Disorder; Dise | 2018 |
Role of the spinal TrkB-NMDA receptor link in the BDNF-induced long-lasting mechanical hyperalgesia in the rat: A behavioural study.
Topics: Animals; Brain-Derived Neurotrophic Factor; Central Nervous System Sensitization; Disease Models, An | 2017 |
Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Depression; Depressive Disorder, Major; Diseas | 2017 |
Involvement of NMDA receptors in the antidepressant-like effect of tramadol in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dizocilpine Maleate; Do | 2017 |
Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder.
Topics: Animals; Blinking; Conditioning, Classical; Conditioning, Psychological; Cues; Disease Models, Anima | 2017 |
Ketamine promotes increased freezing behavior in rats with experimental PTSD without changing brain glucose metabolism or BDNF.
Topics: Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder; Disease Mo | 2017 |
Elucidating Mechanisms of Bladder Repair after Hyaluronan Instillation in Ketamine-Induced Ulcerative Cystitis in Animal Model.
Topics: Animals; Cystitis; Disease Models, Animal; Female; Hyaluronan Receptors; Hyaluronic Acid; Inflammati | 2017 |
Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model.
Topics: Animals; Antidepressive Agents; Behavior Rating Scale; Behavior, Animal; Depressive Disorder; Diseas | 2017 |
Average spectral power changes at the hippocampal electroencephalogram in schizophrenia model induced by ketamine.
Topics: Animals; Behavior, Animal; Brain Waves; Disease Models, Animal; Electrocardiography; Hippocampus; Ke | 2018 |
Vicarious Social Defeat Stress Induces Depression-Related Outcomes in Female Mice.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Body Weight; Chlordiazepoxide; Corticosterone; D | 2018 |
Cortical functional hyperconnectivity in a mouse model of depression and selective network effects of ketamine.
Topics: Animals; Antidepressive Agents; Aspartic Acid; Behavior, Animal; Cerebral Cortex; Depression; Diseas | 2017 |
Cortex-wide optical imaging and network analysis of antidepressant effects.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Ketamine; M | 2017 |
Morin Pretreatment Attenuates Schizophrenia-Like Behaviors in Experimental Animal Models.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Dose-Response Relatio | 2018 |
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.
Topics: Animals; Behavior, Animal; Brain; Buprenorphine; Disease Models, Animal; Excitatory Amino Acid Antag | 2018 |
The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Enzyme Inhibitors; Indoleamine-Pyrrole | 2018 |
Behavioural and computational methods reveal differential effects for how delayed and rapid onset antidepressants effect decision making in rats.
Topics: Acoustic Stimulation; Amphetamine; Analgesics; Animals; Antidepressive Agents; Association Learning; | 2017 |
Region-specific alterations in astrocyte and microglia morphology following exposure to blasts in the mouse hippocampus.
Topics: Anesthetics; Animals; Astrocytes; Blast Injuries; Brain Injuries, Traumatic; Disease Models, Animal; | 2018 |
CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dendritic Spines; Disease Models, Anima | 2018 |
Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Gastrointestinal Microbiome; Ket | 2017 |
5-Hydroxytryptamine-Independent Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Chromatography, Liquid; Disease Models, Ani | 2018 |
Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Excitatory | 2018 |
Prenatal exposure to ketamine in rats: Implications on animal models of schizophrenia.
Topics: Animals; Behavior, Animal; CA3 Region, Hippocampal; Cognitive Dysfunction; Disease Models, Animal; E | 2018 |
Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Animals; Behavior, Animal; Brain; Disease Models, Ani | 2018 |
Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Ketamine; Magnetic Resonance Spe | 2018 |
Protein kinase Mζ in medial prefrontal cortex mediates depressive-like behavior and antidepressant response.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Excitatory | 2018 |
Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder; Disease Models, Animal; Gastrointestinal | 2017 |
Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antioxidants; Brain; Chronic Disease; Depressive Diso | 2018 |
Downregulation of Egr-1 Expression Level via GluN2B Underlies the Antidepressant Effects of Ketamine in a Chronic Unpredictable Stress Animal Model of Depression.
Topics: Animals; Antidepressive Agents; Dendritic Spines; Depressive Disorder; Disease Models, Animal; Disks | 2018 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Drug Therapy, C | 2018 |
Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats.
Topics: Animals; Behavior, Addictive; Behavior, Animal; Disease Models, Animal; Excitatory Amino Acid Antago | 2018 |
Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.
Topics: Animals; Antidepressive Agents; Brain; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depressio | 2018 |
What Are the Causes for Discrepancies of Antidepressant Actions of (2R,6R)-Hydroxynorketamine?
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug | 2018 |
Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways.
Topics: Acetylcholinesterase; Animals; Antipsychotic Agents; Catalase; Disease Models, Animal; Doxycycline; | 2018 |
A novel rat model of extremity trauma for prehospital pain management research.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Emergency Medical Services; Fentanyl; Fibula; F | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Effects on adult cognitive function after neonatal exposure to clinically relevant doses of ionising radiation and ketamine in mice.
Topics: Analgesics; Animals; Animals, Newborn; Behavior, Animal; Cognition; Cognition Disorders; Disease Mod | 2018 |
Anxiolytic effects of ascorbic acid and ketamine in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Ascorbic Acid; Behavior, Animal; Diazepam; Disease Models, An | 2018 |
Effects of rhynchophylline on the hippocampal miRNA expression profile in ketamine-addicted rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Computational Biology; Cy | 2018 |
Brain-wide Electrical Spatiotemporal Dynamics Encode Depression Vulnerability.
Topics: Animals; Brain; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depression; Disease Models, Anim | 2018 |
Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.
Topics: Animals; Antidepressive Agents; Brain; Chromatography, Liquid; Depression; Disease Models, Animal; I | 2018 |
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Brain-Derived Neurotrophic Factor; Catalase; Dise | 2018 |
Alarmin HMGB1 induces systemic and brain inflammatory exacerbation in post-stroke infection rat model.
Topics: Animals; Bacterial Infections; Behavior, Animal; Brain; Cyclooxygenase 2; Disease Models, Animal; HM | 2018 |
Potential learning and memory disruptors and enhancers in a simple, 1-day operant task in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adjuvants, Anesthesia; Animals; Conditioning, Operant; Disea | 2018 |
Applying ketamine to alleviate the PTSD-like effects by regulating the HCN1-related BDNF.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dose-Response Relationship, Drug | 2018 |
A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Delusions; Disease Mo | 2018 |
Protective effects of stigmasterol against ketamine-induced psychotic symptoms: Possible behavioral, biochemical and histopathological changes in mice.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Catalepsy; Disease Models, Animal; Dopamine; ga | 2018 |
Ketamine ameliorates oxidative stress-induced apoptosis in experimental traumatic brain injury via the Nrf2 pathway.
Topics: Animals; Apoptosis; Brain Injuries, Traumatic; Cell Survival; Disease Models, Animal; Dose-Response | 2018 |
Ketamine differentially restores diverse alterations of neuroligins in brain regions in a rat model of neuropathic pain-induced depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2018 |
Mechanisms of ketamine on mice hippocampi shown by gas chromatography-mass spectrometry-based metabolomic analysis.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Excitatory Amino Acid A | 2018 |
Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders.
Topics: Animals; Astrocytes; Cells, Cultured; Central Nervous System Agents; Cerebral Cortex; Disease Models | 2018 |
Changes in behavioural parameters, oxidative stress and neurotrophins in the brain of adult offspring induced to an animal model of schizophrenia: The effects of FA deficient or FA supplemented diet during the neurodevelopmental phase.
Topics: Animals; Behavior, Animal; Brain; Dietary Supplements; Disease Models, Animal; Female; Folic Acid; F | 2018 |
Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.
Topics: Affect; Alcohol-Related Disorders; Animals; Disease Models, Animal; Female; Ketamine; Long-Term Pote | 2018 |
(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
Topics: Animals; Antidepressive Agents; Cell Membrane; Cytosol; Depressive Disorder; Disease Models, Animal; | 2018 |
Anesthetics alleviate learning and memory impairment induced by electroconvulsive shock by regulation of NMDA receptor-mediated metaplasticity in depressive rats.
Topics: Anesthetics; Animals; Behavior, Animal; Cognitive Dysfunction; Depression; Disease Models, Animal; E | 2018 |
Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.
Topics: Animals; Antioxidants; Antipsychotic Agents; Disease Models, Animal; Flavonoids; Hippocampus; Ketami | 2018 |
Subanesthetic ketamine reverses neuronal and astroglial metabolic activity deficits in a social defeat model of depression.
Topics: Acetates; Analgesics; Animals; Astrocytes; Carbon Isotopes; Depressive Disorder; Disease Models, Ani | 2018 |
Impaired pupillary control in "schizophrenia-like" WISKET rats.
Topics: Anesthetics; Animals; Chloral Hydrate; Cognition; Disease Models, Animal; Ketamine; Male; Motivation | 2018 |
Protective effects of Spinacia oleracea seeds extract in an experimental model of schizophrenia: Possible behavior, biochemical, neurochemical and cellular alterations.
Topics: Anesthetics, Dissociative; Animals; Antipsychotic Agents; Avoidance Learning; Brain Chemistry; Disea | 2018 |
Role of Inflammatory Bone Markers in the Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.
Topics: Animals; Antidepressive Agents; Biomarkers; Depressive Disorder; Disease Models, Animal; Dominance-S | 2018 |
Impaired GAD1 expression in schizophrenia-related WISKET rat model with sex-dependent aggressive behavior and motivational deficit.
Topics: Aggression; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Glutamate De | 2019 |
Lack of Antidepressant Effects of Low-Voltage-Sensitive T-Type Calcium Channel Blocker Ethosuximide in a Chronic Social Defeat Stress Model: Comparison with (R)-Ketamine.
Topics: Animals; Antidepressive Agents; Calcium Channel Blockers; Calcium Channels, T-Type; Depressive Disor | 2018 |
Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior.
Topics: Adolescent; Analgesics; Animals; Anorexia; Anxiety; Disease Models, Animal; Eating; Female; Humans; | 2018 |
The behavioral study on the interactive aggravation between pruritus and depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Chloroquine; Depression; Depressive Disorder; Dise | 2018 |
A comprehensive analysis of auditory event-related potentials and network oscillations in an NMDA receptor antagonist mouse model using a novel wireless recording technology.
Topics: Acoustic Stimulation; Animals; Biological Clocks; Disease Models, Animal; Dizocilpine Maleate; Elect | 2018 |
Ketamine Corrects a Deficit in Reversal Learning Caused by Chronic Intermittent Cold Stress in Female Rats.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Disease Models, Animal; Disks Large Homolog 4 Prot | 2018 |
Early life stress leads to sex differences in development of depressive-like outcomes in a mouse model.
Topics: Age Factors; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; F | 2019 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex.
Topics: Adjuvants, Immunologic; Animals; Avoidance Learning; Behavior, Animal; Chronic Pain; Disease Models, | 2018 |
Dissociated features of social cognition altered in mouse models of schizophrenia: Focus on social dominance and acoustic communication.
Topics: Animals; Antipsychotic Agents; Cognition; Disease Models, Animal; Dizocilpine Maleate; Excitatory Am | 2019 |
Parvalbumin Loss Following Chronic Sub-Anesthetic NMDA Antagonist Treatment is Age-Dependent in the Hippocampus: Implications for Modeling NMDA Hypofunction.
Topics: Age Factors; Anesthetics; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Hippoc | 2018 |
Ethanolic extract of Erythrina velutina Willd ameliorate schizophrenia-like behavior induced by ketamine in mice.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Erythrina; Humans; Ketamine; Locomotion; Male; Ma | 2018 |
The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive-like rats.
Topics: Animals; Dentate Gyrus; Depressive Disorder, Major; Dexamethasone; Disease Models, Animal; Drug Eval | 2019 |
Prefrontal cortex miR-29b-3p plays a key role in the antidepressant-like effect of ketamine in rats.
Topics: 3' Untranslated Regions; Animals; Antidepressive Agents; Apoptosis; Calcium; Cell Survival; Disease | 2018 |
Standardized extract of Erythrina velutina Willd. attenuates schizophrenia-Like behaviours and oxidative parameters in experimental animal models.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Erythrina; Hippocampus; Ketamine; Li | 2019 |
Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus.
Topics: Animals; Antidepressive Agents; Corticosterone; Depressive Disorder, Treatment-Resistant; Disease Mo | 2019 |
Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Disease Models, A | 2019 |
VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dep | 2019 |
Preliminary validation of natural depression in macaques with acute treatments of the fast-acting antidepressant ketamine.
Topics: Animals; Antidepressive Agents; Conditioning, Operant; Depressive Disorder; Disease Models, Animal; | 2019 |
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex.
Topics: Anhedonia; Animals; Blood Pressure; Callithrix; Citalopram; Conditioning, Classical; Discrimination, | 2019 |
Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression.
Topics: Actinobacteria; Animals; Antidepressive Agents; Behavior, Animal; Biomarkers; Depression; Depressive | 2019 |
Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain.
Topics: Animals; Disease Models, Animal; Female; Ketamine; Mice; Mice, Inbred C57BL; Neuralgia; Treatment Ou | 2019 |
Effects of chronic lithium exposure in a modified rodent ketamine-induced hyperactivity model of mania.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Disease Models, Animal; Excitatory Amino Acid Antagonis | 2019 |
Ketamine‑induced bladder dysfunction is associated with extracellular matrix accumulation and impairment of calcium signaling in a mouse model.
Topics: Animals; Biomarkers; Body Weight; Calcium Signaling; Disease Models, Animal; Extracellular Matrix; F | 2019 |
MTOR-Mediated Autophagy Is Involved in the Protective Effect of Ketamine on Allergic Airway Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Autophagy; Bronchoalveolar Lavage Fluid; Cytokines; Disea | 2019 |
Ketamine improved depressive-like behaviors via hippocampal glucocorticoid receptor in chronic stress induced- susceptible mice.
Topics: Animals; Anxiety; Corticosterone; Depression; Depressive Disorder; Disease Models, Animal; Gene Expr | 2019 |
Downregulation of Npas4 in parvalbumin interneurons and cognitive deficits after neonatal NMDA receptor blockade: relevance for schizophrenia.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cognitive Dysfunction; Disease Models, Animal | 2019 |
Morin decreases cortical pyramidal neuron degeneration via inhibition of neuroinflammation in mouse model of schizophrenia.
Topics: Animals; Antioxidants; Behavior, Animal; Cerebellar Cortex; Disease Models, Animal; Flavonoids; Huma | 2019 |
(
Topics: Amino Acids; Animals; Antidepressive Agents; Behavior, Animal; Bridged Bicyclo Compounds, Heterocycl | 2019 |
Transition from status epilepticus to interictal spiking in a rodent model of mesial temporal epilepsy.
Topics: Animals; Anticonvulsants; Brain Waves; Diazepam; Disease Models, Animal; Drug Combinations; Electroe | 2019 |
Lack of dopamine D
Topics: Animals; Antidepressive Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Ant | 2020 |
Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
Topics: Amygdala; Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Disease Models, | 2019 |
Anti-depressant effects of oil from fructus gardeniae via PKA-CREB-BDNF signaling.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Pr | 2019 |
Prophylactic Ketamine Treatment Promotes Resilience to Chronic Stress and Accelerates Recovery: Correlation with Changes in Synaptic Plasticity in the CA3 Subregion of the Hippocampus.
Topics: Animals; Antidepressive Agents; Behavior, Animal; CA3 Region, Hippocampal; Depression; Disease Model | 2019 |
Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system.
Topics: Animals; Antidepressive Agents; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Dep | 2019 |
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.
Topics: Animals; Antidepressive Agents; Corticosterone; Dendritic Spines; Depressive Disorder; Disease Model | 2019 |
Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.
Topics: Animals; Antidepressive Agents; Biomarkers; Bone Density; Depression; Depressive Disorder; Disease M | 2019 |
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive | 2019 |
Depression and antidepressant action-from molecules to networks.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Depressive Disorder, Major; Disease Models, Ani | 2019 |
Subanesthetic Dose of Ketamine Improved CFA-induced Inflammatory Pain and Depression-like Behaviors Via Caveolin-1 in Mice.
Topics: Analgesics; Animals; Behavior, Animal; Caveolin 1; Depression; Disease Models, Animal; Freund's Adju | 2020 |
Evaluation of the Memory Enhancing Activity of Dichloromethane Fraction of the Methanolic Extract of Pycnanthus angolensis Stem Bark on Experimental Models of Memory Impairment.
Topics: Acetylcholinesterase; Amnesia; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Ga | 2019 |
Auditory Steady State Response; nature and utility as a translational science tool.
Topics: Acoustic Stimulation; Adult; Animals; Auditory Cortex; Brain; Disease Models, Animal; Electroencepha | 2019 |
Map2k7 Haploinsufficiency Induces Brain Imaging Endophenotypes and Behavioral Phenotypes Relevant to Schizophrenia.
Topics: Animals; Behavior, Animal; Brain; Connectome; Dextroamphetamine; Disease Models, Animal; Dopamine Up | 2020 |
Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depre | 2019 |
Oral ketamine alleviates behavioral despair without cognitive impairment in Wistar rats.
Topics: Administration, Oral; Animals; Antidepressive Agents; Behavior, Animal; Brain; Cognitive Dysfunction | 2019 |
Differences between ketamine's short-term and long-term effects on brain circuitry in depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Cerebrum; Connectome; Depression; | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Epigenetic regulation of COX‑2 expression by DNA hypomethylation via NF‑κB activation in ketamine‑induced ulcerative cystitis.
Topics: Animals; Chromatin Immunoprecipitation; CpG Islands; Cyclooxygenase 2; Cystitis; Disease Models, Ani | 2019 |
Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Glycine; Inflammation; Ketamine; | 2019 |
(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism.
Topics: Animals; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Ketamine; Lipopolysacch | 2019 |
Depression researchers rethink popular mouse swim tests.
Topics: Animal Rights; Animals; Animals, Laboratory; Depression; Disease Models, Animal; Ketamine; Learning; | 2019 |
Effects of pregabalin on behavioral alterations induced by ketamine in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonist | 2013 |
Chronic exposure to cigarette smoke during gestation results in altered cholinesterase enzyme activity and behavioral deficits in adult rat offspring: potential relevance to schizophrenia.
Topics: Animals; Cholinesterases; Disease Models, Animal; Female; Ketamine; Maternal Exposure; Motor Activit | 2013 |
Bilateral central pain sensitization in rats following a unilateral thalamic lesion may be treated with high doses of ketamine.
Topics: Analgesics; Animals; Disease Models, Animal; Hemorrhage; Hyperalgesia; Ketamine; Pain Measurement; R | 2013 |
Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats.
Topics: Amino Acids; Animals; Corticosterone; Depressive Disorder, Treatment-Resistant; Disease Models, Anim | 2013 |
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.
Topics: Amino Acids; Animals; Atrophy; Brain Mapping; Bridged Bicyclo Compounds, Heterocyclic; Disease Model | 2013 |
NMDA receptor antagonists distort visual grouping in rats performing a modified two-choice visual discrimination task.
Topics: Animals; Choice Behavior; Discrimination Learning; Disease Models, Animal; Dose-Response Relationshi | 2013 |
One-trial object recognition memory in the domestic rabbit (Oryctolagus cuniculus) is disrupted by NMDA receptor antagonists.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory A | 2013 |
Effects of ketamine on context-processing performance in monkeys: a new animal model of cognitive deficits in schizophrenia.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Antagonists; Ketamine; M | 2013 |
In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; K | 2014 |
microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents; Computational Biology; Depre | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia.
Topics: Acetylcholinesterase; Aging; Animals; Avoidance Learning; Behavior, Animal; Disease Models, Animal; | 2013 |
Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia.
Topics: Animals; Disease Models, Animal; Ketamine; Long-Term Potentiation; Mice; Phenotype; Receptors, N-Met | 2013 |
Chronic ketamine produces altered distribution of parvalbumin-positive cells in the hippocampus of adult rats.
Topics: Animals; Cell Movement; Disease Models, Animal; Excitatory Amino Acid Antagonists; Hippocampus; Keta | 2013 |
Prepubertal chronic stress and ketamine administration to rats as a neurodevelopmental model of schizophrenia symptomatology.
Topics: Age Factors; Animals; Attention; Behavior, Animal; Central Nervous System; Chronic Disease; Disease | 2013 |
Nonhuman primate model of schizophrenia using a noninvasive EEG method.
Topics: Acoustic Stimulation; Adult; Animals; Brain Mapping; Disease Models, Animal; Electroencephalography; | 2013 |
The impact of four different classes of anesthetics on the mechanisms of blood pressure regulation in normotensive and spontaneously hypertensive rats.
Topics: Anesthetics; Anesthetics, Combined; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressur | 2013 |
Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model.
Topics: Animals; Anxiety; Chickens; Depression; Disease Models, Animal; Ketamine | 2013 |
Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in mice.
Topics: Analgesics, Opioid; Animals; Arrestins; beta-Arrestin 2; beta-Arrestins; Brain; Clonidine; Disease M | 2013 |
Immediate ketamine treatment does not prevent posttraumatic stress responses in an animal model for PTSD.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Corticosterone; Dexamethasone; Disease Models, A | 2014 |
Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: an 11.7 T 1H-MRS study in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Chromatography, High Pressure Liquid; Depressi | 2014 |
Anesthetic-induced transient hyperglycemia and insulin resistance do not depend on the sympathoadrenal axis.
Topics: Adrenal Medulla; Adult; Anesthetics; Animals; Disease Models, Animal; Drug Combinations; Glucose Int | 2013 |
Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia.
Topics: Animals; Brain; Brain Injuries; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acid | 2014 |
Evaluation of the antipsychotic effects of 2-(dimethylamino)- and 2-(methylamino)-7H-naphtho[1,2,3-de]quinolin-7-one derivatives in experimental model of psychosis in mice.
Topics: Animals; Antipsychotic Agents; Aporphines; Disease Models, Animal; Ketamine; Male; Mice; Naphthoquin | 2014 |
Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Area Under Curve; Brain; Clozapine; Disease Mod | 2014 |
Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Dizocilpine Male | 2014 |
[Apoptosis in adult mouse brain after chronic poisoning of ketamine].
Topics: Animals; Apoptosis; Behavior, Animal; Brain; Caspase 3; Disease Models, Animal; Dose-Response Relati | 2013 |
Ketamine prevents stress-induced cognitive inflexibility in rats.
Topics: Animals; Behavior, Animal; Cognition; Cognition Disorders; Disease Models, Animal; Excitatory Amino | 2014 |
Random-ratio schedules produce greater demand for i.v. drug administration than fixed-ratio schedules in rhesus monkeys.
Topics: Administration, Intravenous; Analgesics, Opioid; Anesthetics, Dissociative; Animals; Cocaine; Diseas | 2014 |
The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis.
Topics: Amino Acids; Animals; Antipsychotic Agents; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, | 2014 |
The phosphodiesterase-4 inhibitor Ro 20-1724 reverses learning and memory impairments, and downregulation of CREB in the hippocampus and cortex induced by ketamine anesthesia in immature rats.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Anesthetics, Dissociative; Animals; Blotting, Wester | 2014 |
A touch-screen based paired-associates learning (PAL) task for the rat may provide a translatable pharmacological model of human cognitive impairment.
Topics: Amphetamine; Animals; Cognition Disorders; Conditioning, Operant; Disease Models, Animal; Dose-Respo | 2014 |
Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring.
Topics: Age Factors; Analgesics; Animals; Animals, Newborn; Body Temperature; Cell Proliferation; Disease Mo | 2014 |
The effect of ketamine on optical and electrical characteristics of spreading depolarizations in gyrencephalic swine cortex.
Topics: Animals; Cerebral Cortex; Cerebrovascular Circulation; Cortical Spreading Depression; Disease Models | 2014 |
The role of miR-124 in modulating hippocampal neurotoxicity induced by ketamine anesthesia.
Topics: Animals; Animals, Newborn; Apoptosis; Disease Models, Animal; Hippocampus; In Vitro Techniques; Keta | 2015 |
Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.
Topics: Adaptation, Psychological; Amino Acids; Animals; Antidepressive Agents; Depression; Disease Models, | 2014 |
Effects of repetitive exposure to anesthetics and analgesics in the Tg2576 mouse Alzheimer's model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analgesics; Anesthetics; A | 2014 |
Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity.
Topics: Action Potentials; Animals; Antidepressive Agents; Benzazepines; Brain; Depression; Disease Models, | 2014 |
Dexmedetomidine provides neuroprotection: impact on ketamine-induced neuroapoptosis in the developing rat brain.
Topics: Analgesics, Non-Narcotic; Analysis of Variance; Anesthetics, Dissociative; Animals; Apoptosis; Brain | 2014 |
Ketamine inhibits LPS-induced HGMB1 release in vitro and in vivo.
Topics: Animals; Cecum; Cell Line; Disease Models, Animal; HMGB1 Protein; Humans; Imidazoles; Ketamine; Lipo | 2014 |
Evaluation of acetylcholinesterase activity and behavioural alterations induced by ketamine in an animal model of schizophrenia.
Topics: Acetylcholinesterase; Animals; Brain; Corpus Striatum; Disease Models, Animal; Hippocampus; Ketamine | 2014 |
Effects of lurasidone on ketamine-induced joint visual attention dysfunction as a possible disease model of autism spectrum disorders in common marmosets.
Topics: Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Callithrix; Child Deve | 2014 |
Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder.
Topics: Animals; Anti-Anxiety Agents; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Excitatory | 2015 |
Heat-Irrigate Effect' of Radiofrequency Ablation on Relevant Regional Hepatocyte in Living Swine Liver-Initial Study on Pathology.
Topics: Anesthesia; Animals; Catheter Ablation; Disease Models, Animal; Electrodes; Female; Hepatocytes; Hot | 2015 |
α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Ketamine; Male; Neuropsycho | 2015 |
Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice.
Topics: Action Potentials; Animals; Animals, Newborn; Disease Models, Animal; Excitatory Postsynaptic Potent | 2016 |
Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Arginine; Behavior, Animal; Cyclic GMP; D | 2015 |
[Ketamine alters socially-evoked activity in the amygdala].
Topics: Amygdala; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dizocilpine Malea | 2014 |
Comparative Investigation of Protective Effects of Metyrosine and Metoprolol Against Ketamine Cardiotoxicity in Rats.
Topics: alpha-Methyltyrosine; Animals; Antioxidants; Biomarkers; Cytoprotection; Disease Models, Animal; DNA | 2015 |
The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.
Topics: Affect; Animals; Antidepressive Agents; Antimanic Agents; Antioxidants; Behavior, Animal; Brain-Deri | 2014 |
Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Ketamine; Male; Motor Activity; Nitric Oxide | 2015 |
Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice.
Topics: Animals; Behavior, Animal; Behavioral Symptoms; Disease Models, Animal; Excitatory Amino Acid Antago | 2015 |
Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and "depressed" mice exposed to chronic mild stress.
Topics: Animals; Antidepressive Agents; Aspartic Acid; Chronic Disease; Depressive Disorder; Disease Models, | 2015 |
Ketamine treatment partly reverses alterations in brain derived- neurotrophic factor, oxidative stress and energy metabolism parameters induced by an animal model of depression.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Creatine Kinase; | 2015 |
RETRACTED: Ketamine reduces lipopolysaccharide-induced high-mobility group box-1 through heme oxygenase-1 and nuclear factor erythroid 2-related factor 2/ p38 mitogen-activated protein kinase.
Topics: Acute Lung Injury; Anesthetics, Dissociative; Animals; Cell Line; Cell Survival; Disease Models, Ani | 2015 |
Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Electrophysiology; Exploratory Behavior; F | 2015 |
A single dose of S-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain; Catalase; Depressive Disorder; Disease Models, Ani | 2015 |
Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis.
Topics: Animals; Caudate Nucleus; Conditioning, Classical; Disease Models, Animal; Excitatory Amino Acid Ant | 2015 |
Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy.
Topics: Animals; Antidepressive Agents; Association Learning; Brain; Cannabinoid Receptor Antagonists; Carbo | 2015 |
Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Excitatory Ami | 2015 |
Macaques exhibit a naturally-occurring depression similar to humans.
Topics: Animals; Behavior, Animal; Depressive Disorder; Discriminant Analysis; Disease Models, Animal; Femal | 2015 |
Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, A | 2015 |
Long-Term Antihyperalgesic and Opioid-Sparing Effects of 5-Day Ketamine and Morphine Infusion ("Burst Ketamine") in Diabetic Neuropathic Rats.
Topics: Analgesics; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; | 2015 |
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Dextromethorphan; | 2015 |
Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Blepharoptosis; Disease Models, Animal | 2015 |
Observation of Distressed Conspecific as a Model of Emotional Trauma Generates Silent Synapses in the Prefrontal-Amygdala Pathway and Enhances Fear Learning, but Ketamine Abolishes those Effects.
Topics: Animals; Avoidance Learning; Basolateral Nuclear Complex; Disease Models, Animal; Electroshock; Fear | 2015 |
Effect of sepsis on behavioral changes on the ketamine-induced animal model of schizophrenia.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Interpersonal Relations; Ketamine | 2015 |
Coupling in the cortico-basal ganglia circuit is aberrant in the ketamine model of schizophrenia.
Topics: Animals; Basal Ganglia; Brain Waves; Disease Models, Animal; Electrocorticography; Electrodes, Impla | 2015 |
Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal | 2015 |
Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
Topics: Analysis of Variance; Animals; Antioxidants; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic | 2015 |
D-Amphetamine withdrawal-induced decreases in brain-derived neurotrophic factor in sprague-dawley rats are reversed by treatment with ketamine.
Topics: Amphetamine-Related Disorders; Animals; Brain-Derived Neurotrophic Factor; Central Nervous System St | 2015 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Cystitis; Disease Model | 2015 |
Withdrawal from Acute Amphetamine Induces an Amygdala-Driven Attenuation of Dopamine Neuron Activity: Reversal by Ketamine.
Topics: Action Potentials; Amphetamine; Amphetamine-Related Disorders; Animals; Basolateral Nuclear Complex; | 2016 |
Role of the nitric oxide donor sodium nitroprusside in the antidepressant effect of ketamine in mice.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dose-Response Relations | 2015 |
Preventive Treatment with Ketamine Attenuates the Ischaemia-Reperfusion Response in a Chronic Postischaemia Pain Model.
Topics: Analgesics; Animals; Behavior, Animal; Chronic Disease; Complex Regional Pain Syndromes; Disease Mod | 2015 |
Beneficial effects of a ketamine/atropine combination in soman-poisoned rats under a neutral thermal environment.
Topics: Animals; Anticonvulsants; Atropine; Body Temperature; Brain; Brain Injuries; Chemical Warfare Agents | 2015 |
Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Antidepressive Agents; C-Reactive Protei | 2015 |
Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.
Topics: Amygdala; Animals; Anxiety; Brain Waves; Disease Models, Animal; Electroencephalography; Excitatory | 2015 |
Gender and estrous cycle influences on behavioral and neurochemical alterations in adult rats neonatally administered ketamine.
Topics: Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Endophenotypes | 2016 |
The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cytokines; Depression; Disease Models, Animal; Dow | 2015 |
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
Topics: Allosteric Site; alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Attention; | 2016 |
Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor.
Topics: Administration, Oral; Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; D | 2015 |
The modulatory effect of CA1 GABAb receptors on ketamine-induced spatial and non-spatial novelty detection deficits with respect to Ca(2+).
Topics: Analysis of Variance; Animals; Baclofen; CA1 Region, Hippocampal; Calcium; Calcium Channel Blockers; | 2015 |
Plasma membrane Ca(2+)-ATPase is a novel target for ketamine action.
Topics: Anesthetics, Dissociative; Animals; Calcium; Calmodulin; Catalytic Domain; Cell Membrane; Cerebral C | 2015 |
Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Brain; Depression; Dis | 2015 |
The fibrosis of ketamine, a noncompetitive N-methyl-d-aspartic acid receptor antagonist dose-dependent change in a ketamine-induced cystitis rat model.
Topics: Animals; Cystitis; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid A | 2016 |
Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Depression; | 2015 |
Delayed emergence of behavioral and electrophysiological effects following juvenile ketamine exposure in mice.
Topics: Animals; Behavior, Animal; Brain; Cognition; Cognition Disorders; Disease Models, Animal; Electroenc | 2015 |
Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia.
Topics: Animals; Brain Chemistry; Brain-Derived Neurotrophic Factor; Dietary Supplements; Disease Models, An | 2015 |
Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice.
Topics: Acute Disease; Analgesics; Animals; Chronic Disease; Complex Regional Pain Syndromes; Disease Models | 2015 |
LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Ketamine; Male; Memor | 2016 |
The Role of Nitric Oxide in the Antidepressant Actions of 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside in Insulin-Resistant Mice.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Animals; Antidepressive Agents; Combined Modality Ther | 2016 |
High-Speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Central Ner | 2015 |
GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.
Topics: Animals; Cognition; Disease Models, Animal; Excitatory Amino Acid Antagonists; Ketamine; Male; Memor | 2016 |
Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corticosterone; | 2016 |
Regional brain dysregulation of Ca(2+)-handling systems in ketamine-induced rat model of experimental psychosis.
Topics: Animals; Behavior, Animal; Brain; Calcium; Cell Separation; Cell Survival; Disease Models, Animal; G | 2016 |
Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation.
Topics: Animals; Antidepressive Agents; Cells, Cultured; Cerebral Cortex; Cysteine; Depression; Disease Mode | 2016 |
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Conditioning, Classical; Disease Models, Animal; Fear; Hippocampus; Interneuro | 2016 |
Mechanisms of propofol attenuation of ketamine-induced neonatal brain injury.
Topics: Anesthetics, Intravenous; Animals; Apoptosis; Brain Diseases; Cognition Disorders; Disease Models, A | 2016 |
Instant and Lasting Down-Regulation of NR1 Expression in the Hippocampus is Associated Temporally with Antidepressant Activity After Acute Yueju.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Disease Models, A | 2016 |
NMDA receptor antagonists attenuate the proconvulsant effect of juvenile social isolation in male mice.
Topics: Age Factors; Animals; Animals, Newborn; Disease Models, Animal; Dizocilpine Maleate; Dose-Response R | 2016 |
Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model.
Topics: Analgesics; Animals; Annexin A2; Antidepressive Agents; Chronic Disease; Depression; Disease Models, | 2016 |
Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antago | 2016 |
[Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats].
Topics: Animals; Brain; Depression; Depressive Disorder; Disease Models, Animal; Down-Regulation; Imipramine | 2016 |
Baicalin Attenuates Ketamine-Induced Neurotoxicity in the Developing Rats: Involvement of PI3K/Akt and CREB/BDNF/Bcl-2 Pathways.
Topics: Anesthetics, Dissociative; Animals; Brain-Derived Neurotrophic Factor; Caspase 3; Cell Death; Cells, | 2016 |
The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets.
Topics: Animals; Antipsychotic Agents; Benzopyrans; Callithrix; Cognition Disorders; Disease Models, Animal; | 2016 |
Ketamine decreases inflammatory and immune pathways after transient hypoxia in late gestation fetal cerebral cortex.
Topics: Animals; Anti-Inflammatory Agents; Cerebral Cortex; Disease Models, Animal; Female; Fetal Hypoxia; G | 2016 |
Effect of ketamine administration, alone and in combination with E-6837, on climbing behavior.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administra | 2016 |
Electrophysiological alterations in a complex rat model of schizophrenia.
Topics: Acoustic Stimulation; Age Factors; Animals; Disease Models, Animal; Electroencephalography; Evoked P | 2016 |
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.
Topics: Amino Acids; Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic | 2016 |
Ketamine attenuates osteoarthritis of the knee via modulation of inflammatory responses in a rabbit model.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent As | 2016 |
PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Bindi | 2016 |
Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease | 2016 |
N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2016 |
Proteomic systems evaluation of the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Humans; Ketamine; Machine Learning; Male; M | 2016 |
Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine.
Topics: Animals; Attention Deficit and Disruptive Behavior Disorders; Disease Models, Animal; Dose-Response | 2016 |
Antinociceptive and Anti-Inflammatory Effects of Ketamine and the Relationship to Its Antidepressant Action and GSK3 Inhibition.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Behavior, Anima | 2016 |
Ketamine Inhalation Ameliorates Ovalbumin-Induced Murine Asthma by Suppressing the Epithelial-Mesenchymal Transition.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Epi | 2016 |
Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Depression; Depressive Disorder, Major; Disease Model | 2016 |
Evaluation of urinary bladder fibrogenesis in a mouse model of long-term ketamine injection.
Topics: Animals; Disease Models, Animal; Female; Fibrosis; Injections, Intraperitoneal; Ketamine; Male; Mice | 2016 |
Neurovascular plasticity of the hippocampus one week after a single dose of ketamine in genetic rat model of depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Immobility Response | 2016 |
Reactive Oxygen Species-mediated Loss of Phenotype of Parvalbumin Interneurons Contributes to Long-term Cognitive Impairments After Repeated Neonatal Ketamine Exposures.
Topics: Acetophenones; Animals; Anxiety; Brain; Cognitive Dysfunction; Cohort Studies; Disease Models, Anima | 2016 |
Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression.
Topics: Amygdala; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Helplessness, Learned; | 2017 |
Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder.
Topics: Analgesics; Animals; Cells, Cultured; Cystitis; Disease Models, Animal; Fibrosis; Humans; Infant, Ne | 2016 |
Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; CA3 Region, Hippocampal; D | 2016 |
Acute single dose of ketamine relieves mechanical allodynia and consequent depression-like behaviors in a rat model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Freund's Adjuv | 2016 |
Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.
Topics: Animals; Anticonvulsants; Brain; Cholinergic Agents; Disease Models, Animal; Drug Synergism; Drug Th | 2016 |
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Topics: Analgesics; Animals; Antiparkinson Agents; Cerebrovascular Circulation; Disease Models, Animal; Fema | 2016 |
Differential regulation of GluA1 expression by ketamine and memantine.
Topics: Animals; Benzylamines; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Excita | 2017 |
The effects of edaravone in ketamine-induced model of mania in rats.
Topics: Analysis of Variance; Animals; Antimanic Agents; Antipyrine; Bipolar Disorder; Brain; Catalase; Dise | 2016 |
Lack of effect of chronic ketamine administration on depression-like behavior and frontal cortex autophagy in female and male ICR mice.
Topics: Analgesics; Analysis of Variance; Animals; Autophagy; Beclin-1; Depression; Disease Models, Animal; | 2017 |
Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Disease Models, Animal; Disks Large Homolog 4 Prot | 2016 |
Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Depressive Disorder, Treatment-Re | 2017 |
Transgenerational impairment of hippocampal Akt-mTOR signaling and behavioral deficits in the offspring of mice that experience postpartum depression-like illness.
Topics: Age Factors; Animals; Depression, Postpartum; Disease Models, Animal; Eating; Excitatory Amino Acid | 2017 |
Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Immunologic Factors; Immunomodulation; | 2017 |
3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
Topics: Acrylamides; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic | 2017 |
Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Glycogen Synth | 2017 |
Chronic stress prior to pregnancy potentiated long-lasting postpartum depressive-like behavior, regulated by Akt-mTOR signaling in the hippocampus.
Topics: Animals; Depression, Postpartum; Disease Models, Animal; Female; Hippocampus; Humans; Ketamine; Male | 2016 |
Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Depression; Discrimination Learning; Disease Mo | 2017 |
Preventive effects of blueberry extract on behavioral and biochemical dysfunctions in rats submitted to a model of manic behavior induced by ketamine.
Topics: Animals; Bipolar Disorder; Blueberry Plants; Brain; Catalase; Disease Models, Animal; Glutathione Pe | 2016 |
Hippocampal Perineuronal Nets Are Required for the Sustained Antidepressant Effect of Ketamine.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Chondroitinases and Chondroitin Lyases; Depres | 2017 |
S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression.
Topics: Animals; Depression; Disease Models, Animal; Hippocampus; Immobility Response, Tonic; Ketamine; Male | 2017 |
Evaluation of 50-kHz ultrasonic vocalizations in animal models of mania: Ketamine and lisdexamfetamine-induced hyperlocomotion in rats.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Central Nervous System Stimulants; Disease Models, Anim | 2016 |
Pulmonary Phototherapy to Treat Carbon Monoxide Poisoning in Rats.
Topics: Androstanols; Animals; Blood Pressure; Body Temperature; Carbon Monoxide; Carbon Monoxide Poisoning; | 2017 |
Posttraumatic administration of a sub-anesthetic dose of ketamine exerts neuroprotection via attenuating inflammation and autophagy.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Autophagy; Brain; Brain Injuries, Traumat | 2017 |
Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease Models, Animal; | 2017 |
(R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dominance-Subordination | 2017 |
Effects of early or late prenatal immune activation in mice on behavioral and neuroanatomical abnormalities relevant to schizophrenia in the adulthood.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Brain; Disease Models, Animal; Embryo, | 2017 |
Alterations of Macrophage Migration Inhibitory Factor Expression in the Nervous System of the Rat Cystitis Model.
Topics: Animals; Cystitis; Disease Models, Animal; Female; Immunohistochemistry; Inflammation; Intramolecula | 2017 |
Structural Integrity in the Sustained Antidepressant Effect of Ketamine.
Topics: Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Ketamine; Swimming | 2017 |
Increased risk of developing schizophrenia in animals exposed to cigarette smoke during the gestational period.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Animals, Newborn; Avoidance Learning; Choline O | 2017 |
Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced Schizophrenia-Like Symptoms in Rats.
Topics: Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dopamin | 2016 |
Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia.
Topics: Alloxan; Animals; Behavior, Animal; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2017 |
Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Conditioning, Operant; Depression; Disease Models, | 2017 |
Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relati | 2008 |
Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model.
Topics: Amnesia; Animals; Disease Models, Animal; Drug Delivery Systems; Ketamine; Male; Memory; Prefrontal | 2008 |
Human rabies therapy: lessons learned from experimental studies in mouse models.
Topics: Animals; Apoptosis; Disease Models, Animal; Female; Humans; Ketamine; Mice; Mice, Inbred ICR; Minocy | 2008 |
Coupling between neuronal nitric oxide synthase and glutamate receptor 6-mediated c-Jun N-terminal kinase signaling pathway via S-nitrosylation contributes to ischemia neuronal death.
Topics: Animals; Cell Death; Disease Models, Animal; Disks Large Homolog 4 Protein; Dithiothreitol; Enzyme I | 2008 |
Selective disturbance of pain sensitivity after social isolation.
Topics: Analgesics; Animals; Animals, Newborn; Carrageenan; Disease Models, Animal; Hot Temperature; Hyperal | 2009 |
Ketamine anesthesia reduces intestinal ischemia/reperfusion injury in rats.
Topics: Anesthetics, Dissociative; Animals; Disease Models, Animal; Gastrointestinal Motility; Intestinal Di | 2008 |
"Resting" CBF in the epileptic baboon: correlation with ketamine dose and interictal epileptic discharges.
Topics: Animals; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Elec | 2008 |
COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia.
Topics: Animals; Apolipoproteins E; Brain; Disease Models, Animal; Infarction, Middle Cerebral Artery; Ketam | 2009 |
A modified suture technique produces consistent cerebral infarction in rats.
Topics: Analysis of Variance; Anesthetics; Animals; Brain Ischemia; Cerebrovascular Circulation; Disease Mod | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous | 2009 |
Left ventricular systolic and diastolic function in healthy adult bonnet macaques (Macaca radiata). New echocardiographic indices in Old World monkeys.
Topics: Anesthetics, Dissociative; Animals; Diastole; Disease Models, Animal; Echocardiography; Female; Keta | 2009 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
The effect of ketamine and saffan on the beta-endorphin and ACTH response to hemorrhage in the minipig.
Topics: Adrenocorticotropic Hormone; Alfaxalone Alfadolone Mixture; Anesthetics; Animals; beta-Endorphin; Bi | 2009 |
Large differences in blood measures, tissue weights, and focal areas of damage 1 year after postseizure treatment with acepromazine or ketamine.
Topics: Acepromazine; Analysis of Variance; Animals; Blood Pressure; Brain; Disease Models, Animal; Dopamine | 2009 |
Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Disease | 2009 |
Inhibiting astrocytic activation: a novel analgesic mechanism of ketamine at the spinal level?
Topics: Analgesics; Anesthesia; Animals; Astrocytes; Disease Models, Animal; Drug Administration Routes; Gli | 2009 |
Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease.
Topics: Anesthetics, Inhalation; Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; | 2009 |
Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Behavior, Animal; Corticosterone; Disease Mode | 2009 |
Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats.
Topics: Anesthetics, Dissociative; Animals; Brain; Catalase; Disease Models, Animal; Dose-Response Relations | 2009 |
Ketamine delays mortality in an experimental model of hemorrhagic shock and subsequent sepsis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Exc | 2009 |
Low-dose ketamine combined with pentobarbital in a miniature porcine model for a cardiopulmonary bypass procedure: a randomized controlled study.
Topics: Adjuvants, Anesthesia; Anesthetics, Combined; Anesthetics, Dissociative; Animals; Cardiopulmonary By | 2009 |
Effects of ketamine on the balance of ions Ca2+, Mg2+, Cu2+ and Zn2+ in the ischemia-reperfusion affected spinal cord tissues in rabbits.
Topics: Animals; Aorta, Abdominal; Calcium; Cations, Divalent; Constriction; Copper; Disease Models, Animal; | 2009 |
[Effects of ketamine and splenectomy on cognition and synaptic plasticity in hippocampus of senile rats].
Topics: Animals; Behavior, Animal; Cognition; Disease Models, Animal; Female; Hippocampus; Ketamine; Male; M | 2009 |
Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia.
Topics: 5,7-Dihydroxytryptamine; Amphetamines; Animals; Cocaine; Disease Models, Animal; Dose-Response Relat | 2009 |
The comparison of the effects of anesthetic doses of ketamine, propofol, and etomidate on ischemia-reperfusion injury in skeletal muscle.
Topics: Anesthetics, Dissociative; Anesthetics, Intravenous; Animals; Disease Models, Animal; Etomidate; Fem | 2010 |
[Behavior study of ketamine-induced symptoms similar to schizophrenia in mice].
Topics: Animals; Ataxia; Disease Models, Animal; Dose-Response Relationship, Drug; Forensic Psychiatry; Inje | 2009 |
Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Behavior, Animal; Brain Chemistry; C | 2010 |
Ketamine and the myenteric plexus in intestinal ischemia/reperfusion injury.
Topics: Animals; Antithrombin III; Benzalkonium Compounds; Biomarkers; Disease Models, Animal; Immunohistoch | 2010 |
Efficacy of hyperbaric oxygen therapy and medical ozone therapy in experimental acute necrotizing pancreatitis.
Topics: Amylases; Animals; Disease Models, Animal; Glutathione Peroxidase; Humans; Hyperbaric Oxygenation; K | 2010 |
Intrastrain differences in seizure susceptibility, pharmacological response and basal neurochemistry of Wistar rats.
Topics: Analysis of Variance; Anesthetics, Dissociative; Animals; Biogenic Monoamines; Body Weight; Brain; B | 2009 |
Rat model of influenza-associated encephalopathy (IAE): studies of electroencephalogram (EEG) in vivo.
Topics: Adrenergic alpha-Agonists; Anesthetics, Dissociative; Animals; Brain; Brain Diseases; Cerebral Corte | 2010 |
Effects of ketamine on hypoxic pulmonary vasoconstriction in the isolated perfused lungs of endotoxaemic mice.
Topics: Anesthetics, Dissociative; Animals; Blood Pressure; Disease Models, Animal; Endotoxemia; Hypoxia; Ke | 2010 |
The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Disease Models, Animal; Glycine Plasma Membrane Tran | 2010 |
[The correlation between ketamine-induced schizophrenia-like signs in mice and the expressions of NRG1, ErbB4 mRNA].
Topics: Animals; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Hippoc | 2009 |
Murine pulmonary inflammation model: a comparative study of anesthesia and instillation methods.
Topics: Acute Disease; Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Biomarkers; Bronchoalveolar | 2010 |
Opioid-induced hyperalgesia in a mice model of orthopaedic pain: preventive effect of ketamine.
Topics: Analgesics; Analgesics, Opioid; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Drug | 2010 |
Tyrosine phosphorylation of the N-Methyl-D-Aspartate receptor 2B subunit in spinal cord contributes to remifentanil-induced postoperative hyperalgesia: the preventive effect of ketamine.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamic Aci | 2009 |
The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
Topics: Allosteric Regulation; Animals; Disease Models, Animal; Humans; Ketamine; N-Methylaspartate; Rats; R | 2009 |
[Effect of temperature and time on stability of ketamine in biological samples].
Topics: Animals; Brain; Cryopreservation; Disease Models, Animal; Drug Stability; Female; Forensic Toxicolog | 2009 |
Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys.
Topics: Anesthetics, Dissociative; Animals; Behavior, Animal; Disease Models, Animal; Drug Tolerance; Excita | 2010 |
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Animals, Ne | 2010 |
The control of kainic acid-induced status epilepticus.
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug S | 2010 |
Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats.
Topics: Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Models, Animal; Drug Therapy, Combinatio | 2011 |
Sympathetic modulation of the host defense response to infectious challenge during recovery from hemorrhage.
Topics: Animals; Disease Models, Animal; Hemorrhage; Immune Tolerance; Immunity, Innate; Inflammation; Ketam | 2010 |
Analysis of heart rate variability in a rat model of induced pulmonary hypertension.
Topics: Animals; Disease Models, Animal; Electrocardiography; Entropy; Heart Rate; Hypertension, Pulmonary; | 2010 |
Propofol pretreatment increases antidepressant-like effects induced by acute administration of ketamine in rats receiving forced swimming test.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
Electro-acupuncture reduces the need for additional anesthetics in experimental studies.
Topics: Acupuncture Analgesia; Acupuncture Points; Anesthetics, Combined; Anesthetics, Dissociative; Animals | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Ketamine; Membrane Glycoproteins; Mice; Mice, Inbred | 2010 |
Multi-limb acquisition of motor evoked potentials and its application in spinal cord injury.
Topics: Analgesics; Animals; Biophysics; Disease Models, Animal; Electric Stimulation; Evoked Potentials, Mo | 2010 |
Morphine exposure in early life increases nociceptive behavior in a rat formalin tonic pain model in adult life.
Topics: Age Factors; Analgesics, Opioid; Analysis of Variance; Anesthetics, Dissociative; Animals; Animals, | 2011 |
Ketamine reduces intestinal injury and inflammatory cell infiltration after ischemia/reperfusion in rats.
Topics: Analysis of Variance; Animals; Antithrombin III; Disease Models, Animal; Excitatory Amino Acid Antag | 2010 |
Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Autoradiography; Biological Transport; Brain; B | 2011 |
Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers.
Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Excitatory Amino Acid Antagonists; gamma- | 2011 |
Impaired growth and force production in skeletal muscles of young partially pancreatectomized rats: a model of adolescent type 1 diabetic myopathy?
Topics: Adolescent; Analgesics; Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Humans; Ketamine | 2010 |
Deep anesthesia suppresses ventricular tachyarrhythmias in rabbit model of the acquired long QT syndrome.
Topics: Adrenergic alpha-2 Receptor Agonists; Anesthesia, General; Anesthetics, Combined; Animals; Anti-Arrh | 2011 |
Effects of methylene blue and volatile anesthetics on survival in a murine hemorrhage resuscitation model.
Topics: Analysis of Variance; Animals; Chi-Square Distribution; Disease Models, Animal; Fluid Therapy; Halot | 2010 |
Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine.
Topics: Animals; Brain; Disease Models, Animal; Electron Transport; Electron Transport Complex I; Electron T | 2011 |
Ketamine depresses toll-like receptor 3 signaling in spinal microglia in a rat model of neuropathic pain.
Topics: Analgesics; Analysis of Variance; Animals; CD11b Antigen; Cell Count; Disease Models, Animal; Dose-R | 2011 |
Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Elemen | 2011 |
Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics.
Topics: Acoustic Stimulation; Animals; Brain; Brain Waves; Disease Models, Animal; Dose-Response Relationshi | 2011 |
Effect of general anesthetics on IOP in elevated IOP mouse model.
Topics: Anesthesia, General; Anesthetics, Combined; Anesthetics, General; Animals; Behavior, Animal; Disease | 2011 |
Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.
Topics: Amino Acid Substitution; Animals; Antidepressive Agents; Cerebral Cortex; Depression; Disease Models | 2011 |
Assessment of parameters influencing the blood flow velocities in cerebral arteries of the rat using ultrasonographic examination.
Topics: Animals; Blood Flow Velocity; Brain; Brain Infarction; Cerebral Arteries; Cerebrovascular Circulatio | 2011 |
Successful pain relief in non-responders to spinal cord stimulation: the combined use of ketamine and spinal cord stimulation.
Topics: Analgesics; Animals; Chronic Pain; Combined Modality Therapy; Disease Models, Animal; Electric Stimu | 2011 |
[Effects of electroacupuncture on expression of tyrosine hydroxylase and c-fos in hippocampal CA 1 area in ketamine-addiction rats].
Topics: Animals; Disease Models, Animal; Electroacupuncture; Female; Hippocampus; Humans; Ketamine; Male; Pr | 2011 |
Stress-induced hyperalgesia is associated with a reduced and delayed GABA inhibitory control that enhances post-synaptic NMDA receptor activation in the spinal cord.
Topics: Analgesics; Animals; Diazepam; Disease Models, Animal; Excitatory Postsynaptic Potentials; Flumazeni | 2011 |
The median effective dose of ketamine and gabapentin in opioid-induced hyperalgesia in rats: an isobolographic analysis of their interaction.
Topics: Amines; Analgesics; Analgesics, Opioid; Analysis of Variance; Animals; Cyclohexanecarboxylic Acids; | 2011 |
Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
Endogenous opioids released during non-nociceptive environmental stress induce latent pain sensitization Via a NMDA-dependent process.
Topics: Analgesics, Opioid; Analysis of Variance; Animals; Carrageenan; Disease Models, Animal; Excitatory A | 2011 |
Involvement of purinergic neurotransmission in ketamine induced bladder dysfunction.
Topics: Animals; Disease Models, Animal; Female; Ketamine; Mice; Mice, Inbred C57BL; Receptors, Purinergic; | 2011 |
Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: role of opioid and N-methyl-D-aspartate receptors.
Topics: Analgesia; Analgesics, Opioid; Animals; Disease Models, Animal; Electric Stimulation; Excitatory Ami | 2012 |
The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; | 2012 |
Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
Topics: Amino Acids; Analysis of Variance; Animals; Bridged Bicyclo Compounds; Depression; Dicarboxylic Acid | 2011 |
Acute D-serine treatment produces antidepressant-like effects in rodents.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Calcium-Calmodulin-Dependent Protein Kinase Ty | 2012 |
Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats.
Topics: Animals; Antipsychotic Agents; Attention; Cognition Disorders; Dibenzothiazepines; Disease Models, A | 2012 |
Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Ketamine; Male; Memory, Short-Ter | 2011 |
Is the acute NMDA receptor hypofunction a valid model of schizophrenia?
Topics: Animals; Corpus Callosum; Disease Models, Animal; Dopamine; Glutamic Acid; Humans; Ketamine; Parvalb | 2012 |
Complex receptor mediation of acute ketamine application on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophrenia.
Topics: Animals; Disease Models, Animal; Electroencephalography; Excitatory Amino Acid Antagonists; GABAergi | 2011 |
Fentanyl administration in infant rats produces long-term behavioral responses.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Animals; Animals, Newborn; Disease Models, Animal; Fe | 2012 |
Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems.
Topics: Anesthetics, Dissociative; Animals; Carbon Radioisotopes; Deoxyglucose; Disease Models, Animal; Keta | 2013 |
Inhibition of itch-related responses at spinal level in rats.
Topics: 5-Methoxytryptamine; Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Drug Interaction | 2011 |
Evaluation of the antipsychotic potential of Panax quinquefolium in ketamine induced experimental psychosis model in mice.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Ketamine; Male; | 2012 |
Thrombotic stroke in the anesthetized monkey (Macaca mulatta): characterization by MRI--a pilot study.
Topics: Anesthesia; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Atracurium; Craniotomy; Dif | 2012 |
Apoptotic neurodegeneration and spatial memory are not affected by sedative and anaesthetics doses of ketamine/medetomidine combinations in adult mice.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Animals; Apoptosis; Behavior, Animal; Brain; Disea | 2012 |
Strategies to defeat ketamine-induced neonatal brain injury.
Topics: Anesthetics, Dissociative; Animals; Animals, Newborn; Apoptosis; Brain Injuries; Disease Models, Ani | 2012 |
Neuroprotective effects of racemic ketamine and (S)-ketamine on spinal cord injury in rat.
Topics: Animals; Disease Models, Animal; Injections, Intraperitoneal; Ketamine; Laminectomy; Lipid Peroxidat | 2012 |
Oxygen breathing affects 3'-deoxy-3'-18F-fluorothymidine uptake in mouse models of arthritis and cancer.
Topics: Anesthesia; Animals; Ankle; Arthritis; Artifacts; Biological Transport; Carbon Dioxide; Cell Line, T | 2012 |
Antidepressant-like effects of methanol extract of Hibiscus tiliaceus flowers in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, A | 2012 |
Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Female; Hippoc | 2012 |
Inflammatory immune responses in a reproducible mouse brain death model.
Topics: Anesthesia; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Blood Pressure; Brain De | 2012 |
The effects of anesthesia, mouse strain and age on intraocular pressure and an improved murine model of experimental glaucoma.
Topics: Acepromazine; Aging; Anesthesia; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Axons; | 2012 |
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperi | 2012 |
Deficits in emotional learning and memory in an animal model of schizophrenia.
Topics: Analysis of Variance; Animals; Brain; Conditioning, Classical; Disease Models, Animal; Excitatory Am | 2012 |
The expression of genes involved in glucose metabolism is affected by N-methyl-D-aspartate receptor antagonism: a putative link between metabolism and an animal model of psychosis.
Topics: Animals; Autoradiography; Brain; Convulsants; Disease Models, Animal; Glucose; Glucose Transporter T | 2012 |
Ischemia-reperfusion injury of the mouse kidney.
Topics: Anesthetics, General; Animals; Disease Models, Animal; Female; Hypnotics and Sedatives; Isoflurane; | 2012 |
The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Behavior, Animal; Benzylidene Compounds; Cholinest | 2013 |
Antinociception by metoclopramide, ketamine and their combinations in mice.
Topics: Acute Pain; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Syne | 2012 |
Improved methods for thermal rearrangement of alicyclic α-hydroxyimines to α-aminoketones: synthesis of ketamine analogues as antisepsis candidates.
Topics: Animals; Anti-Infective Agents, Local; Disease Models, Animal; Female; Imines; Interleukin-6; Ketami | 2012 |
Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Ketamine; Male; Nicotine; | 2012 |
Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury.
Topics: Acute Lung Injury; Analysis of Variance; Anesthesia; Anesthetics, Dissociative; Anesthetics, General | 2012 |
Kindling-induced learning deficiency and possible cellular and molecular involved mechanisms.
Topics: Animals; Apoptosis; Avoidance Learning; Demyelinating Diseases; Disease Models, Animal; Electron Tra | 2013 |
Comparison of brain and blood gene expression in an animal model of negative symptoms in schizophrenia.
Topics: Animals; Behavior, Animal; Brain; Conditioning, Psychological; Disease Models, Animal; Fear; Gene Ex | 2012 |
Effect of cigarette smoke exposure in the behavioral changes induced by ketamine.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Excitatory Amino Acid Antag | 2012 |
Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia.
Topics: Analysis of Variance; Animals; Avoidance Learning; Brain; Brain-Derived Neurotrophic Factor; Cogniti | 2012 |
Ketamine potentiates hippocampal neurodegeneration and persistent learning and memory impairment through the PKCγ-ERK signaling pathway in the developing brain.
Topics: Analgesics; Analysis of Variance; Animals; Animals, Newborn; Brain; Disease Models, Animal; Enzyme I | 2012 |
Effects of pretreatment with etomidate, ketamine, phenytoin, and phenytoin/midazolam on acute, lethal cocaine toxicity.
Topics: Animals; Cocaine; Disease Models, Animal; Etomidate; Ketamine; Mice; Midazolam; Phenytoin; Random Al | 2012 |
Evaluation of behavioral and neurochemical changes induced by ketamine in rats: implications as an animal model of mania.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Disease Models, Animal; Drug Interact | 2012 |
New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Barbiturates | 2013 |
The effects of anesthetic regimen in 90% hepatectomy in rats.
Topics: Anesthesia; Anesthetics; Anesthetics, Inhalation; Animals; Blood Glucose; Disease Models, Animal; Gl | 2012 |
Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment.
Topics: Animals; Autonomic Nervous System; Cerebellum; Disease Models, Animal; Excitatory Amino Acid Antagon | 2012 |
Role of NMDA and opioid receptors in neuropathic pain induced by chronic constriction injury of sciatic nerve in rats.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Excitatory Amino Acid Agonists; Ketamine; Male; | 2012 |
Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys.
Topics: Adolescent; Analysis of Variance; Animals; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; | 2014 |
Antipsychotic compounds differentially modulate high-frequency oscillations in the rat nucleus accumbens: a comparison of first- and second-generation drugs.
Topics: Animals; Antipsychotic Agents; Biological Clocks; Disease Models, Animal; Dizocilpine Maleate; Dose- | 2013 |
Characterization of gene-environment interactions by behavioral profiling of selectively bred rats: the effect of NMDA receptor inhibition and social isolation.
Topics: Acoustic Stimulation; Animals; Behavior, Animal; Breeding; Disease Models, Animal; Gene-Environment | 2013 |
Intrathecal ketamine and pregabalin at sub-effective doses synergistically reduces neuropathic pain without motor dysfunction in mice.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Synergism; gamma-Aminobutyric Acid; Hyperalgesia; | 2013 |
GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Topics: Acoustic Stimulation; Action Potentials; Animals; Antidepressive Agents; Brain; Conditioning, Operan | 2013 |
Effects of different anesthetics in the murine model of EHV-1 infection.
Topics: Analysis of Variance; Anesthetics; Animals; Cell Death; Cell Proliferation; Disease Models, Animal; | 2013 |
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Enzym | 2013 |
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Guanosine 5'-O-(3-Thiotriphospha | 2002 |
Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia.
Topics: Acetates; Adrenergic Uptake Inhibitors; Amines; Aminopyridines; Analgesia; Analgesics; Animals; Cell | 2002 |
Effects of different anesthetics on the paired-pulse depression of the h reflex in adult rat.
Topics: Administration, Inhalation; Alfaxalone Alfadolone Mixture; Anesthetics; Animals; Disease Models, Ani | 2002 |
Management of rabies in humans.
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal; Antibodies, Viral; Combined Modality Thera | 2003 |
Protection of the ischemic heart during reperfusion: role of the low flow to avoid calcium overload into the myocardium in a pig model.
Topics: Animals; Calcium; Disease Models, Animal; Excitatory Amino Acid Antagonists; Heart Arrest; Ketamine; | 2002 |
The brain matrix and multifocal brain damage following a single injection of ketamine in young adult rats: conspicuous changes in old age.
Topics: Acepromazine; Age Factors; Animals; Brain; Brain Damage, Chronic; Disease Models, Animal; Ketamine; | 2002 |
Age and anesthetic effects on murine electrocardiography.
Topics: Aging; Anesthetics, Combined; Anesthetics, Inhalation; Animals; Disease Models, Animal; Electrocardi | 2003 |
Experience with ketamine and sodium pentobarbital as anesthetics in a rat model of cardiac arrest and resuscitation.
Topics: Anesthetics, Dissociative; Animals; Brain; Cardiopulmonary Resuscitation; Disease Models, Animal; He | 2003 |
Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia.
Topics: Anesthetics, Dissociative; Animals; Anxiety; Disease Models, Animal; Injections, Intraperitoneal; Ke | 2003 |
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Amino Acids; Analysis of Variance; Animals; Area Under Curve; | 2003 |
Topical capsaicin-induced allodynia in unanesthetized primates: pharmacological modulation.
Topics: Aminobutyrates; Analgesics; Animals; Benzeneacetamides; Capsaicin; Disease Models, Animal; Dizocilpi | 2003 |
Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats.
Topics: Anesthetics, Dissociative; Animals; Disease Models, Animal; Endotoxins; Hemodynamics; Hypnotics and | 2003 |
Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice.
Topics: Acepromazine; Adrenergic alpha-Agonists; Age Factors; Anesthesia; Anesthetics; Animals; Body Weight; | 2003 |
The neuromatrix and the epileptic brain: behavioral and learning preservation in limbic epileptic rats treated with ketamine but not acepromazine.
Topics: Acepromazine; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Chi-Squa | 2004 |
Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Clorgyline; Disease Models, Animal; Dizocilpine Male | 2004 |
Effect of gamma-hydroxybutyric acid on tissue Na+,K- ATPase levels after experimental head trauma.
Topics: Adrenergic alpha-Agonists; Analgesics; Analysis of Variance; Animals; Blood Gas Analysis; Blood Pres | 2004 |
Normal spatial and contextual learning for ketamine-treated rats in the pilocarpine epilepsy model.
Topics: Animals; Disease Models, Animal; Epilepsy; Ketamine; Male; Maze Learning; Pilocarpine; Rats; Rats, W | 2004 |
The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components.
Topics: Animals; Disease Models, Animal; Evoked Potentials, Auditory; Humans; Ketamine; Mice; Mice, Inbred C | 2004 |
[Protective effect of ketamine against septic shock in rats].
Topics: Analgesics; Animals; Disease Models, Animal; Hemodynamics; Interleukin-6; Ketamine; Male; Random All | 2004 |
[Effects of ketamine on hypoxic-ischemic brain damage in newborn rats].
Topics: Animals; Animals, Newborn; Brain; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; | 2004 |
Ketamine reduces mortality of severely burnt rats, when compared to midazolam plus fentanyl.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Animals; Burns; Disease | 2004 |
Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Analysis of Variance; Animals; Brachial Plexus; Brachial Plexus Neurop | 2004 |
Increased neurogenesis in a rat ketamine model of schizophrenia.
Topics: Animals; Antigens; Bromodeoxyuridine; Cell Differentiation; Cell Division; Disease Models, Animal; E | 2004 |
Gender differences and the effects of ketamine in healthy volunteers.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Ketamine; Male; Psychoses | 2004 |
Ketamine potentiates the effect of electroacupuncture on mechanical allodynia in a rat model of neuropathic pain.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Electroacupuncture; Female; Ketam | 2004 |
Isoflurane preserves central nervous system blood flow during intraoperative cardiac tamponade in dogs.
Topics: Analgesics; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Cardiac Tamponade; Central N | 2004 |
Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior, Animal; Behavior | 2004 |
Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats.
Topics: Animals; Disease Models, Animal; Dopamine; Electric Stimulation; Evoked Potentials; Fornix, Brain; G | 2005 |
Ketamine/xylazine anesthesia for radiologic imaging of neurologically impaired rats: dose response, respiratory depression, and management of complications.
Topics: Anesthesia; Anesthetics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Infarcti | 2004 |
Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats.
Topics: Animals; Disease Models, Animal; Drug Synergism; Fentanyl; Hindlimb; Ketamine; Male; Pain, Postopera | 2005 |
Preemptive effect of intravenous ketamine in the rat: concordance between pain behavior and spinal fos-like immunoreactivity.
Topics: Analgesics; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Disinfectants; | 2005 |
The effects of ketamine and propofol on bacterial translocation in rats after burn injury.
Topics: Analgesics; Anesthetics, Intravenous; Animals; Bacterial Translocation; Blood Pressure; Burns; Disea | 2005 |
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
Topics: Adaptor Proteins, Vesicular Transport; Aged; Animals; Antipsychotic Agents; Behavior, Animal; Cognit | 2005 |
Neuroprotective effects of preconditioning ischaemia on ischaemic brain injury through inhibition of mixed-lineage kinase 3 via NMDA receptor-mediated Akt1 activation.
Topics: Animals; Blotting, Western; Brain; Brain Ischemia; Cell Death; Chromones; Dimethyl Sulfoxide; Diseas | 2005 |
Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat.
Topics: Anesthetics; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Female; I | 2005 |
Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.
Topics: Acetophenones; Allosteric Regulation; Animals; Brain; Cross-Linking Reagents; Disease Models, Animal | 2005 |
Divergent effects of bicuculline and picrotoxin on ketamine-induced apneustic breathing.
Topics: Animals; Apnea; Bicuculline; Blood Pressure; Cats; Disease Models, Animal; GABA Antagonists; GABA-A | 2005 |
Weak, physiologically patterned magnetic fields do not affect maze performance in normal rats, but disrupt seized rats normalized with ketamine: possible support for a neuromatrix concept?
Topics: Analgesics; Animals; Behavior, Animal; Brain; Disease Models, Animal; Electromagnetic Fields; Ketami | 2006 |
Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats.
Topics: Anesthetics; Animals; Brain; Brain Injuries; Cell Survival; Cognition Disorders; Diazepam; Disease M | 2006 |
Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness.
Topics: Animals; Disease Models, Animal; Entorhinal Cortex; Evoked Potentials; Excitatory Amino Acid Agonist | 2006 |
Transcriptional response to the neuroleptic-like compound Ampullosporin A in the rat ketamine model.
Topics: Animals; Antipsychotic Agents; Brain; Calcium; Disease Models, Animal; Gene Expression Regulation; K | 2006 |
Rabies virus infection of primary neuronal cultures and adult mice: failure to demonstrate evidence of excitotoxicity.
Topics: Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Cells, Cultured; Cysteine Proteinase Inhibitors; | 2006 |
Pain sensitivity is altered in animals after subchronic ketamine treatment.
Topics: Analgesics; Analgesics, Opioid; Animals; Cerebral Cortex; Disease Models, Animal; Dose-Response Rela | 2006 |
Failure of therapeutic coma and ketamine for therapy of human rabies.
Topics: Adult; Animals; Brain; Coma; Disease Models, Animal; Excitatory Amino Acid Antagonists; Fatal Outcom | 2006 |
[Improved method of acute myocardial ischemic rat model].
Topics: Acute Disease; Anesthesia, General; Animals; Coronary Vessels; Disease Models, Animal; Intubation, I | 2006 |
Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthetics, Combined; Animals; Biogenic Monoamines; C | 2007 |
[Effect of ketamine on endotoxin-induced septic shock in rats and its mechanism].
Topics: Anesthetics, Dissociative; Animals; Cyclic AMP; Disease Models, Animal; Female; HSP70 Heat-Shock Pro | 2007 |
Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits.
Topics: Analgesics; Anesthetics, Combined; Anesthetics, Intravenous; Animals; Animals, Newborn; Anti-Anxiety | 2007 |
[Protective effects of ketamine on allergen-induced airway inflammatory injure and high airway reactivity in asthma: experiment with rats].
Topics: Airway Resistance; Allergens; Animals; Asthma; Blotting, Western; Bronchial Hyperreactivity; Bronchi | 2007 |
The expression of Troponin T1 gene is induced by ketamine in adult mouse brain.
Topics: Age Factors; Animals; Behavior, Animal; Brain; Brain Diseases; Disease Models, Animal; Excitatory Am | 2007 |
Inhibitory effect of ketamine on phosphorylation of the extracellular signal-regulated kinase 1/2 following brain ischemia and reperfusion in rats with hyperglycemia.
Topics: Animals; Apoptosis; Brain Ischemia; Cerebral Cortex; Disease Models, Animal; Excitatory Amino Acid A | 2007 |
Determination of sensitivity of male Wistar rats to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia in comparison with control group.
Topics: Adrenergic alpha-Agonists; Anesthesia; Anesthetics, Dissociative; Animals; Chronic Disease; Disease | 2007 |
A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation.
Topics: Animals; Cerebral Cortex; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug S | 2008 |
Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-Aminobutyric | 2007 |
Delayed pharmacological pre-conditioning effect of mitochondrial ATP-sensitive potassium channel opener on neurologic injury in a rabbit model of spinal cord ischemia.
Topics: Analgesics; Animals; Blood Gas Analysis; Diazoxide; Disease Models, Animal; Ischemic Preconditioning | 2008 |
Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity.
Topics: Amphetamine; Animals; Antipsychotic Agents; Arousal; Brain; Disease Models, Animal; Dopamine; Dose-R | 2008 |
Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment.
Topics: Anesthetics, Dissociative; Animals; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal | 2008 |
A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia.
Topics: Adult; Analysis of Variance; Animals; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Elec | 2008 |
Effects of anesthesia on a model of uncontrolled hemorrhage in rats.
Topics: Analysis of Variance; Anesthetics; Animals; Disease Models, Animal; Droperidol; Drug Combinations; F | 1995 |
Effects of MK-801 (dizocilpine) and ketamine on strychnine-induced convulsions in rats: comparison with benzodiazepines and standard anticonvulsants.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dizocilpine Maleate; Ketamine; Male; Rats; Rats, W | 1994 |
Developmental changes of ketamine action against epileptic afterdischarges induced by hippocampal stimulation in rats.
Topics: Age Factors; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Dose-Response Relat | 1994 |
Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents.
Topics: Animals; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; | 1994 |
Heat shock proteins following rat cerebral ischemic/reperfusion episode: effect of ketamine.
Topics: Animals; Brain Ischemia; Cerebral Cortex; Disease Models, Animal; Hippocampus; HSP70 Heat-Shock Prot | 1994 |
Power spectral analysis of electromyographic and systemic arterial pressure signals during fentanyl-induced muscular rigidity in the rat.
Topics: Anesthesia, Intravenous; Animals; Blood Pressure; Disease Models, Animal; Electromyography; Fentanyl | 1994 |
Models of simple partial and absence seizures in freely moving rats: action of ketamine.
Topics: Animals; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Electroencephalo | 1993 |
Influence of anesthetics on the peripheral blood microfilaremia of Brugia malayi in the Mongolian jird, Meriones unguiculatus.
Topics: Analysis of Variance; Anesthetics; Animals; Brugia malayi; Disease Models, Animal; Elephantiasis, Fi | 1996 |
Excitotoxic neurotoxicity in an in vitro brain slice model.
Topics: Animals; Apoptosis; Brain; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Amino | 1995 |
Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?
Topics: Adolescent; Adult; Age Factors; Animals; Cerebral Cortex; Child; Disease Models, Animal; Dizocilpine | 1995 |
Average spectrum of cochlear activity: a possible synchronized firing, its olivo-cochlear feedback and alterations under anesthesia.
Topics: Acoustic Stimulation; Action Potentials; Anesthesia; Anesthetics, Dissociative; Animals; Auditory Th | 1996 |
Blockade of morphine-induced hindlimb myoclonic seizures in mice by ketamine.
Topics: Amino Acids; Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 1997 |
Anesthetic regimen effects on a pediatric porcine model of asphyxial arrest.
Topics: Adjuvants, Anesthesia; Anesthesia, General; Anesthetics, Combined; Anesthetics, Dissociative; Anesth | 1997 |
The chicken retina as an experimental model for investigation of central nervous lesions.
Topics: Animals; Central Nervous System Diseases; Chickens; Disease Models, Animal; Electric Stimulation; Gl | 1997 |
The effects of intravenous anesthetics on intracranial pressure and cerebral perfusion pressure in two feline models of brain edema.
Topics: Analysis of Variance; Anesthetics, Intravenous; Animals; Blood Pressure; Brain Edema; Cats; Cerebrov | 1997 |
Doppler echocardiographic reference values for healthy rhesus monkeys under ketamine hydrochloride sedation.
Topics: Anesthetics, Dissociative; Animals; Cardiovascular System; Disease Models, Animal; Echocardiography, | 1997 |
Effect of narcotic agents and of bleeding on systemic and renal haemodynamics in healthy and CCl4-treated cirrhotic rats.
Topics: Animals; Blood Pressure; Butyrophenones; Carbon Tetrachloride; Diazepam; Disease Models, Animal; Dru | 1997 |
[Suppressive effects of ketamine on neuropathic pain].
Topics: Acute Disease; Anesthetics, Dissociative; Animals; Disease Models, Animal; Dose-Response Relationshi | 1998 |
E. Coli bacteremia-induced changes in the skeletal muscle microcirculation vary with anesthetics.
Topics: Anesthetics; Animals; Bacteremia; Chloralose; Decerebrate State; Disease Models, Animal; Escherichia | 1998 |
[The use of ketamine in an experimental model of generalized cerebral ischemia].
Topics: Animals; Brain Ischemia; Disease Models, Animal; Drug Evaluation, Preclinical; Excitatory Amino Acid | 1998 |
N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Anticonvulsants; Disease Models, A | 1999 |
A word of caution in extrapolating the spinal cord protective effects of memantine obtained in a rabbit model under ketamine anesthesia.
Topics: Anesthetics, Dissociative; Animals; Blood-Brain Barrier; Body Temperature; Disease Models, Animal; E | 1999 |
A word of caution in extrapolating the riluzole spinal cord injury protective effects obtained in a rabbit model under ketamine anesthesia.
Topics: Anesthetics, Dissociative; Animals; Cardiopulmonary Bypass; Disease Models, Animal; Drug Synergism; | 1999 |
The effect of ketamine isomers on both mice behavioral responses and c-Fos expression in the posterior cingulate and retrosplenial cortices.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Gyrus | 2000 |
Domestic swine model for the assessment of chemical warfare agent-anesthetic interactions: some effects of sulfur mustard.
Topics: Anesthesia, General; Anesthetics; Animals; Apnea; Chemical Warfare; Disease Models, Animal; Drug Eva | 2000 |
Repeated administration of low dose ketamine for the treatment of monoarthritic pain in the rat.
Topics: Analgesics; Animals; Ankle Joint; Arthritis, Experimental; Body Weight; Disease Models, Animal; Dose | 2000 |
Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Infarction; Ketamine; Neuroprote | 2000 |
Deliberate seizure induction with repetitive transcranial magnetic stimulation in nonhuman primates.
Topics: Anesthesia, General; Animals; Brain; Disease Models, Animal; Electroencephalography; Electromagnetic | 2001 |
Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia.
Topics: Animals; Discrimination Learning; Disease Models, Animal; Dizocilpine Maleate; DOM 2,5-Dimethoxy-4-M | 2000 |
Influence of anesthetic agent on survival following hemorrhage.
Topics: Anesthetics; Animals; Blood Pressure; Blood Volume; Body Weight; Disease Models, Animal; Ethers; Hal | 1976 |
Myoclonus developing after vermisectomy in photosensitive Papio papio.
Topics: Animals; Cerebellum; Diazepam; Disease Models, Animal; Electroencephalography; Haplorhini; Ketamine; | 1978 |
Progress report from the NIDA Addiction Research Center.
Topics: Animals; Decerebrate State; Disease Models, Animal; Dogs; Humans; Ketamine; Mice; Phencyclidine; Rec | 1979 |
Ketamine block of bronchospasm in experimental canine asthma.
Topics: Airway Resistance; Anesthesia, Intravenous; Animals; Antigens; Ascaris; Asthma; Bronchial Spasm; Dis | 1979 |
Clinicopathological validation of a primate stroke model.
Topics: Anesthesia, General; Animals; Brain; Cerebral Arteries; Cerebrovascular Disorders; Disease Models, A | 1975 |
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.
Topics: Adrenergic alpha-Agonists; Animals; Atropine; Biperiden; Clonidine; Disease Models, Animal; Dizocilp | 1991 |
Effects of NMDA receptor antagonists following spinal ischemia in the rabbit.
Topics: Animals; Dibenzocycloheptenes; Disease Models, Animal; Dizocilpine Maleate; Hindlimb; Ischemia; Keta | 1990 |
N-methyl-D-aspartate receptors mediate activation of the c-fos proto-oncogene in a model of brain injury.
Topics: Animals; Anticonvulsants; Atropine; Brain; Brain Injuries; Dibenzocycloheptenes; Disease Models, Ani | 1990 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |
Metoclopramide fails to suppress linguopharyngeal events in a rat dyskinesia model.
Topics: Animals; Deglutition; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Ind | 1989 |
Ketamine-induced tongue protrusions in rats.
Topics: Animals; Deglutition; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Hypoglo | 1989 |
Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.
Topics: Animals; Anticonvulsants; Dibenzocycloheptenes; Disease Models, Animal; Dizocilpine Maleate; Dose-Re | 1989 |
Inciting excitotoxic cytocide among central neurons.
Topics: Action Potentials; Animals; Brain; Cell Survival; Chick Embryo; Cholinergic Fibers; Disease Models, | 1986 |
Animal models of intravenous phencyclinoid self-administration.
Topics: Animals; Cocaine; Conditioning, Operant; Disease Models, Animal; Female; Infusions, Intravenous; Ket | 1987 |
[Use of ketamine anesthesia in experimental animal investigations].
Topics: Anesthesia, General; Animals; Disease Models, Animal; Dogs; Hexobarbital; Injections, Intramuscular; | 1986 |
Prophylactic and delayed treatment with indomethacin in a porcine model of early adult respiratory distress syndrome induced by endotoxaemia.
Topics: Anesthesia, General; Animals; Blood Pressure; Disease Models, Animal; Endotoxins; Female; Hemodynami | 1986 |
Porphyrinogenicity of etomidate and ketamine as continuous infusions. Screening in the DDC-primed rat model.
Topics: 5-Aminolevulinate Synthetase; Anesthesia, Intravenous; Animals; Dicarbethoxydihydrocollidine; Diseas | 1985 |
Comparison of inflammatory changes in established type II collagen- and adjuvant-induced arthritis using outbred Wistar rats.
Topics: Animals; Antibody Formation; Arthritis; Arthritis, Experimental; Blood Proteins; Collagen; Copper; D | 1985 |
A teaching model for pediatric intubation utilizing ketamine-sedated kittens.
Topics: Animals; Cats; Disease Models, Animal; Education, Medical, Continuing; Education, Nursing, Graduate; | 1974 |
Ketamine-induced stress ulcers in the rat.
Topics: Anesthesia, Intravenous; Animals; Disease Models, Animal; Halothane; Humans; Ketamine; Phenoxybenzam | 1974 |
Ketamine-induced postanesthetic delirium attenuated by tetrahydroaminoacridine.
Topics: Acridines; Analysis of Variance; Anesthesia, Intravenous; Animals; Delirium; Disease Models, Animal; | 1974 |